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 Hypervalent iodine complexes can be used to deliver a variety of functional 
groups to arenes.  Delivery of fluorine-18, in a manner compatible with positron emission 
tomography (PET), is especially attractive.  VizamylTM, an injectable solution of 
[18F]Flutemetamol, is currently used to diagnose and monitor the progression of 
Alzheimer’s Disease (AD), the most common form of dementia.  AD affects 47.5 million 
people across the world as of 2015, and is projected to affect 1 in 85 people by 2050.  An 
improved radiosynthesis of [18F]Flutemetamol via a diaryliodonium salt is described.  
The use of nonpolar solvents minimizes disproportionation and other side reactions, 
leading to higher fluorination yields.  The use of an electron-withdrawing protecting 
group allows functionalization of the highly electron-rich aniline ring.  Upon initial 
testing, thermolysis of this salt provides radiochemical yields (RCY) of more than twice 
that of the best previously reported syntheses. Another class of heterocycles, 2-aryl-5-
fluorobenzimidazoles, was also investigated.  A variety of these suspected anti-tumor, 
   
anti-microbial, and anti-inflammatory compounds were fluorinated for screening and 
additionally synthesized by thermolysis of diaryliodonium salts, suitable for 
radiosynthesis. 
 Hypervalent iodine complexes involving stabilized α-nitroester enolates were 
developed and studied.  Thermolysis of these diaryliodonium salts leads to selective 
formation of α-alkyl α-aryl α-nitroesters, which can be reduced and hydrolyzed to form 
the analogous quaternary α-alkyl α-aryl amino acids.  These unnatural quaternary amino 
acids have no enolizable proton, so racemization is not possible, and oxidation pathways 
that involve abstraction of the proton on the α-carbon are also prevented.  This 
convergent, rapid synthesis provides access to a variety of unnatural quaternary amino 
acids that can be used for screening and studying biological pathways.  Synthesis of an 
enantiopure cyclophanyl-substituted diaryliodonium salt was investigated as a potential 
method for stereoselectively generating these compounds. 
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CHAPTER 1 
IMPROVED METHODOLOGY FOR FLUORINATION OF ANILINES VIA 
HYPERVALENT IODINE COMPLEXES: APPLICATION TO THE 
SYNTHESIS OF [18F]FLUTEMETAMOL 
 
1.1 Introduction 
 
1.1.1 Alzheimer’s Disease 
Alzheimer’s disease (AD) is the most common form of dementia, accounting for 
50 to 80 percent of dementia cases.1  The disease typically presents in elderly individuals.  
It affects more than 4 million people in the United States alone, presenting in 1% of 
people aged in their 60s and increasing to nearly 30% of people aged up to 85 years old.  
As of 2015, 47.5 million people across the world were afflicted with AD.  Brookmeyer et 
al., predicted that by the year 2050 Alzheimer’s disease will affect 1 in 85 people.2  The 
disease affects memory, cognitive skills, and behavior.  As a degenerative disease, mental 
function continues to degrade over time, eventually ending in death.  There are currently 
no known treatments to stop or reverse the progression of the disease; however, some 
treatments may temporarily alleviate symptoms.  Some treatments, such as 
acetylcholinesterase inhibitors and N-methyl D-aspartate receptor antagonists are 
effective for only slightly more than half of the patients taking these drugs, and do not 
cure AD, but may modestly slow progression of the disease.3 Good methods to diagnose 
and monitor AD are necessary to treat the disease early (slowing progression before 
15 
symptoms appear), and also to further study Alzheimer’s disease in order to develop 
better treatments. 
 In 1959, Vassar and Culling introduced a cationic benzothiazole dye, thioflavin T 
(ThT),4 which was found to show enhanced fluorescence upon binding to amyloid protein 
in tissue sections (Figure 1.1).  Brain matter from AD afflicted patients could be stained 
postmortem with ThT to confirm the AD diagnosis, based on dementia symptoms.  By 
1984, a guideline was established to diagnose patients with dementia from AD.  The 
guideline proposed that the disease pathology and clinical symptoms were synonymous; 
i.e. the patient either fully exhibited AD pathology, was demented, and therefore had 
developed Alzheimer’s disease, or they were completely free from Alzheimer’s disease 
pathology (and were either not demented, or their dementia was caused by other forms of 
cognitive impairment).  Only postmortem could the diagnosis be confirmed by brain 
tissue staining. 
 
16 
 
 
Figure 1.1: Thioflavin T chemical structure and Thioflavin T Congo Red stain of ß-
amyloid plaques in brain tissue.5 
 
In 2001, researchers at the University of Pittsburgh developed a carbon-11 radiolabeled 
version of ThT, [N-methyl-11C]6-Me-BTA-1 (Figure 1.2), that later became known as the 
Pittsburgh compound B (PiB).6  Using positron emission tomography (PET), images of ß-
amyloid plaques in a patient’s brain, before death, are able to be acquired (PET will be 
disscussed further in section 1.1.2 below).   
 
 
Figure 1.2: Pittsburgh compound B, [N-methyl-11C]6-Me-BTA-1 
 
Studies began to test the effectiveness of the recently developed PiB compound as a 
diagnostic agent, both for cognitive impairment (potentially due to diseases such as AD) 
N
SH3C
N
CH3
CH3
CH3Cl
N
SHO
N
11CH3
H
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and traumatic brain injury.7,8  It was found that generally 30% to 35% of healthy people 
in their 70s and 80s, exhibiting no cognitive impairment, tested positive in PiB scans.  In 
2004, a collaborative initiative, the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI), began to seek out new methods to diagnose and monitor AD.   More than 800 
volunteers underwent testing every 6 to 12 months.  Cerebrospinal fluid (CSF) testing, 
magnetic resonance imaging (MRI), and positron emission tomography (PET) were 
performed.  After five years, some patients who showed no cognitive impairment 
developed mild cognitive impairment (MCI), some patients who presented with MCI 
progressed fully to dementia.  Nearly 60% of patients who tested positive in PiB scans 
and had MCI advanced to Alzheimer’s disease within a year or two.  The results from the 
ADNI initiative prompted the development of a new set of guidelines for diagnosis of 
AD.9  These guidelines emphasize the importance of the new biomarkers discovered by 
the ADNI, most notably low CSF levels of the Aß42 protein and elevated CSF tau protein 
levels, and PET imaging data.  This underscores the importance of further research into 
PET imaging for AD. 
 
1.1.2 Positron Emission Tomography 
Positron emission tomography is a non-invasive imaging technique that provides 
a three-dimensional image of functional processes in biological systems.10  PET has 
proven exceptionally useful for early detection and monitoring of disease (a non-invasive 
clinical diagnosis), for medical research to aid in understanding physiological processes 
and metabolic pathways, and for drug development and discovery.  A PET scan utilizes a 
18 
molecule labeled with a positron (β+) emitting radionuclide, i.e. a radiotracer or 
radiopharmaceutical.  The radiotracer is administered to the patient and the metabolite 
localizes in the body.  As the radionuclide decays it ejects a positron, which collides with 
a nearby electron (Figure 1.3).  
 
 
Figure 1.3: Diagram of the annihilation event11 
 
This annihilation event generates two coincident 511 keV γ-rays (corresponding to the 
masses of the positron and electron).  A scintillation detector array monitors these 
photons, and the detected signals are processed to extrapolate the source of each 
annihilation event.  The distance traveled by the positron before it collides with an 
electron depends on the kinetic energy (KE) of the ejected positron.  Lower KE emitters 
provide higher resolution images (as they travel less before colliding with an electron).  
The spatial resolution of a PET scan can show detail as precise as 2–3 mm, depending on 
the radionuclide used.  A PET scan is often acquired along with an X-ray computed 
tomography scan (X-ray CT, CAT, or simply CT scan) to give anatomical information as 
19 
well. An X-ray CT scan acquires a large number of X-ray images, taken from various 
angles, and computationally combines these images to produce cross-sectional slices.  
These slices can be used to generate a three-dimensional image of the inside of the region 
being scanned. 
 
1.1.3 Fluorine-18 as a Radionuclide 
 
Isotope Half Life Decay Mode 
Avg. 
Positron KE 
Eβ+ avg 
[keV] 
Avg. (Max.) 
Range in 
Tissue [mm] 
11C 20.39 min β
+ (99.8%) 
EC (0.24%) 385 1 (3.8) 
13N 9.965 min β
+ (99.8%) 
EC (0.2%) 491 1.5 (5) 
15O 122.24 s β
+ (99.9%) 
EC (0.01%) 735 2.7 (7.6) 
18F 109.77 min β
+ (96.73%) 
EC (3.3%) 242 0.3 (2.2) 
124I 4.18 d β
+ (22.8%) 
EC (77.2%) 830 3.3 (9.7) 
 
Table 1.1: Nuclear properties of commonly used positron (β+) emitters for PET12 
 
Table 1.1 lists some commonly used positron emitting radionuclides for PET.  Of 
these radionuclides, [18F], fluorine-18, has the optimal physical properties for certain PET 
20 
applications.  First, its half-life, about 2 hours, is convenient for relatively complex 
radiotracer synthesis.  It is short enough to collect kinetic data in a reasonable time 
period, provided the unbound radiopharmaceutical is metabolized quickly, and 
radioactivity in the patient is short-lived, allowing the PET scan to be an outpatient 
procedure.  Its half-life is long enough to synthesize the radiotracer at a lab with an on-
site cyclotron and transport it to nearby satellite PET centers (that lack a full 
radiochemical lab and cyclotron).  Second, the low positron KE of fluorine-18 ensures a 
short range in tissue; the annihilation event occurs fairly close to the site of radiotracer 
decay, providing a high resolution PET scan.  Third, the decay of fluorine-18 yields 
innocuous 18O as the product atom.  Finally, the nuclear reaction for formation of 
fluorine-18 from oxygen-18, 18O(p,n)18F on 18O-enriched water (H218O), can yield several 
Curie (Ci) amounts of fluorine-18 from a single cyclotron run.  As only 5–15 mCi of 
radiotracer need to be injected for a single human dose, this allows for many PET scans 
from a single cyclotron run. 
 Along with the benefits of using fluorine-18 as a radionuclide, fluorine 
substitution in drugs often leads to improved pharmacological profiles.13,14  Despite the 
relatively high abundance of fluorine in the earth’s crust, organofluorine compounds are 
rare in nature.15,16  However, approximately one third of prescribed pharmaceuticals 
contain a fluorine atom.  The high electronegativity and small atomic radius of the 
fluorine atom, along with the short C–F bond length, cause relatively small structural 
perturbations compared to other functional group substitutions, but drastically alter the 
electronic properties, and often improve the bioavailability of the compound.17,18  
21 
Fluorine can act as a bioisostere for a variety of functional groups, such as C–H, C=O, 
and C–OH — pharmaceuticals where these groups have been replaced with fluorine 
exhibit similar biological properties to the original pharmaceutical.  These features make 
fluorine-18 an attractive radionuclide to use for PET radiotracers; however, introduction 
of fluoride onto a target drug can be difficult. 
 
1.1.4 Introduction of Fluoride-18 on a Target Molecule 
There are several methods for introducing fluoride-18 onto a target molecule.  
Fluoride-18 is generated in a cyclotron and incorporated into a radiotracer via chemical 
reaction(s) performed in a lead-shielded, and typically automated system. 
 
 
 
 
 
 
 
Figure 1.4: A cyclotron (left)19 and an automated synthesis module (right)20 
 
A fundamental challenge of introducing fluoride into a target molecule is the difficulty of 
forming C–F bonds.  Fluorine is the most oxidizing and most electronegative element.  
The fluoride anion, because of its small ionic radius (1.33 Å) and high electronegativity, 
tends to form strong hydrogen bonds with most hydrogen bond donors (e.g. water, 
22 
alcohols, amines), which makes reactions with fluoride difficult to control.  Fluoride, in 
the absence of hydrogen bonding, is a potent nucleophile and a strong base, but is rather 
unreactive when hydrogen bonds are present.  A variety of methods have been developed 
to introduce fluoride-18 onto a target molecule: (a) electrophilic methods (i.e. [18F]F2), 
(b) nucleophilic methods (i.e. [18F]F-), (c) metal-mediated methods, and (d) thermolysis 
of hypervalent iodine complexes, typically diaryliodonium triflates or diaryliodonium 
hexafluorophosphates.  
Electrophilic methods, based upon F2, tend to be harsh and not selective, so the 
[18F]F2 that is generated is often converted into more selective, less reactive 18F-labeled 
fluorination agents, such as N-substituted DABCO derivatives (e.g. Selectfluor®), N-
fluorosulfonimides (e.g. NFSI), N-fluoropyridiniums, acetyl hypofluorite (AcO18F), 
xenon difluoride (Xe18F2), and others.  The largest drawback to electrophilic methods is 
that the maximum theoretical radiochemical yield (RCY) can only be 50%.10  This is 
because the fluorine-18 produced by the cyclotron must be captured with fluorine-19 gas, 
forming 18F–19F, giving rise to a mixture of 18F and 19F being added to the target 
molecule.  In addition, an excess of 19F2 must be added to recover the [18F]F2 from the 
reactor/vessel walls, giving low specific activity (the amount of radioactivity per unit 
mass of radiotracer).  Electrophilic labeling routes are only useful where high specific 
radioactivity tracers are not necessary.  
 Radiotracers can be generated by nucleophilic methods without adding 
fluoride-19 in the form of [19F]F2.  These methods are referred to as “no carrier added” 
(nca) and offer higher specific activity (4 x 104 GBq µmol-1) than radiotracers generated 
23 
through carrier-added methods.10  High specific activity is necessary for radiotracers 
targeting receptors that have high binding affinities (i.e. subnanomolar dissociation 
constants) often radiotracers targeted at imaging the brain.  With a low specific activity 
radiotracer, the excess of 19F-labeled compound can saturate the target receptor, so little 
18F-labeled compound may bind, leading to low signal for imaging.  This can be 
countered by administering a larger dose, but larger doses often can reach the 
physiological range of effect, causing side-effects or toxicity.  This is especially 
problematic for PET images on younger children, where larger doses are not safe.  
Nucleophilic methods, generating high specific activity, can be administered as low does 
(typically about 50 pmol), minimizing toxicity and allowing PET scans for children. 
 From the cyclotron, [18F]F- is obtained as H18F in aqueous media.21,22 When 
hydrated, fluoride is very unreactive.  To activate it for nucleophilic reactions the fluoride 
must be dehydrated and stabilized in a polar, aprotic solvent.  H18F can be captured on an 
ion exchange resin, recovering the unreacted H218O.  The [18F]F- is typically recovered by 
eluting with aqueous solutions of alkali metal (K+, Rb+, Cs+) salts.  Residual water is 
removed by multiple evaporations using a polar, organic solvent that azeotropes with 
water, such as acetonitrile.  Since most alkali metals bind tightly to fluoride and these 
salts tend to be nearly insoluble in organic solvents, cryptands (such as Kryptofix 2.2.2) 
are used to promote ion separation and solubilization of the [18F]F-.  Although these 
solutions are generally free from water, the specific level of hydration is not known and it 
is very unlikely these solutions are completely anhydrous.13 
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Scheme 1.1: Process to capture 18F- 21  
 
[18F]F- can also be recovered by eluting with aqueous solutions of quaternary ammonium 
(tetramethylammonium, tetrabutylammonium, etc) salts of weakly nucleophilic bases 
(e.g. bicarbonate, carbonate, hydroxide) and dried in a similar fashion.  These salts tend 
to be more soluble in organic solvents, but again complete dehydration is problematic.  
For example, dried tetrabutylammonium fluoride (TBAF)23 is reported to decompose by 
Hofmann elimination at room temperature.  After dehydration the salt is contaminated 
with large amounts of bifluoride (HF2-) and tributylamine.  DiMagno and Sun have 
reported a direct synthesis of highly anhydrous tetrabutylammonium fluoride from ultra-
dry starting materials,24 and a “fluoride relay” method, using wet [19F]F-, that can be 
adapted to an anhydrous [18F]F- synthesis.25  
 The drawbacks to the previous methods are mostly due to the reactivity of 
fluorine sources — electrophilic sources, F2, are highly reactive but often unselective and 
O
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do not tolerate many functional groups.  Nucleophilic sources, in contrast, are only 
weakly nucleophilic unless rigorously dried, in which case fluoride’s basicity often 
results in unwanted side products.  With nucleophilic fluorination harsh conditions are 
often necessary, in theory a consequence of the kinetic barrier to C–F bond formation.  
However, as the C–F bond is the strongest of all the C–X single bonds, fluorination of 
aryl halides is typically a thermodynamically favorable process, and can be approached 
by catalysis.  In the past few years, several methods of metal-mediated fluorination have 
been reported, successfully converting aryl bromides and/or aryl iodides to the 
corresponding aryl fluorides.26-50 This began with a breakthrough in 2009 by Buchwald 
and coworkers, using nucleophilic sources of fluoride.26 Later Sanford and coworkers 
developed a fluorination procedure by oxidizing palladium(II) to palladium(IV) using 
xenon difluoride.26,27 Unfortunately, many of these methods are not compatible with PET 
methodology, as they require an excess of the fluoride source or an added carrier, provide 
low yields, or require long reaction times.  Recently, Ritter and coworkers have published 
a series of advances using palladium and nickel complexes.51 
 
 
Scheme 1.2: Generation of aryl fluoride from Nickel complex36  
 
A nickel complex is oxidized in the presence of aqueous fluoride.  The reductive 
elimination takes place at room temperature in less than a minute.  This method makes 
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use of extensive drying procedures (used in the previously described nucleophilic 
methods) unnecessary.  The precursor nickel complexes were easily synthesized, and 
were stable when stored.  The authors used this methodology under PET conditions, but 
on a scale below that of a PET dosage.  It is unknown whether this chemistry can produce 
a sufficient amount of an 18F-labeled radiopharmaceutical to be used for a PET scan. 
 Another approach that has shown recent advancement is the use of hypervalent 
iodine(III) complexes to deliver a fluorine atom to an arene.  The aryl fluoride is 
eliminated during thermolysis of diaryliodonium fluoride salts;52–54 this is the method we 
use in our lab.  Pike and coworkers were the first to use diaryliodonium salts for 
radiotracer synthesis.55  Reactions were carried out in acetonitrile and DMF, polar aprotic 
solvents, based on the theory that thermolysis of the iodine(III) complex proceeds via an 
SNAr-style mechanism.  Stang and coworkers have emphasized the similarities between 
iodonium salt and transition metal chemistries.56  Using this knowledge we reasoned that 
the conceptual framework used to optimize transition metal reactions should be 
applicable to this chemistry.  Removing residual ionic salts and switching to nonpolar 
solvents dramatically improved yields in our hands.57   
Emert and coworkers compared various radiosyntheses of symmetrical and 
unsymmetrical diaryliodonium salts (Scheme 1.3).58 
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Scheme 1.3: Synthesis of 1-bromo-[18F]fluorobenzene56  
 
From their results it is clear that the reaction of the symmetrical bis(4-
bromophenyl)iodonium salt provides the best radiochemical yields.  The unsymmetrical 
diaryliodonium salt provides a significantly lower yield, because it could also react 
through another regiochemical pathway, generating [18F]fluorobenzene.  Although yields 
of symmetrical precursors are significantly improved, synthesizing symmetrical 
diaryliodonium salts is challenging when the arenes are more complex.  These syntheses 
can be more time consuming syntheses, and more expensive.  Additionally, the 
thermolysis of unsymmetrical diaryliodonium salts can lead to multiple products that may 
not be easily separable. 
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Figure 1.5: Diagram of unsymmetrical diaryliodonium salt thermolysis  
(reprinted with permission from John Wiley and Sons)59 
 
It is believed that in the SNAr-style nucleophilic attack of fluoride the fluoride 
preferentially occurs at the ipso-carbon of the electron-poor arene.60 The electron-poor 
arene is better able to stabilize the developing negative charge in the transition state.  This 
makes fluorination of electron-rich aromatics challenging.  Using 4-methoxyphenyl as a 
directing group allows for regioselective fluorination of arenes more electron-poor than a 
para methoxy group.  Highly electron-rich arenes, such as arenes with ortho- or para-
alcohols/ethers, or anilines can still be problematic, though we have developed alternative 
strategies for highly electron-rich arenes such as these.57,61,62 
 
1.1.5 [18F]Flutemetamol and Its Synthesis 
Several other PET radiotracers have been introduced since the development of 
PiB in 2001 (Figure 1.6).63 
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Figure 1.6: Examples of Aß plaque PET imaging agents  
 
In 2004, Klunk, Mathis, and Wang developed a fluorinated analog of PiB, by introducing 
a fluoride onto the ortho-position of the aniline ring (Scheme 1.4).64  The longer half-life 
of fluorine-18 allows for the production of the radiopharmaceutical at a hospital with a 
cyclotron and transport to neighboring hospitals for PET scans.  The lower kinetic energy 
of fluorine-18, compared to carbon-11, allows for a higher resolution image (i.e. the 
fluoride-18 nuclide travels a short distance in tissue, so the annihilation event occurs 
fairly close to the site of radiotracer decay). 
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Scheme 1.4: Initial patented synthesis of [18F]Flutemetamol 
 
Their approach involved nucleophilic fluorination on an electron-poor nitroarene (1), by 
SNAr.  This reaction takes over 60 minutes.  After introduction of the radionuclide, three 
subsequent steps were performed to transform the nitroarene into an N-methylaniline for 
the final product (2): (1) reduction of the aryl nitro, (2) methylation of the resulting 
aniline, and (3) acidic cleavage of the methoxymethyl (MOM) protecting group.  The 
entire process takes 120 minutes, giving a radiochemical yield (not decay corrected) of 
0.5%.  The large number of steps after generation of the radionuclide in the cyclotron, 
and the long reaction time, make this synthesis cost-prohibitive. 
 In 2007, an improved synthesis (Scheme 1.5) was reported.63,65  As this synthesis 
only involves one step after introduction of the radionuclide, acidic cleavage of the 
ethoxymethyl (EOM) and N-formyl protecting groups, radiochemical yields are much 
higher, 15–25% after optimization for the GE FASTlabTM synthesizer. 
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Scheme 1.5: Improved synthesis of Flutemetamol 
 
Several studies showed that [18F]flutemetamol performs similarly to [11C]PiB, and 
provides repeatable results.  Flutemetamol was licensed by GE Healthcare and the 
injected product solution was named VizamylTM.  In 2015, VizamylTM entered phase III 
clinical trials.66 VizamylTM received FDA approval and is currently the only PET imaging 
tracer that is approved for visual interpretation of color images to detect amyloid plaques 
(rather than black and white images used for other compounds).67  These results make 
flutemetamol an attractive imaging agent for AD diagnosis, monitoring, and research.  
Although the reduced number of steps after introduction of the radionuclide makes this 
synthesis more affordable, nucleophilic fluorination by SNAr reactions still typically 
involve long reaction times and harsh conditions. 
 
1.2 Results and Discussion 
 
1.2.1 Synthesis of [19F]Flutemetamol via an Iodonium salt 
 The low radiochemical yield is the most significant drawback to the existing 
methodologies for the synthesis of Flutemetamol (Scheme 1.4, Scheme 1.5).  Given that 
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construction and operation of a cyclotron and PET facility is expensive, low 
radiochemical yields directly translate to high patient costs for each PET scan.  Using 
faster methods, such as thermolysis of diaryliodonium salts, could provide significantly 
higher yields.  A retrosynthesis was designed for flutemetamol using diaryliodonium salt 
thermolysis.  Since the base structure of flutemetamol is a 2-arylbenzothiazole, a 
convergent synthesis, coupling a benzothiazole synthon with an aniline synthon, was 
chosen.  Protecting groups would be installed either before or after coupling.  After 
coupling, a halogen (nominally iodine or bromine) would be added, or the halogen could 
potentially be brought in with the aniline moiety.  The DiMagno group has shown a 
number of strategies for synthesizing diaryl iodonium salts from aryl iodides and aryl 
bromides.57,59,61,72,73  
 
  
 
Scheme 1.6: Initial retrosynthesis of [19F]Flutemetamol 
 
Protecting groups were chosen that could be removed in one step, thus minimizing the 
number of steps after addition of the radionuclide.  Electron-rich aromatics are often 
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more difficult to fluorinate and very few aniline-containing iodonium salts have been 
reported in the literature68,69  For example, (4-dimethylaminophenyl)iodonium salts have 
only been isolated as relatively short-lived compounds; inner sphere electron transfer 
from the arene(s) to the iodine center may be the cause of rapid decomposition.  Knowing 
this, an aniline protecting group was chosen that would remove electron density from the 
aromatic ring. 
 
 
 
Scheme 1.7: Final synthesis of [19F]Flutemetamol 
 
A number of synthetic routes were attempted to make the precursor to the iodonium salt.  
For the initial synthesis a Kumada coupling was attempted, by metalating a 2-
chlorobenzothiazole and coupling with a 2,4-diiodoaniline. 
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Scheme 1.8: Kumada coupling (R=Me, EtOCH2; X=I, H; PG=OAc, Boc) 
 
It was theorized that coupling would preferentially take place at the less sterically 
hindered 4-position.  This would eliminate the need to later selectively iodinate the 
aniline in the presence of the methoxybenzothiazole ring.  Unfortunately, no methods 
were successful in metalating the benzothiazole.  Preparation of the organozinc analog (to 
use in a Negishi coupling) was attempted using Rieke zinc, but no metalation occurred.  
Finally, a variety of butyllithium reagents were reacted with 2-chloro-6-
methoxybenzothiazole (3) and 2-chloro-6-ethoxymethoxybenzothiazole (4), but in every 
case the butyl group inserted into the C=N bond of the benzothiazole. 
 
 
 
Scheme 1.9: Addition of butyllithium (R=Me, EtOCH2; R’=n-Bu, s-Bu, t-Bu) 
 
An alternate strategy was adopted, by metalating the aniline and coupling with the 2-
chlorobenzothiazole.  Similar attempts were tried to metalate the iodo-N-methylaniline 
(both 4-iodo-N-methylaniline (5)  and 2,4-diiodo-N-methylaniline (6)), but both 
protecting groups used on the nitrogen (OAc and Boc) caused issues.  Either the aniline 
N
SRO
MgCl
N CH3
PGX
I
Pd catalyst
Ligand
N
SRO
N
PG
CH3
X
N
SRO
Cl
R'Li
-78 ˚C or warmer N
SRO
R'
3, 4 
35 
was not metalated or, using stronger metalating agents, nucleophilic attack occurred on 
the protecting group. 
Since the 2-position on the benzothiazole ring is far more acidic than a typical 
aromatic C-H (In DMSO, the pKa of benzothiazole is 27 vs. ~43 for benzene70) 6-
methoxybenzothiazole (7) could potentially be used in a Sonogoshira-style coupling. 
 
 
 
Scheme 1.10: Sonogoshira-style coupling used 
 
Due to previous difficulties in synthesizing 2,4-diiodoaniline (8) (even with ICl addition 
of the second iodide proceeded slowly, in very low yield), 4-bromo-N-methylaniline (9) 
and 2,4-dibromo-N-methylaniline (10) were synthesized.  Coupling with 10 proceeded 
smoothly, though yields were low due to the ortho-coupled side-product and a number of 
other side-products (the desired product and the ortho-coupled product could couple 
again with 7).  After Boc-protection of the product, no methods were found to form the 
iodonium salt.  Typically, an aryl iodide is oxidized to an aryliodonium diacetate, or an 
aryl halide is converted to a potassium aryltrifluoroborate by formation of a Grignard 
reagent or by palladium-catalyzed borylation with bis(pinacolato)diboron (Miyaura 
borylation).  The aryl bromide (11) was unreactive to form the Grignard reagent at the 
low temperatures necessary to be compatible with the Boc protecting group.  Miyaura 
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borylation proceeded to remove the Boc protecting group, but the product mixture could 
not be identified (the borylated product, without the Boc-group, did not appear to be 
present).  
 
 
 
Scheme 1.11: Coupling with 4-bromo-N-methylaniline  
 
Coupling with the mono-bromoaniline 5, to form 4-(6-methoxybenzothiazolyl)-N-
methylaniline (12), proceeds in much higher yields to furnish a more easily purifiable 
product.  The challenge with this route is the difficulty in iodinating the aniline ring.  It 
was presumed that iodination would be facile on both rings, leading to a mixture of 
multiple mono- and di-iodinated products; unexpectedly iodination was generally slow 
for both rings.  One example from literature showed ICl in acetic acid could selectively 
iodinate the aniline ring.71  No experimental conditions were reported in the paper, but all 
attempts I performed gave no reaction.  Strong iodinating agents such as (a) AgOTf/I2 
gave no conversion, and (b) (bis(trifluoroacetoxy)iodo)benzene/I2, gave less than 10% 
conversion to the iodinated product (13) after all of the oxidant was consumed.  It was 
discovered that iodinating under basic conditions gave the best results. 
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Scheme 1.12: Iodination under basic conditions 
 
This reaction proved quite challenging as stirring the biphasic reaction dramatically 
decreased yields, by increasing the formation of a black, nearly insoluble tar.  Increasing 
the scale of the reaction also decreased the yield.  Using ICl instead of I2 decreased 
formation of the tar byproduct and improved conversion, but overall gave similar to 
worse yields due to other side products, (a) chlorination on the aniline ring, (b) second 
iodination on the benzothiazole ring, and (c) a product with an unidentified substitution 
directly on the amine.  After an in-depth survey of reaction variables (overall reaction 
scale, ratios of each reagent, temperature, stirring speed, dimensions of the reaction 
vessel) it was found that the optimal conditions were to run multiple reactions, each on a 
1 g scale, and combine the reaction mixtures before work-up. 
 Although the aniline ring was initially thought to be fairly electron-rich, after 
these results it was suspected that the benzothiazole ring is sufficiently withdrawing.  
This challenge continued with the Boc-protection.  A Schotten–Baumann reaction gave 
low yields, but using a gross excess of all other reagents, (a) di-tert-butyl dicarbonate, (b) 
dimethylaminopyridine, and (c) triethylamine, and running the reaction concentrated in 
acetonitrile, moderately high yields (60–70%) of 14 were achieved after three days. 
 We are able to oxidize a variety of aryl iodides with SelectfluorTM, using 
methodology developed in our group.72  However, oxidation of compound 14 proceeded 
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far more slowly than the oxidant (SelectfluorTM) was consumed (presumably the aniline 
ring was electron-poor and also sterically hindered by the Boc group).  Using a Miyaura 
borylation (as was attempted on the corresponding bromo-compound) also removed the 
Boc protecting group and did not appear to generate the desired compound (even without 
the Boc group).  Lithiation, followed by generation of the organozinc (as we have used 
before on less functionalized targets), was not attempted due to the fragile Boc protecting 
group.  However, we theorized that using a milder metalating agent (isopropyl 
magnesium chloride), under cold conditions, could be successful.  
 
 
 
Scheme 1.13: Magnesium-halogen exchange reaction 
 
Halogen-metal exchange using isopropyl magnesium chloride at -78 ˚C proved workable 
and proceeded without attack on the Boc protecting group.  Though the resulting yields 
were low (23%), coupling with bis(acetoxy)iodoanisole (15) generated the desired 
product (16).  
 Although many diaryliodonium salts are fairly soluble in ethyl acetate, 16 was 
nearly insoluble in ethyl acetate, so the crude iodonium salt, 16, was purified by 
triturating with hexanes and ethyl acetate to remove the bulk of the impurities.  
Diaryliodonium salts can be unstable when heated, so recrystallization is usually 
performed by layering, vapor diffusion, or slow evaporation.  These conditions, using a 
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variety of binary and tertiary solvent sets, produced only impure oils.  The crude 
iodonium salt, 16, is fully soluble in acetonitrile, but almost completely insoluble in 
methyl tert-butyl ether (MTBE).  The crude salt was dissolved in a small portion of 
acetonitrile and added dropwise to stirring MTBE.  Unlike a typical precipitation (e.g. 
DCM into hexanes), the solution remained homogeneous until stirring was stopped and 
the solution was aged for several minutes.  After several minutes the pure diaryliodonium 
salt gradually crystalized out of solution.  We have theorized that MTBE is a weakly 
coordinating ligand for the iodonium center.  Acetonitrile is a strongly coordinating 
ligand (reducing a solution of 16 under high dynamic vacuum will not liberate all of the 
acetonitrile).  Due to the gross excess of MTBE there is a shift in equilibrium and the 
bound acetonitrile is replaced by MTBE.  The MTBE-salt complex is no longer soluble 
and crystallizes out.  This is observed by residual MTBE in NMR spectra, that does not 
change despite hours to days of dynamic high vacuum.  
 
 
 
Scheme 1.14: Thermolysis reaction 
 
Thermolysis of 16 was performed by dissolving the pure iodonium salt in 
acetonitrile in an NMR tube fitted with a Teflon screw cap closure.  A substoichiometric 
amount of fluoride, from tetramethylammonium fluoride (TMAF) was added and the 
TfO- to F- exchange was observed by 1H and 19F NMR.  The exact amount of fluoride 
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added was determined by 1H NMR, based on the integration of TMAF (based on the 12 
methyl protons) compared to the integration of the diaryliodonium salt.  Polar solvents 
and stoichiometric or superstoichiometric amounts of fluoride promote aryl swapping.  
Aryl swapping is a process that can occur with unsymmetrical diaryliodonium salts 
(Figure 1.7).73  The degree of electronic differentiation between the two arenes 
determines the ratio of the resulting iodonium complexes.  A diaryliodonium salt bearing 
two similarly electron-rich arenes undergoes aryl exchange to provide a nearly statistical 
mixture of diaryliodonium salts (1 A2IF : 2 ABIF : 1 B2IF).  A diaryliodonium salt 
bearing an electron-rich and an electron-poor arene may undergo aryl exchange, but the 
unsymmetrical diaryliodonium salt predominates. 
 
 
Figure 1.7: Diagram of the aryl swapping process 
 
Aryl swapping was not observed after addition of fluoride to 16, consistent with how 
electron-poor the flutemetamol arene appeared (based on previous reactions).  Under high 
dynamic vacuum acetonitrile-d3 was removed to give an oily solid.  The NMR tube was 
returned to a glove box and dry benzene-d6 was added.  As mentioned previously, 
nonpolar aprotic solvents allow thermolysis with much less chance of side-products.  
Ionic salts are much less soluble in benzene, so filtration does not appreciably improve 
the results.57  The NMR tube was sealed and heated at 60 ˚C, shielded from light.  The 
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reaction was monitored by 1H and 19F NMR.  After 30 minutes, it was found that the 
reaction was nearly 75% complete (based on integrations of the product (17) and the 
starting iodonium salt (16), given that a substoichiometric amount of fluoride was added).  
After one hour, conversion had slowed significantly.  The final conversion was 83%.  No 
fluoroanisole was observed in 1H or 19F NMR, indicative of high regioselectivity for the 
reductive elimination pathway that favors fluorination of the aniline ring.  This further 
suggests that the Boc-protected aniline (with an electron withdrawing benzothiazole 
group) was sufficiently electron-poor (relative to anisole) to favor elimination of 4-
iodoanisole, and sufficiently electron-poor to impede aryl swapping during the fluoride 
exchange.  It was also found that heating the reaction using acetonitrile in benzene-d6 
(10% v/v) as the solvent, at 100 ˚C, for 10 minutes proved successful. 
 These results suggested that in the radiochemical lab we could see higher 
radiochemical yields than what is reported for the current VizamylTM preparation of 
[18F]Flutemetamol (15–25%). 
 
1.2.2 Synthesis of [19F]Flutemetamol HPLC Standards 
Since such a small amount of [18F]-labeled radiotracer is produced at a PET 
facility, purification is performed using a gamma detector, and collecting fractions at high 
radioactivity.  To ensure the desired radiotracer is collected and not free 18F- or some 
other by-product, 19F standards are also run on HPLC, using a UV detector, to determine 
the proper retention time.  Given the potential difficulty in removing the methoxy 
protecting group, I opted to prepare three 19F standards for HPLC: a fully protected 
42 
flutemetamol (17), a partially deprotected flutemetamol (18), after removal of the Boc 
protecting group, and the fully deprotected [19F]Flutemetamol (19). 
Using 2-fluoro-4-iodo-N-methylaniline (20), which we previously prepared in our 
lab, 6-methoxybenzothiazole (7) was coupled with the same Sonogashira-style reaction.  
Boc-protection of this product yielded the fully protected flutemetamol, 17.  Boron 
tribromide deprotection of this product yielded the fully deprotected flutemetamol, 19. 
 
 
 
Scheme 1.15: Synthesis of 19F HPLC standards 
 
These compounds were fully characterized by NMR and MS, and using this alternate 
route the identity of the thermolysis product, described in the previous section, was 
confirmed. 
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1.2.3 Synthesis of [18F]Flutemetamol via a Diaryliodonium Salt 
 A larger scale synthesis of diaryliodonium salt 16 was performed.  The purified 
salt was passed down an ion-exchange column (using an Amberlite quaternary 
ammonium resin, previously equilibrated with sodium triflate) to ensure no other anions 
were present, even as minor impurities.  The salt was weighed into vials in 8 mg portions 
inside a nitrogen-charged glove box.  These vials were sealed and kept free from light.  
The vials were shipped to St. Jude Children’s Research Hospital where radiochemistry 
was performed.  Thermolysis was confirmed by radio-TLC (the reaction mixture was 
spotted on a TLC plate and visualized by UV and gamma detector) and the crude product 
was purified by HPLC.   
 
Run Amount of salt Temp. Time 
Starting 
Activity 
Radio-
TLC 
Product % 
HPLC 
Product 
% 
RCY 
1 8 mg 80 ˚C 10 min 9.37 mCi 64% – 32.2% 
2 8 mg 120 ˚C 6 min 8.37 mCi 78% – 38.1% 
3 4 mg 60 ˚C 15 min 13.88 mCi 18% – – 
4 4 mg 120 ˚C 20 min 11.59 mCi 95% 95% 53.6% 
5 4 mg 120 ˚C 20 min 5.69 mCi 82% 81% 53.5% 
6 4 mg 120 ˚C 20 min 11.04 mCi 74% 77% 48.0% 
 
Table 1.2: Radiochemical thermolyses of 16 
 
It was found that only half the amount of diaryliodonium salt (4 mg) was necessary.  
Heating at 120 ˚C for 20 minutes gave the best results.  By radio-TLC (Figure 1.8), 95% 
of the total radioactivity was found on the product; only 5% remained at the baseline 
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(likely unreacted fluoride-18 salts).  HPLC of the reaction mixture (Figure 1.8) showed 
the same results: 95% of the total radioactivity was found at the same retention time as 
the previously prepared 19F standard; only 5% was found in the void volume peak (the 
solvent front). 
 
  
 
 
 
 
Figure 1.8: Radio-TLC of run 4 (left);  
HPLC trace of 19F standard (top right); HPLC trace of run 4 (bottom right) 
 
HPLC data are acquired with a gamma detector as well as UV-Vis.  As the amount of 
18F-radiotracer is small, the compound appears only with gamma detection; a UV-Vis 
trace is co-acquired to confirm that other impurities (such as the unlabeled 19F analog of 
the radiotracer) are not present when the radiotracer is collected.  After isolation of the 
N
SO
N
Boc
CH3
19F
N
SO
N
Boc
CH3
18F Gamma 
detector 
UV-Vis 
(254 nm) 
UV-Vis 
(220 nm) 
UV-Vis 
(254 nm) 
UV-Vis 
(220 nm) 
45 
product, correcting for radioactive decay, the radiochemical yield (RCY) was found to be 
53.6% (average of 51.7% over three runs).  This result is significantly higher than 
previously reported results (15–25%) for the synthesis of [18F]Flutemetamol.  Additional 
optimization could be performed to potentially raise this yield further.  For example, in 
this run, 15.9% of the starting activity was found remaining in the vial after reaction.  
Although the composition was not analyzed, this residue may contain some 
radiofluorinated product; this could potentially be recovered by improving the reaction 
vessel rinsing step. 
Deprotection of the Boc protecting group was performed with the second run, 
using 4 M aqueous HCl for 10 minutes at 95 ˚C, and removal was confirmed by 
comparison on HPLC to the previously prepared 19F standard.  Based on reactions run on 
14, deprotection of the methoxy group should also be facile, but requires the use of boron 
tribromide, or hydroiodic acid and high temperatures (150 ˚C).  Do to the effect of these 
harsh conditions on the equipment used at St. Jude Children’s Research Hospital, and the 
potential safety risk associated with using such conditions, this deprotection step was not 
performed.   
 
1.2.4 Future Directions 
 Although an ethoxymethoxy-protected analog of 16 was not synthesized, the 
route to the corresponding coupling component, 6-ethoxymethoxybenzothiazole (21),  
was briefly investigated (Scheme 1.16).  Deprotection of 6-methoxybenzothiazole (7) to 
produce 6-hydroxybenzothiazole (22) proceeded smoothly with boron tribromide.  The 
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lower than expected yield is presumably due to the presence of water in the starting 
material; more thorough drying of 7 (by vacuum sublimation) may improve this yield.  
Reacting 22 with aqueous sodium carbonate and chloromethoxyethane did not generate 
the desired product.  Sodium hydride was used, but due to the its strong basicity, 
deprotonation at the 7-position occurred (as evidenced by the formation of 6-
ethoxymethoxy-7-ethoxybenzothiazole), significantly lowering the reaction yield.  It may 
be possible to improve the yield by refluxing 22 with sodium carbonate under anhydrous 
conditions before adding chloromethoxyethane. 
 
  
 
Scheme 1.16: Initial synthesis of 6-ethoxymethoxybenzothiazole (21) 
 
The rest of the synthesis, using the same or similar conditions, should be possible using 
21 in place of 7, as each of the synthetic routes were chosen to be compatible with acid 
sensitive groups.  Diaryliodonium salts are known to be compatible with ethoxymethoxy 
(EOM) protecting groups.72 
 
1.3 Conclusion 
 As research on effective, accessible, and affordable diagnosing, monitoring, and 
study of Alzheimer’s disease continues to intensify, readily available and affordable PET 
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radiotracers will continue to be sought after.  Our demonstration of the ability to prepare 
[18F]Flutemetamol using thermolysis of a diaryliodonium triflate, with an initially 
optimized radiochemical yield of 53.6%, proved quite promising.  This yield is 
substantially higher than the highly optimized 15–25% yields reported by Mason and co-
workers.63,65  Although deprotection was not performed under our best conditions, it is 
unlikely this step will hinder the yield significantly.  In the future an ethoxymethoxy 
protecting group could be used, likely with the same or similar synthetic approach 
outlined here.  This type of protecting group has been shown to be compatible with 
diaryliodonium salt thermolysis using fluorine-1972 as well as fluorine-18.74 Expanding 
the approach outlined in this work to develop a diaryliodonium salt using an EOM 
protecting group, and fully optimizing the radiochemical procedure could offer a very 
promising alternative to the methodology currently being used for VizamylTM.  
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1.5 Experimental 
 
6-Methoxybenzothiazole (7): 
 
tert-Butyl nitrite (18.5 mL, 155.2 mmol) was dissolved in 50 mL THF and heated to 
reflux under N2.  2-amino-6-methoxybenzothiazole (14.00 g, 77.6 mmol) was dissolved 
in 150 mL THF and added dropwise with a pressure-equalizing addition funnel over 1 
hour.  The solution was refluxed for an additional 3 hours under N2 and cooled to room 
temperature.  The solution was diluted with ethyl ether and washed three times with 
sodium thiosulfate in brine (10 g/L). The aqueous layers were extracted once with ethyl 
ether. The combined organic layers were dried over sodium sulfate, filtered, and the 
solvent was removed in vacuo. The crude oil was precipitated with ether and filtered. The 
filtrate was concentrated in vacuo to yield an oily orange solid, which was 
chromatographed on silica with ethyl acetate/hexanes (1:1, v/v). The orange solid was 
sublimed under high dynamic vacuum, at 60 ˚C.  The pale yellow solid was recrystallized 
from nearly boiling hexanes, cooled slowly to room temperature, and rinsed with cold 
hexanes, to yield a colorless solid (8.05 g, 62.8%). 1H NMR (CDCl3, 400 MHz, 298 K): δ 
8.83 (s, 1H), 8.01 (d, J = 9.0 Hz, 1H), 7.40 (d, J=2.4 Hz, 1H), 7.13 (dd, J=9.0 Hz, J=2.4 
Hz, 1H), 3.89 (s, 3H); 13C NMR (CDCl3, 100 MHz, 298 K): δ 158.30, 151.65, 147.86, 
135.26, 124.15, 116.13, 104.22, 56.02; HRMS: (EI) calcd. for C8H7NOS [M]+ 165.0248 
found 165.0248. 
N
SO
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Doyle, M. P.; Dellaria, J. F. Jr.; Siegfried, B.; Bishop, S. W. J. Org. Chem. 1977, 42, 
3494–3498. 
 
4-Bromo-N-methylaniline (9): 
 
N-Methylaniline (10.8 mL, 0.10 mol) was dissolved in 85 mL dichloromethane in a 500 
mL round bottom flask.  The solution was cooled to -20 ˚C with a sodium chloride/ice 
bath. Tetraethylammonium chloride (1.66 g, 0.01 mol) was dissolved in 2.0 mL methanol 
and added to the flask.  Bromine (5.64 mL, 0.11 mmol) was dissolved in 15 mL 
dichloromethane and added by syringe pump over 1 hour.  The solution was allowed to 
warm slowly to room temperature overnight, in the dark. The reaction was neutralized 
with saturated aqueous sodium bicarbonate.  The organic layer was washed twice with 
saturated aqueous sodium bicarbonate and once with brine.  The organic layer was dried 
over sodium sulfate, filtered, and solvent was removed in vacuo.  The crude liquid was 
fractionally distilled at 100 mTorr (boiling point 58–61 ˚C) to yield a yellow liquid 
(12.53 g, 67.4 %). 1H NMR (CDCl3, 400 MHz, 298 K): δ 7.28 (d, J = 8.7 Hz, 2H), 6.50 
(d, J = 8.7 Hz, 2H), 3.74 (br s, NH), 2.83 (s, 3H); 13C NMR (CDCl3, 100 MHz, 298 K): δ 
148.35, 132.05, 114.19, 109.07, 30.95; HRMS: (EI) calcd. for C7H8BrN [M]+ 184.9840, 
186.9820 found 184.9840, 186.9827. 
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Gervat, S.; Léonel, E.; Barraud, J.; Ratovelomanana, V. Tetrahedron Lett., 1993, 34, 
2115–2118. 
 
2,4-Dibromo-N-methylaniline (10): 
 
N-Methylaniline (10.8 mL, 0.10 mol) was dissolved in 100 mL dichloromethane in a 250 
mL round bottom flask.  Bromine (12.8 mL, 0.25 mol) was added dropwise at a rate 
sufficient to maintain reflux.  The solution was refluxed overnight. The reaction was 
neutralized with saturated aqueous sodium bicarbonate.  The organic layer was washed 
twice with saturated aqueous sodium bicarbonate and once with brine.  The organic layer 
was dried over sodium sulfate, filtered, and solvent was removed in vacuo.  The crude oil 
was chromatographed on silica with ethyl acetate/hexanes (1:99, v/v) to yield a pale 
yellow solid (14.7 g, 55.3 %). 1H NMR (CDCl3, 400 MHz, 298 K): δ 7.54 (d, J = 2.2 Hz, 
1H), 7.30 (dd, J = 8.7 Hz, J = 2.2 Hz, 1H), 6.49 (d, J = 8.7 Hz, 1H), 4.40 (br s, NH), 2.88 
(s, 3H); 13C NMR (CDCl3, 400 MHz, 298 K): δ 145.27, 134.32, 131.44, 111.86, 109.91, 
108.01, 30.80; HRMS: (EI) calcd. for C7H8Br2N [M]+ 264.8925, 262.8945, 266.8904 
found 264.8894, 262.8939, 266.8910. 
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2-(3-Bromo-4-(methylamino)phenyl)-6-methoxybenzothiazole (11): 
 
In a nitrogen-charged glove box, 6-methoxybenzothiazole (99.1 mg, 0.60 mmol), 2,4-
dibromo-N-methylaniline (317.9 mg, 1.2 mmol), palladium(II) acetate (6.7 mg, 0.03 
mmol), tri(tert-butyl)phosphine (12.1 mg, 0.06 mmol), and copper(I) bromide (17.2 mg, 
0.12 mmol) were dissolved in 10 mL dry DMF.  The solution was transferred to an 
airfree storage tube. Solid cesium carbonate (215.1 mg, 0.66 mmol) was added directly to 
the tube.  The reaction was heated at 150 ˚C for 8 hours.  After cooling to room 
temperature the mixture was diluted with ether, and washed five times with water.  The 
aqueous layers were extracted three times with ether.  The combined organic layers were 
washed with brine, dried over sodium sulfate, and filtered.  The solvent was removed in 
vacuo and the crude oil was chromatographed on silica with ethyl acetate/hexanes (10:90 
v/v) to yield a pale yellow solid (25.6 mg, 12.2%). 
 
Cole, G. B.; Keum, G.; Liu, J.; Small, G. W.; Satyamurthy, N.; Kepe, V.; Barrio, J. R. 
Proc. Natl. Acad. Sci. USA 2010, 107, 6222–6227. 
 
Alternate method: In a tall Schlenk tube, 2-(4-(methylamino)phenyl)-6-
methoxybenzothiazole (1.00 g, 2.5 mmol) was dissolved in 20 mL DCM.  The solution 
was cooled to -78 ˚C. Bromine (0.14 mL, 2.7 mmol) was diluted with 2 mL DCM and 
N
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added dropwise over 15 minutes.  The reaction was allowed to warm slowly to room 
temperature and stirred overnight.  The solution was diluted with DCM and washed twice 
with saturated aqueous sodium bicarbonate, three times with a 10 g/L solution of sodium 
thiosulfate in brine, and once with brine.  The organic layer was dried over sodium 
sulfate, filtered, and the solvent was removed in vacuo.  The crude solid was 
chromatographed on silica with ethyl acetate/hexanes (90:10 v/v) to yield a pale yellow 
solid (0.6164 g, 70.6%). 1H NMR (CDCl3, 400 MHz, 298 K): δ 8.18 (d, J = 2.0 Hz, 1H), 
7.88 (d, J = 8.9 Hz, 1H), 7.86 (dd, J = 8.6 Hz, J = 2.0 Hz, 1H), 7.33 (d, J = 2.8 Hz, 1H), 
7.06 (dd, J = 8.9 Hz, J = 2.8 Hz, 1H), 6.67 (d, J = 8.6 Hz, 1H); HRMS: (ESI) calcd. for 
C15H14BrN2OS [M+H]+ 349.0010, 350.9990 found 349.0012, 351.0001. 
 
2-(4-(Methylamino)phenyl)-6-methoxybenzothiazole (12): 
 
In a nitrogen-charged glove box, 6-methoxybenzothiazole (7.00 g, 42.4 mmol), 4-bromo-
N-methylaniline (9.46 g, 50.9 mmol), palladium(II) acetate (0.48 g, 2.1 mmol), tri(tert-
butyl)phosphine (0.86 g, 4.2 mmol), and copper(I) bromide (1.22 g, 8.5 mmol) were 
dissolved in 200 mL dry DMF.  The mixture was transferred to a 500 mL airfree storage 
flask. Solid cesium carbonate (15.19 g, 46.6 mmol) was added directly to the flask.  The 
reaction was heated at 150 ˚C, with stirring, for 4 hours.  After cooling to room 
temperature the mixture was diluted with ether, and washed five times with water.  The 
aqueous layers were extracted three times with ether.  The combined organic layers were 
N
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washed with brine, dried over sodium sulfate, and filtered.  The solvent was removed 
in vacuo and the crude oil was chromatographed on silica with ethyl 
acetate/hexanes/dichloromethane (1:4:5 v/v/v) to yield a pale yellow solid (7.94 g, 
69.3%).  1H NMR (CDCl3, 400 MHz, 298 K): δ 7.88 (d, J = 8.6 Hz, 1H), 7.87 (d, J = 9.0 
Hz, 1H), 7.33 (d, J = 2.5 Hz, 1H), 7.05 (dd, J = 9.0 Hz, J = 2.5 Hz, 1H), 6.65 (d, J = 8.6 
Hz, 1H), 4.10 (br q, J = 5.0 Hz, NH), 2.91 (d, J = 5.0 Hz, 3H); 13C NMR (CDCl3, 100 
MHz, 298 K): δ 166.67, 157.35, 151.46, 148.96, 135.93, 128.96, 122.97, 122.89, 115.16, 
112.26, 104.56, 77.53, 77.22, 76.90, 56.00, 30.56; HRMS: (ESI) calcd. for 
C15H14N2NaOS [M+Na]+ 293.0725 found 293.0737. 
 
Cole, G. B.; Keum, G.; Liu, J.; Small, G. W.; Satyamurthy, N.; Kepe, V.; Barrio, J. R. 
Proc. Natl. Acad. Sci. USA 2010, 107, 6222–6227. 
 
2-(3-Iodo-4-(methylamino)phenyl)-6-methoxybenzothiazole (13): 
 
In a tall Schlenk storage tube, 2-(4-(methylamino)phenyl)-6-methoxybenzothiazole (1.00 
g, 2.5 mmol) was dissolved in 20 mL dichloromethane.  Iodine (1.28 g, 5.0 mmol) was 
added with stirring. Saturated aqueous sodium bicarbonate (5 mL) was layered on top. 
The reaction was heated to 50 ˚C for 3 days, without stirring.  After cooling, more iodine 
(1.92g, 7.5 mmol) was added, the solution was mixed gently, and the reaction was heated 
for an additional 2 days at 50 ˚C, without stirring.  The solution was diluted with 
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dichloromethane and brine, and the layers were separated.  The organic layer was 
washed three times with small portions of sodium thiosulfate in brine (10 g/L), and 
washed once with brine.  The organic layer was dried over sodium sulfate, filtered, and 
the solvent was removed in vacuo.  The black solid was triturated three times with boiling 
MTBE and filtered.  MTBE was removed in vacuo, and the crude solid was 
chromatographed on silica with ethyl acetate/hexanes (90:10 v/v) to yield a light orange 
solid (468.0 mg, 31.9%). 1H NMR (CD2Cl2, 400 MHz, 298 K): δ 8.38 (d, J = 2.0 Hz, 
1H), 7.88 (dd, J = 8.6 Hz, J = 2.0 Hz, 1H), 7.82 (d, J = 8.9 Hz, 1H), 7.35 (d, J = 2.5 Hz, 
1H), 7.04 (dd, J = 8.9 Hz, 2.5 Hz, 1H), 6.61 (d, J = 8.6 Hz, 1H), 4.64 (q, J = 5.0 Hz, NH), 
3.87 (s, 3H), 2.96 (d, J = 5.0 Hz, 3H); 13C NMR (CD2Cl2, 100 MHz, 298 K): δ 164.74, 
157.98, 150.58, 149.30, 137.99, 136.51, 129.32, 124.57, 123.39, 115.67, 109.77, 104.85, 
84.92, 56.32, 31.22; HRMS: (ESI) calcd. for C15H14IN2NaOS [M+Na]+ 418.9691 found 
418.9680. 
 
2-(4-(N-tert-Butyloxycarbonyl-3-iodo-N-methyl)phenyl)-6-benzothiazole (14): 
 
2-(3-Iodo-4-(methylamino)phenyl)-6-methoxybenzothiazole (1.43 g, 3.60 mmol) was 
dissolved in 25 mL THF.  Dimethylamino pyridine (1.32 g, 10.80 mmol) and 
triethylamine (1.5 mL, 10.80 mmol) were added.  Di-tert-butyl dicarbonate (4.71 g, 21.60 
mmol) was added in portions with stirring.  The solution was stirred for 3 days, under N2.  
THF was removed in vacuo. The oily solid was dissolved in minimal dichloromethane 
N
SO
N
CH3
I O
O
 65 
and precipitated with 10% diethyl ether in hexanes and filtered. The filtrate was 
reduced in vacuo and chromatographed on silica (deactivated with triethylamine/hexanes 
(5:95 v/v)) with triethylamine/ethyl acetate/hexanes (0.5:15:84.5 v/v). The crude solid 
was recrystallized from room temperature ethyl acetate/ether/hexanes, gradually chilling 
to -20 ˚C, to yield a white solid (1.25 g, 69.9%). [Note: two rotamers are visible due to 
restricted rotation of the carbamate bond] 1H NMR (CD3CN, 400 MHz, 298 K): δ 8.50 
(d, J = 1.9 Hz, 1H), 7.99 (br d, J = 8.2 Hz, 1H), 7.88 (d, J = 9.0 Hz, 1H), 7.51 (d, J = 2.5 
Hz, 1H), 7.38 (d, J = 8.2 Hz, 1H), 7.11 (dd, J = 9.0 Hz, J = 2.5 Hz, 1H), 3.86 (s, 3H), 
3.13 (br s, NCH3 rotomer), 3.10 (br s, NCH3 rotomer), 1.52 (br s, tert-butyl rotomer), 
1.33 (br s, tert-butyl rotomer); 13C NMR (CD3CN, 100 MHz, 298 K): δ 163.40, 159.25, 
154.49, 149.45, 138.17, 137.81, 134.94, 130.17, 129.07, 124.78, 117.14, 105.47, 100.95, 
80.97, 56.62, 36.82, 28.54, 28.17; HRMS: (ESI) calcd. for C20H21IN2NaO3S [M+Na]+ 
519.0215 found 519.0219. 
 
Bis(acetoxy)iodoanisole (15): 
 
Sodium periodate (11.000g, 51.5 mmol) and sodium acetate (9.000 g, 110.0 mmol) were 
added to a 100 mL Schlenk storage tube with a stirbar. Acetic acid (50 mL) and acetic 
anhydride (7.5 mL) were added. 4-iodoanisole (sublimed under vacuum) (11.700 g, 50.0 
mmol) was suspended in 25 mL acetic acid and added to the tube with stirring. The tube 
was sealed and heated to 115 ˚C for 2.5 hours, stirring vigorously. The mixture was 
cooled to room temperature and diluted with water (300 mL) and dichloromethane (100 
O I(OAc)2
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mL). The layers were separated and the aqueous layer was extracted twice with 
dichloromethane (100 mL). The combined organic layers were dried over sodium sulfate 
and dichloromethane was removed in vacuo. The pale yellow oil was diluted with 200 
mL hexanes, triturated, and sonicated until the oil had solidified. The mixture was filtered 
and the solid was triturated twice with hexanes. The solid was transferred to a 250 mL 
Schlenk flask along with 100 mL hexanes and 1 mL acetic acid. The mixture was heated 
to 35 ˚C under vacuum overnight to yield a colorless solid (16.139 g, 91.7%). 1H NMR 
(CD3CN, 400 MHz, 298 K): δ 8.05 (d, J = 9.1 Hz, 2H), 7.05 (d, J = 9.1 Hz, 2H), 3.86 (s, 
3H), 1.90 (s, 6H); 13C NMR (CD3CN, 100 MHz, 298 K) δ 177.7, 163.7, 138.7, 118.0, 
112.0, 56.8, 20.8; HRMS: (HRFAB) calcd. for C14H13NO4I [M-2OAc+(3-NBA)]+ 
385.9889 found 385.9885. 
 
K. P. Landge, K. S. Jang, S. Y. Lee, D. Y. Chi, J. Org. Chem. 2012, 77, 5705. 
 
(2-(N-tert-Butyloxycarbonyl-N-methyl)amino-5-(6-methoxybenzothiazolyl))(4-
methoxyphenyl)iodonium triflate (16): 
 
In a nitrogen charged glovebox, 2-(3-iodo-4-(N-tert-butyloxycarbonyl-N-methyl)phenyl)-
6-benzothiazole (550.1 mg, 1.11 mmol) was dissolved in 5 mL dry THF in a flame-dried 
50 mL Schlenk tube, chilled to -78 ˚C, and iPrMgCl (2.0 M in THF, 1.1 mL, 2.22 mmol) 
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was added dropwise, with stirring. The solution was stirred for 5 minutes, and 
transferred by cannula to another 50 mL flame-dried Schlenk tube, containing 
bis(acetoxy)iodoanisole (1.17 g, 3.33 mmol) in 10 mL dry THF, at -78 ˚C. The solution 
was stirred for 15 minutes at -78 ˚C and allowed to warm slowly to room temperature 
overnight, in the dark. The solution was concentrated in vacuo and diluted with 15 mL 
methanol. Sodium triflate (1.91 g, 11.1 mmol) was dissolved in 10 mL water/methanol 
(1:2, v/v) and added dropwise, with vigorous stirring. The solution was stirred 
vigorously, in the dark, for 30 minutes, concentrated in vacuo to remove methanol, and 
extracted three times with dichloromethane. The organic layers were dried over sodium 
sulfate and solvent was removed in vacuo. The crude oil was triturated, using sonication, 
with hexanes, and decanted. The solid was sonicated in 15 mL ethyl acetate, chilled to 0 
˚C, and filtered. The solid was dissolved in acetonitrile, and reduced to an oil in vacuo. 
The oil was dissolved in 8 mL acetonitrile and added to 100 mL methyl tert-butyl ether, 
with stirring. The solution was stirred for 5 minutes and then left undisturbed for 1 hour, 
as precipitate slowly begins to form. The mixture was cooled gradually to -20 ˚C, filtered, 
and washed with cold methyl tert-butyl ether. The solid was dissolved in 
acetonitrile/water (90:10 v/v) and passed through a column of Amberlite-IRA 400 ion 
exchange resin (previously conditioned with sodium triflate). Acetonitrile was removed 
in vacuo. Water was removed by addition of acetonitrile and removal in vacuo, repeated 
three times. The oil was dissolved in 8 mL acetonitrile and added to 100 mL methyl tert-
butyl ether, with stirring. The solution was stirred for 5 minutes and then left undisturbed 
for 1 hour, as precipitate slowly begins to form. The mixture was cooled slowly to -20 ˚C, 
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filtered, and washed with cold methyl tert-butyl ether. The colorless solid was dried in 
vacuo (0.188 g, 22.5%). 1H NMR (CD3CN, 700 MHz, 298 K): δ 8.36 (br s, 1H), 8.22 (dd, 
J = 8.5 Hz, J = 1.8 Hz, 1H), 8.08 (d, J = 9.0 Hz, 2H), 7.88 (d, J = 8.9 Hz, 1H), 7.64 (d, J 
= 8.5 Hz, 1H), 7.54 (d, J = 2.5 Hz, 1H), 7.14 (dd, J = 8.9 Hz, J = 2.5 Hz, 1H), 7.12 (d, J = 
9.0 Hz, 2H), 3.87 (s, 3H), 3.86 (s, 3H), 3.37 (br s, NCH3), 3.13 (s, 3H from MTBE-
complex, 5%), 1.56 (s, 9H), 1.14 (s, 9H from MTBE-complex, 5%); 19F NMR (CD3CN, 
376 MHz, 298 K): δ -79.30; 13C NMR (CD3CN, 176 MHz, 298 K): δ 164.70, 164.68, 
162.39, 159.52, 159.50, 157.92, 149.26, 145.63, 139.57, 137.90, 134.95, 132.55, 127.92, 
124.91, 123.06, 121.23, 117.51, 105.50, 103.35, 85.28, 56.83, 56.65, 38.44; HRMS: 
(ESI) calcd. for C27H28IN2O4S [M-OTf]+ 603.0809 found 603.0795.  
 
2-(4-(N-tert-Butyloxycarbonyl-3-fluoro-N-methyl)phenyl)-6-benzothiazole (17): 
 
In a nitrogen-charged glove box, (2-(N-tert-butyloxycarbonyl-N-methyl)amino-5-(6-
methoxybenzothiazolyl))(4-methoxyphenyl)iodonium triflate (10.0 mg, 0.013 mmol) was 
dissolved in 0.6 mL acetonitrile-d3 in an NMR	 tube	 fitted	 with	 a	 Teflon	 screw	 cap	closure. 0.1 mL aliquot (0.0034 mmol, 0.25 eq.) of a stock solution of tetramethyl 
ammonium fluoride (3.2 mg, 0.034 mmol) in 1.0 mL acetonitrile-d3 was added. 1H- and 
19F-NMR were acquired and the solvent was removed in vacuo.  In a nitrogen-charged 
glove box, dry benzene-d6 (0.6 mL) was added and the tube was heated to 60 ˚C for 1 
hour in the dark (0.0028 mmol product, 82.8% yield, by internal 1H-NMR standard).  
N
SO
N
CH3
F O
O
 69 
Solvent was removed in vacuo, and the crude oil was chromatographed on silica 
(deactivated with triethylamine/hexanes (5:95 v/v)) with ethyl acetate/hexanes (20:80 
v/v) to yield a pale yellow oil. The product was crystallized from boiling hexanes, cooled 
to 0 ˚C, filtered, and washed with cold hexanes to yield a colorless solid (0.7 mg, 54.3%). 
 
Alternate method: In a nitrogen-charged glove box, (2-(N-tert-butyloxycarbonyl-N-
methyl)amino-5-(6-methoxybenzothiazolyl))(4-methoxyphenyl)iodonium triflate (8.0 
mg, 0.010 mmol) was dissolved in acetonitrile-d3 and a 0.1 mL aliquot (0.0025 mmol) of 
a stock solution of tetramethyl ammonium fluoride (2.6 mg, 0.028 mmol) in 1.0 mL 
acetonitrile-d3 was added. The solution was transferred to an NMR	 tube	 fitted	 with	 a	Teflon	 screw	 cap	 closure, 1H- and 19F-NMR were acquired, and the solvent was 
removed in vacuo. In a nitrogen-charged glove box, a solution of acetonitrile in benzene-
d6 (10% v/v) was added.  The NMR tube was heated, in the dark, at 100 ˚C for 10 
minutes. Product formation was confirmed, and found to be quantitative, by 1H and 19F-
NMR. 
 
Alternate method: In a 25 mL round bottom flask 2-(3-fluoro-4-(methylamino)phenyl)-6-
methoxybenzothiazole (9.9 mg, 0.0343 mmol) was dissolved in 1 mL THF. 
Dimethylamino pyridine (13.4 mg, 0.103 mmol) and triethylamine (15.3 µL, 0.137 
mmol) were added.  Di-tert-butyl dicarbonate (48.0 mg, 0.206 mmol) was added with 
stirring.  The solution was stirred for 2 days, under N2.  THF was removed in vacuo. The 
crude oil was chromatographed on silica (deactivated with triethylamine/hexanes (5:95 
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v/v)) with triethylamine/ethyl acetate/hexanes (1:10:89 v/v) to yield a waxy solid (8.8 
mg, 66.0%).  
 
1H NMR (CD3CN, 400 MHz, 298 K): δ 7.92 (d, J = 9.0 Hz, 1H), 7.85 (dd, J = 8.3 Hz, J = 
1.9 Hz, 1H), 7.83 (dd, J = 8.3 Hz, J = 1.9 Hz, 1H), 7.56 (d, J = 2.6 Hz, 1H), 7.45 (dd, J = 
8.5 Hz, J = 8.0 Hz, 1H), 7.14 (dd, J = 9.0 Hz, J = 2.6 Hz, 1H), 3.88 (s, 3H), 3.27 (br s, 
NCH3 rotomer), 3.20 (br s, NCH3 rotomer), 1.46 (br s, tert-butyl rotomer), 1.41 (br s, 
tert-butyl rotomer); 19F NMR (CD3CN, 376 MHz, 298 K): δ -120.89 (br s, 1F); HRMS: 
(ESI) calcd. for C20H21FN2NaO3S [M+Na]+ 411.1155 found 411.1161. 
 
2-(3-Fluoro-4-(methylamino)phenyl)-6-methoxybenzothiazole (18): 
 
In a nitrogen-charged glove box, 6-methoxybenzothiazole (70.1 mg, 0.425 mmol), 2-
fluoro-4-bromo-N-methylaniline (as a 50 mol% mixture with 2-fluoro-N-methylaniline) 
(167.7 mg, 1.02 mmol), palladium(II) acetate (4.8 mg, 0.0212 mmol), tri(tert-
butyl)phosphine (8.6 mg, 0.0425 mmol), and copper(I) bromide (12.2 mg, 0.0849 mmol) 
were dissolved in 4 mL dry DMF.  The mixture was transferred to a small airfree storage 
tube. Solid cesium carbonate (152.1 mg, 0.467 mmol) was added directly to the tube.  
The reaction was heated at 150 ˚C, with stirring, for 4 hours.  After cooling to room 
temperature the mixture was diluted with ether, and washed five times with water.  The 
aqueous layers were extracted three times with ether.  The combined organic layers were 
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washed with brine, dried over sodium sulfate, and filtered.  The solvent was removed 
in vacuo and the crude oil was chromatographed on silica with ethyl acetate/hexanes 
(15:85 v/v). The crude solid was dissolved in boiling hexanes, filtered hot, cooled to 0 ˚C, 
and filtered to yield a pale yellow solid (47.1 mg, 41.0%).  1H NMR (CD3CN, 400 MHz, 
298 K): δ 7.79 (d, J = 8.9 Hz, 1H), 7.67 (m, 2H), 7.48 (d, J = 2.6 Hz, 1H), 7.07 (dd, J = 
2.6 Hz, J = 8.9 Hz, 1H), 6.76 (d, J = 8.4 Hz, 9.0 Hz, 1H), 4.95 (br s, NH), 3.85 (s, 3H), 
2.88 (d, J = 5.2 Hz, 3H); 19F NMR (CD3CN, 376 MHz, 298 K): δ -139.57 (ddd, J = 11.9 
Hz, J = 8.2 Hz, J = 2.5 Hz, 1F); 13C NMR (CD3CN, 176 MHz, 298 K): δ 165.95, 158.55, 
152.77, 151.41, 149.63, 141.54, 141.47, 136.96, 125.52, 123.76, 122.40, 122.36, 116.31, 
113.35, 113.23, 111.98, 111.96, 105.63, 56.55, 56.54, 29.95; HRMS: (ESI) calcd. for 
C15H13FN2NaOS [M+Na]+ 311.0630 found 311.0642. 
 
Cole, G. B.; Keum, G.; Liu, J.; Small, G. W.; Satyamurthy, N.; Kepe, V.; Barrio, J. R. 
Proc. Natl. Acad. Sci. USA 2010, 107, 6222–6227. 
 
2-(3-Fluoro-4-(methylamino)phenyl)-6-hydroxybenzothiazole (19): 
 
In an oven-baked 25 mL Schlenk flask, 2-(3-fluoro-4-(methylamino)phenyl)-6-
methoxybenzothiazole (25.9 mg, 0.0898 mmol) was dissolved in 1 mL of anhydrous 
dichloromethane. The solution was chilled in an ice bath and boron tribromide (27.7 µL, 
0.269 mmol) was added dropwise. The ice bath was removed and the solution was 
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stirred, under N2, in the dark, overnight. Saturate aqueous sodium bicarbonate was 
carefully added dropwise, until bubbling subsided. 10 mL of methanol/dichloromethane 
(1:5 v/v) was added. The organic layer was separated and the aqueous layer was extracted 
twice with 10 mL of methanol/dichloromethane (1:5 v/v). The organic layers were 
washed twice with saturated aqueous sodium bicarbonate (5 mL). The organic layers 
were dried over sodium sulfate, and filtered. Solvents were removed in vacuo. The crude 
solid was recrystallized from boiling acetonitrile to yield a pale yellow solid (5.1 mg, 
20.7%). 1H NMR (CD3CN, 400 MHz, 298 K): δ 7.74 (d, J = 8.8 Hz, 1H), 7.66 (m, 2H), 
7.34 (d, J = 2.5 Hz, 1H), 7.29 (br s, 1H), 6.96 (dd, J = 8.7 Hz, J = 2.5 Hz, 1H), 6.77 (dd, J 
= 9.1 Hz, J = 8.4 Hz), 4.90 (br s, NH), 2.88 (d, J = 5.1 Hz, 3H); 19F NMR (CD3CN, 376 
MHz, 298 K): δ -139.57 (ddd, J = 11.9 Hz, J = 8.2 Hz, J = 2.5 Hz, 1F); 13C NMR 
(Methanol-d4 in Acetone-d6, 176 MHz, 298 K): δ 152.70, 151.34, 141.31, 141.26, 136.91, 
125.28, 123.85, 123.78, 122.57, 116.64, 116.28, 113.09, 112.97, 111.78, 111.76, 107.55, 
105.37, 56.22, 30.38; HRMS: (ESI) calcd. for C14H11FN2NaOS [M+Na]+ 297.0474 found 
297.0488. 
 
Cole, G. B.; Keum, G.; Liu, J.; Small, G. W.; Satyamurthy, N.; Kepe, V.; Barrio, J. R. 
Proc. Natl. Acad. Sci. USA 2010, 107, 6222–6227. 
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6-(Ethoxymethoxy)benzothiazole (21): 
 
In an oven-baked 100 mL Schlenk flask, under N2, 6-methoxybenzothiazole (1.00g, 
6.053 mmol) was dissolved in dichloromethane (20 mL) with stirring. The solution was 
cooled to 0 ˚C ice bath and boron tribromide (1.7 mL, 18.16 mmol) was added by 
syringe, dropwise. The ice bath was removed and the mixture was stirred, under N2, 
overnight. The reaction was quenched, with 0.5 mL deionized water, then carefully 
neutralized to pH 7 with saturated aqueous sodium bicarbonate. The organic layer was 
separated and the aqueous layer was extract twice with dichloromethane. The combined 
organic layers were washed with brine, dried over sodium sulfate, and filtered. 
Dichloromethane was removed in vacuo and the solid was dried under high dynamic 
vacuum. A portion of the solid (500 mg, 3.307 mmol) was dissolved in dry 
tetrahydrofuran (10 mL), in a 100 mL Schlenk flask, and chilled to 0˚ C with an ice bath. 
Under N2, powdered sodium hydride (83.3 mg, 3.472 mmol) was added in portions. The 
mixture was stirred for 15 minutes before chloromethyl ethyl ether (0.4 mL, 3.968 mmol) 
was added dropwise. The solution was allowed to warm to room temperature overnight. 
Saturated aqueous sodium bicarbonate (10 mL) was added and the mixture was diluted 
with ether. The organic layer was separated and washed four times with 2.0 M aqueous 
sodium hydroxide (to remove any residual starting material) and once with brine. The 
organic layer was dried over sodium sulfate, filtered, and solvents were removed in vacuo 
to yield a mostly colorless solid (93.5 mg, 13.5%). 1H NMR (CD3CN, 300 MHz, 298 K): 
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δ 8.94 (s, 1H), 7.96 (d, J = 8.9 Hz), 7.68 (d, J = 2.3 Hz, 1H), 7.20 (dd, J = 8.9 Hz, J = 
2.3 Hz, 1H), 5.28 (s, 2H), 3.71 (q, J = 7.1 Hz, 2H), 1.16 (t, J = 7.1 Hz, 3H); HRMS: (ESI) 
calcd. for C10H11NNaO2S [M+Na]+ 232.0408 found 232.0426. 
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1.6 NMR Spectra 
 
1H NMR (CDCl3, 400 MHz, 298 K) spectrum of 6-methoxybenzothiazole (7) 
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13C NMR (CDCl3, 100 MHz, 298 K) spectrum of 6-methoxybenzothiazole (7) 
  
  
20
0
18
0
16
0
14
0
12
0
10
0
80
60
40
20
0
pp
m
56.02
76.91
77.23
77.54
104.22
116.13
124.15
135.26
147.86
151.65
158.30
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
N
A
M
E
 
 
 
 
 
J
J
K
.
0
5
.
6
0
_
p
o
s
t
c
o
l
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
F
2
 
-
 
A
c
q
u
i
s
i
t
i
o
n
 
P
a
r
a
m
e
t
e
r
s
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 
2
0
1
3
0
7
0
9
T
i
m
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
5
.
5
3
I
N
S
T
R
U
M
 
 
 
 
 
 
 
 
 
 
 
s
p
e
c
t
P
R
O
B
H
D
 
 
 
5
 
m
m
 
P
A
B
B
O
 
B
B
/
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
z
g
p
g
3
0
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
5
5
3
6
S
O
L
V
E
N
T
 
 
 
 
 
 
 
 
 
 
 
C
D
C
l
3
N
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5
1
2
D
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4
S
W
H
 
 
 
 
 
 
 
 
 
 
 
2
4
0
3
8
.
4
6
1
 
H
z
F
I
D
R
E
S
 
 
 
 
 
 
 
 
 
0
.
3
6
6
7
9
8
 
H
z
A
Q
 
 
 
 
 
 
 
 
 
 
 
 
1
.
3
6
3
1
4
8
8
 
s
e
c
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
1
0
.
5
9
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
0
.
8
0
0
 
u
s
e
c
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
.
5
0
 
u
s
e
c
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
9
8
.
1
 
K
D
1
 
 
 
 
 
 
 
 
 
 
 
4
.
0
0
0
0
0
0
0
0
 
s
e
c
D
1
1
 
 
 
 
 
 
 
 
 
 
0
.
0
3
0
0
0
0
0
0
 
s
e
c
T
D
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 
f
1
 
=
=
=
=
=
=
=
=
S
F
O
1
 
 
 
 
 
 
 
 
1
0
0
.
6
2
2
9
9
5
3
 
M
H
z
N
U
C
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
3
C
P
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9
.
0
0
 
u
s
e
c
P
L
W
1
 
 
 
 
 
 
 
 
5
8
.
0
0
0
0
0
0
0
0
 
W
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 
f
2
 
=
=
=
=
=
=
=
=
S
F
O
2
 
 
 
 
 
 
 
 
4
0
0
.
1
3
2
2
6
0
5
 
M
H
z
N
U
C
2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
H
C
P
D
P
R
G
[
2
 
 
 
 
 
 
 
 
w
a
l
t
z
1
6
P
C
P
D
2
 
 
 
 
 
 
 
 
 
 
 
 
 
9
0
.
0
0
 
u
s
e
c
P
L
W
2
 
 
 
 
 
 
 
 
1
2
.
0
0
0
0
0
0
0
0
 
W
P
L
W
1
2
 
 
 
 
 
 
 
 
0
.
1
7
9
2
6
0
0
0
 
W
P
L
W
1
3
 
 
 
 
 
 
 
 
0
.
1
4
5
2
0
0
0
0
 
W
F
2
 
-
 
P
r
o
c
e
s
s
i
n
g
 
p
a
r
a
m
e
t
e
r
s
S
I
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
2
7
6
8
S
F
 
 
 
 
 
 
 
 
 
 
1
0
0
.
6
1
2
9
1
4
5
 
M
H
z
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
S
S
B
 
 
 
 
 
 
0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
.
0
0
 
H
z
G
B
 
 
 
 
 
 
 
0
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
.
4
0
NS
O
H
 77 
1H NMR (CDCl3, 400 MHz, 298 K) spectrum of 4-bromo-N-methylaniline (9) 
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13C NMR (CDCl3, 100 MHz, 298 K) spectrum of 4-bromo-N-methylaniline (9)   
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1H NMR (CDCl3, 400 MHz, 298 K) spectrum of 2-(4-(methylamino)phenyl)-6-
methoxybenzothiazole (12) 
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13C NMR (CDCl3, 100 MHz, 298 K) spectrum of 2-(4-(methylamino)phenyl)-6-
methoxybenzothiazole (12) 
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1H NMR (CD2Cl2, 400 MHz, 298 K) spectrum of 2-(3-iodo-4-(methylamino)phenyl)-
6-methoxybenzothiazole (13) 
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 13C NMR (CD2Cl2, 100 MHz, 298 K) spectrum of 2-(3-iodo-4-(methylamino)phenyl)-
6-methoxybenzothiazole (13) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of 2-(4-(N-tert-butyloxycarbonyl-3-
iodo-N-methyl)phenyl)-6-benzothiazole (14) 
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13C NMR (CD3CN, 100 MHz, 298 K) spectrum of 2-(4-(N-tert-butyloxycarbonyl-3-
iodo-N-methyl)phenyl)-6-benzothiazole (14) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of (2-(N-tert-butyloxycarbonyl-N-
methyl)amino-5-(6-methoxybenzothiazolyl))(4-methoxyphenyl)iodonium triflate (16) 
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13C NMR (CD3CN, 176 MHz, 298 K) spectrum of (2-(N-tert-butyloxycarbonyl-N-
methyl)amino-5-(6-methoxybenzothiazolyl))(4-methoxyphenyl)iodonium triflate (16) 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of (2-(N-tert-butyloxycarbonyl-N-
methyl)amino-5-(6-methoxybenzothiazolyl))(4-methoxyphenyl)iodonium triflate (16) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of 2-(4-(N-butyloxycarbonyl-3-fluoro-
N-methyl)phenyl)-6-benzothiazole (17) 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of 2-(4-(N-butyloxycarbonyl-3-fluoro-
N-methyl)phenyl)-6-benzothiazole (17) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of 2-(3-fluoro-4-
(methylamino)phenyl)-6-methoxybenzothiazole (18) 
 
-1
17
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
pp
m
2.870
2.883
3.853
4.947
6.743
6.764
6.787
7.051
7.057
7.073
7.080
7.478
7.484
7.654
7.659
7.669
7.689
7.781
7.803
0.52
0.51
0.51
1.01
0.51
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
N
A
M
E
 
 
 
 
 
J
J
K
.
0
6
.
8
9
_
r
e
c
r
y
s
t
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
F
2
 
-
 
A
c
q
u
i
s
i
t
i
o
n
 
P
a
r
a
m
e
t
e
r
s
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 
2
0
1
4
1
0
0
9
T
i
m
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
4
.
1
8
I
N
S
T
R
U
M
 
 
 
 
 
 
 
 
 
 
 
s
p
e
c
t
P
R
O
B
H
D
 
 
 
5
 
m
m
 
P
A
B
B
O
 
B
B
/
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
 
 
z
g
3
0
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
5
5
3
6
S
O
L
V
E
N
T
 
 
 
 
 
 
 
 
 
 
 
C
D
3
C
N
N
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8
D
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
S
W
H
 
 
 
 
 
 
 
 
 
 
 
 
8
0
1
2
.
8
2
0
 
H
z
F
I
D
R
E
S
 
 
 
 
 
 
 
 
 
0
.
1
2
2
2
6
6
 
H
z
A
Q
 
 
 
 
 
 
 
 
 
 
 
 
4
.
0
8
9
4
4
6
5
 
s
e
c
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
0
3
.
5
7
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
2
.
4
0
0
 
u
s
e
c
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
.
5
0
 
u
s
e
c
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
9
8
.
0
 
K
D
1
 
 
 
 
 
 
 
 
 
 
 
2
.
0
0
0
0
0
0
0
0
 
s
e
c
T
D
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
=
=
=
=
=
=
=
=
 
C
H
A
N
N
E
L
 
f
1
 
=
=
=
=
=
=
=
=
S
F
O
1
 
 
 
 
 
 
 
 
4
0
0
.
1
3
3
1
3
1
0
 
M
H
z
N
U
C
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
H
P
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
1
.
0
0
 
u
s
e
c
P
L
W
1
 
 
 
 
 
 
 
 
1
2
.
0
0
0
0
0
0
0
0
 
W
F
2
 
-
 
P
r
o
c
e
s
s
i
n
g
 
p
a
r
a
m
e
t
e
r
s
S
I
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
5
5
3
6
S
F
 
 
 
 
 
 
 
 
 
 
4
0
0
.
1
3
0
0
1
5
4
 
M
H
z
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
S
S
B
 
 
 
 
 
 
0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.
1
0
 
H
z
G
B
 
 
 
 
 
 
 
0
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
.
0
0
6.
7
6.
8
6.
9
7.
0
7.
1
7.
2
7.
3
7.
4
7.
5
7.
6
7.
7
7.
8
7.
9
8.
0
8.
1
pp
m
6.743
6.764
6.787
7.051
7.057
7.073
7.080
7.478
7.484
7.654
7.659
7.669
7.689
7.781
7.803
0.52
0.51
0.51
1.01
0.51
NS
O
N C
H 3
F
H
 91 
13C NMR (CD3CN, 176 MHz, 298 K) spectrum of 2-(3-fluoro-4-
(methylamino)phenyl)-6-methoxybenzothiazole (18) 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of 2-(3-fluoro-4-
(methylamino)phenyl)-6-methoxybenzothiazole (18) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of 2-(3-fluoro-4-
(methylamino)phenyl)-6-hydroxybenzothiazole (19) 
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13C NMR (Methanol-d4 in Acetone-d6, 176 MHz, 298 K) spectrum of 2-(3-fluoro-4-
(methylamino)phenyl)-6-hydroxybenzothiazole (19) 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of 2-(3-fluoro-4-
(methylamino)phenyl)-6-hydroxybenzothiazole (19) 
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CHAPTER 2 
SYNTHESIS OF A VARIETY OF QUATERNARY α-ALKYL α-ARYL AMINO 
ACIDS 
 
2.1 Introduction 
We have utilized hypervalent iodine chemistry to synthesize a variety of fluorinated 
and iodinated PET radiotracers and radiopharmaceuticals.  These compounds can be used 
to diagnose and monitor diseases such as Parkinson’s (L-DOPA), Alzheimer’s 
(Flutemetamol), cancer, and others.  Many of the radiotracers we have targeted for cancer 
diagnostics are amino acids (since tumor cells have a higher uptake and metabolism of 
amino acids).  During this research we have gained an appreciation for the synthesis of 
amino acids. 1   As we studied the chemistry of hypervalent iodine complexes and 
continued to develop better methodology we discovered we could use diaryliodonium 
salts to deliver a variety of functional groups (as anions) to a target arene.  Provided the 
anions were moderately weak soft bases (pKa typically lower than 12), 2  we could 
generate a large variety of functionalized arenes.  Using stabilized carbon enolates we 
could generate quaternary α-nitro α-alkyloxycarbonyl arenes that could be reduced and 
hydrolyzed to the analogous quaternary α-amino acid (Scheme 2.1). 
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Scheme 2.1: Synthesis of aryl nitro esters and their reduction/hydrolysis 
 
Unlike most naturally-occurring amino acids, which feature a tertiary α-carbon, 
oxidation pathways that involve abstraction of the proton on the α-carbon are prevented 
on quaternary non-proteinogenic amino acids.3  They have no enolizable proton, so for 
enantioenriched amino acids, racemization is not possible.  Because of this they show 
remarkable stability in vivo, and can be useful for studying enzyme mechanisms, acting 
as enzyme inhibitors.  They have been studied as metabotropic glutamate antagonists, 
part of conformationally constrained thrombin inhibitors, selective ß3 adrenergic receptor 
agonists, sacrificial amine sources for studying dialkylglycine decarboxylase mimics, 
PLP enzyme inactivators, etc. 4 – 12   From a synthetic chemistry perspective these 
compounds are of interest due to the challenge of constructing functionalized quaternary 
stereocenters.  Finally, in studying the formation of the α-nitro, α-alkyloxycarbonyl 
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precursors, during thermolysis of diaryliodonium salts, we can gain more insight into the 
mechanism of hypervalent iodine thermolysis.   
 
2.1.2 Existing Strategies  
In general, there is a wide variety of reported routes to quaternary α-amino 
acids,7–19 though synthesis of α-arylated amino acids has historically been challenging.20  
The Petasis Reaction, a name reaction to form substituted amines, using an amine, 1,2-
diketone, and boronate ester, produces quaternary amino acids (containing substituted 
amines).  Many routes are fairly complex, and involve addition of an aryl or alkyl group 
as a strong nucleophile (ArMgX, ArLi, etc.) or as an electrophile,19 often involving heavy 
metal catalysts (that can be toxic if the products are used in vivo) or reactions that can be 
dangerous, low yielding, or difficult to scale up commercially.  Many are of limited 
scope, some requiring a drastically different synthesis for different amino acids (i.e. 
simultaneously varying the aryl group and the alkyl group requires a new synthesis), or 
are limited to substituted amines.  Demand for quaternary amino acids is high and new 
methods continue to be developed;13–17 for example, a recent development, by Kozlowski 
and co-workers, involves a tandem α-alkylation (using a Grignard reagent) and 
α-allylation (using a palladium catalyst), to synthesize α-allyl α-aryl α-amino acids, a 
previously inaccessible class of quaternary α-amino acids.18  
 Our process involves a convergent synthesis, utilizing aryl iodonium salts that are 
already commercially available (e.g. bis(aryl)iodonium hexafluorophosphates) or facile to 
synthesize.1, 21   The alkyl component is also commercially available or facile to 
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synthesize.  Reduction can be done under mild, non-toxic conditions (e.g. zinc catalyzed 
reduction), and ester hydrolysis can be performed under basic or acidic conditions.  Over 
all steps, using commercially available starting materials, our yields average 70%. 
Various reactions with diaryliodonium salts and stabilized enolates (e.g. 
diketones, diesters, nitroalkanes) have been reported.22,23  Often these routes are plagued 
with long reaction times, harsh conditions, or small substrate scope.  Due to our previous 
work with diaryliodonium salts21 we are able to modify these syntheses and improve 
reaction times and yields.  By switching to less polar solvents and lower temperatures, 
yields are often improved.  Though carbon-carbon bond forming reactions are reported 
with diesters22 and with nitroalkanes,23 at the onset of this project no reactions were 
reporting using nitroesters.  Direct arylation of a nitroester would offer a new method for 
rapidly producing quaternary α-alkyl α-aryl amino acids. 
 
2.2 Results and Discussion 
 
2.2.3 Preparation and Thermolysis of Hypervalent Iodine Complexes 
We first began by testing the thermolysis of an symmetrical electron-rich 
iodonium salt, bis(4-methoxyphenyl)iodonium triflate (1).  Dimethyl methylmalonate (2) 
was chosen as a synthon for the anion to be delivered.  This compound was synthesized 
by deprotonation of commercially available dimethylmalonate, followed by reaction with 
iodomethane (Scheme 2.2). 
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Scheme 2.2: Synthesis of dimethyl methylmalonate 
 
The resulting diester was reacted with sodium methoxide to generate a stable enolate.  
Using what have become fairly standard conditions in our lab,21 the enolate was mixed 
with the iodonium salt in a non-polar solvent (e.g. benzene) and heated, under nitrogen 
and in the dark.  Because the sodium enolate (1,3-dimethoxy-2-methyl-1,3-dioxopropan-
2-ide, 3) is fairly insoluble in non-polar solvents such as benzene, the reaction was run at 
140 ˚C in a sealed NMR tube fitted with a Teflon screw cap closure; however, as will be 
explained later, phase transfer catalysts were used with the nitroesters, facilitating much 
lower thermolysis temperatures.  Formation of the product was monitored by 1H-NMR.  
Due to resonance, three atoms carry a negative charge in the enolate structure (Figure 
2.1).  We were concerned that arylation could also occur at either of the oxygens. 
 
O
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O
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O
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Figure 2.1: Resonance of the enolate, 3 
 
Computational methods were employed to investigate the highest occupied molecular 
orbital (HOMO) of the enolate.  A malonic acid anion was used as a simplified structure.  
The structure was optimized using GAMESS24,25 to determine the ground state geometry.  
A 3D orbital map was plotted (Figure 2.2). 
2 
42% 
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Figure 2.2: 3D orbital map of malonic acid HOMO (B3LYP/6-311G) 
 
Acting as a nucleophile, electrons could be donated from either the carbonyl oxygens or 
the α-carbon.  The Pz orbital coefficient on the α-carbon is slightly larger (0.300) than 
either of the carbonyl oxygens (0.195), so presumably reaction would prefer carbon bond 
formation.  Also, in theory the the hard-hard interaction of the sodium and the triflate 
anion would favor exchange, and soft-soft interaction of the iodonium center and the 
carbanion should be favored over the soft-hard interaction of the iodonium center and the 
oxygens.  As thermolysis of diaryliodonium triflates occurs very slowly,26 so thermolysis 
will effectively only take place on the intermediate complex, A (Scheme 2.3). 
O
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Scheme 2.3: Synthesis of dimethyl 2-(4-methoxyphenyl)-2-methylmalonate (4) 
 
Only one ester product was produced (along with 4-iodoanisole).  NMR analysis of the 
product showed that both esters remained equivalent, suggesting that arylation occurred 
only at the carbon center. 
Next, a methodology for synthesizing α-nitroester enolates was developed.  Some 
α-nitroesters are commercially available, but most are expensive.  However, most of 
these compounds can be synthesized from the much less expensive α-bromoesters 
(Scheme 2.4).  Phloroglucinol (1,3,5-trihydroxybenzene) is added to scavenge an 
undesired nitrite ester by-product.   Kornblum and co-workers note that a combination of 
nitroester, nitrite ester, and sodium nitrite (acting as a base), promotes conversion of 
nitroester product to an analogous oximinoester.27  Ethyl 2-nitropropionate (5) and ethyl 
2-nitrobutyrate (6) were synthesized in moderate scale (10–20 g).28  Synthesis of ethyl 
nitroacetate, by this method, proved unsuccessful, so a small amount was purchased.  
4 
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Kornblum and co-workers,29 report that reaction of ethyl nitroacetate (prepared from 
ethyl acetoacetate30) with sodium nitrite becomes highly exothermic and produces carbon 
dioxide, nitrous oxide, and nitrogen.31  Reaction of ethyl bromoacetate, with temperature 
control, does not form ethyl nitroacetate, but rather yields only minor amounts of oxalic 
acid. 
 
R
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O
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Scheme 2.4: Synthesis of α-nitroesters 
 
Purification was initially performed by fractional vacuum distillation to remove the 
unreacted α-bromoester (forerun), and separate the product (middle fraction) from the 
solid phloroglucinol, sodium nitrate, and other impurities (tail).   
Due to the strongly electron withdrawing nitro group, these esters are even more 
acidic (pKa 9.1 for ethyl nitroacetate in DMSO32) than diesters (pKa 18.0 for dimethyl 
methylmalonate in DMSO33).  A variety of deprotonation conditions were evaluated 
(LDA, sodium hydride, aqueous carbonate, etc).  Deprotonation in dry ethanol using 
sodium ethoxide generated the pure enolate (sodium 1-ethoxy-2-nitroethenolate (7), 
sodium 1-ethoxy-2-nitropropenolate (8) and sodium 1-ethoxy-2-nitrobutenolate (9))  
under mild conditions, and was chosen for scaling up the synthesis of these enolates.  
R = Me: 76% 
R =   Et: 75% 
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Commercial sodium ethoxide may be used, but minor impurities imparted a yellow tint to 
the product, so sodium ethoxide was instead made in situ by adding freshly cut sodium 
metal to cold ethanol.   
Thermolysis of diaryliodonium salts using these enolates showed a small 
(typically less than 10%) formation of nitroarene (e.g. nitrobenzene, 4-nitrotoluene, 4-
nitroanisole).  The identify of this impurity was confirmed by 1H NMR (by doping each 
reaction with an aliquot of commercially obtained nitroarene) and GC-MS.  No 
mechanism could be deduced to directly deliver a nitro group from the ester.  It was 
found that thermolysis of bis(phenyl)iodonium hexafluorophosphate in the presence of 
sodium nitrite at 80 ˚C slowly formed 4-nitroanisole (Scheme 2.5). 
 
I PF6 NaNO2
CD3CN, 80 ˚C
NO2 I
 
Scheme 2.5: Formation of nitrobenzene 
 
To our knowledge this is the first example of formation of nitroarenes via iodonium salts.  
Passing the previously purified α-nitroesters through a silica column before deprotonation 
significantly reduced formation of the nitroarene side-product. 
 We have developed a variety of methods to generate diaryliodonium salts.  The 
salt used for initial testing, bis(4-methoxyphenyl)iodonium triflate, 1, can be made by 
oxidation of 4-iodoanisole to bis(acetoxy)4-iodoanisole (10) using sodium periodate,34 
followed by an electrophilic aromatic substitution on 4-iodoanisole, activated by triflic 
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acid.35  It is believed the coupling reaction proceeds by a substitution of one of the 
acetates by triflate (Scheme 2.6).  
 
I
O
1.03 eq. NaIO4
2.2 eq. NaOAc
AcOH/Ac2O
115 ˚C, 2.5 h
I(OAc)2
O
O
4 eq.
1.1 eq. TfOH
CH2Cl2, -10 ˚C
I OTf
O
O
O
1.05 eq.
1.05 eq. TMS-OTf
CD3CN, r.t.
BF3K I OTf
O
O
 
Scheme 2.6: Synthesis of bis(4-methoxyphenyl)iodonium triflate (1) 
 
The electron-rich anisole ring quickly adds to this highly electrophilic iodonium center.  
This coupling step must be run carefully (-10 ˚C, slow addition, excess anisole) or rapid 
decomposition occurs (observed as a vibrant blue color that quickly deepens to black), 
presumably due to a second substitution of acetate with triflate to form an extremely 
reactive electrophile.  In an effort to improve this yield, and scale up this and similar 
salts, milder coupling conditions were developed, by reacting 10 (synthesized as above), 
commercially available potassium 4-methoxyphenyltrifluoroborate, and a milder 
activating agent, trimethylsilyl trifluoromethanesulfonate (TMS-OTf).  
 Other symmetrical diaryliodonium salts can be purchased commercially.  For 
iodonium thermolysis reactions run with [18F]fluoride (for Positron Emission 
Tomography), using triflate as a counterion is highly preferred as 18F-19F exchange can 
occur with other anions such as tetrafluoroborate (BF4-) or hexafluorophosphate (PF6-).  
10 
1 
1 
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For these reactions this is not an issue, so both triflate salts and hexafluorophosphate salts 
were used interchangeably.  Three symmetrical diaryliodonium salts were 
purchased/synthesized (Figure 2.3), bis(phenyl)iodonium hexafluorophosphate, bis(4-
methylphenyl)iodonium hexafluorophosphate, bis(4-methoxyphenyl)iodonium triflate 
(1), providing a range of arene electron density from neutral to electron-rich.  In order to 
test an electron-poor example, the synthesis of bis(4-nitrophenyl)iodonium 
hexafluorphosphate was attempted.  Although this compound is listed in literature, only 
one successful synthesis is reported.36  This report cites methodology that mentions the 
difficulty of producing highly electron-deficient symmetrical diaryliodonium salts (due to 
the system being too unreactive with electron-poor substrates) and does not report 
synthesis of any diaryliodonium salts as electron-deficient as bis(4-
nitrophenyl)iodonium. 37   All attempts to synthesize this compound, using 4-
iodonitrobenzene and bis(acetoxy)-4-nitrobenzene (11) in our hands provided only an 
impure sample of 4-iodonitrobenzene.  Based on NMR spectra taken during reaction, it is 
suspected that this highly electron-poor iodonium salt may have been generated, but have 
been too unstable to isolate.  Instead, an asymmetrical salt was synthesized, (4-
methoxyphenyl)(4-nitrophenyl)iodonium hexafluorophosphate (12).  The drastic 
electronic difference between the withdrawing nitro group and the donating methoxy 
group would ensure a strong regiochemical preference for elimination of 4-iodoanisole 
rather than 4-iodonitrobenzene.   
 
107 
I PF6 I
PF6 I
OTf
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Figure 2.3: List of diaryliodonium salts used 
 
 Initially the thermolysis reactions were performed in benzene-d6.  A non-polar 
solvent was chosen as with many anions polar solvents tend to promote detrimental side-
reactions (presumably disproportionation).21  Due to the low solubility of the sodium 
enolates in non-polar solvents a high thermolysis temperature, 140 ˚C, was used.  This 
resulted in relatively short reaction times (30 minutes), but also promoted formation of 
nitroarene.  At lower temperature side-reactions are minimized, but solubility of the 
sodium enolates is significantly worse.  Running the thermolysis in a more polar solvent, 
acetonitrile-d3, made little change.  The sodium enolates are somewhat more soluble, but 
not enough to make a significant difference in the necessary temperature.   
We therefore turned to the use of a phase transfer catalyst.  For fluorination 
reactions, more soluble fluoride sources (e.g. TBAF rather than KF) improve reaction 
times and yield.38  Following a similar approach, TBA (tetra n-butyl ammonium) salts 
were added (Table 2.1). 
 
12 1 
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I PF6
H3C
CH3
H3C
O
OEt
NO2Na
1.05 eq
TBA-X
CD3CN, 80 ˚C
H3C
O2N
OEt
O
CH3 CH3
I
 
Phase Transfer Catalyst Equivalents Conversion after 1 h 
TBACl 0.25 91% 
TBACl 1.05 86% 
TBAOTf 0.25 87% 
TBAOTf 1.05 89% 
 
Table 2.1: Phase transfer catalysts added 
 
A substoichiometric amount of TBACl was found to increase reaction rate the 
most.  Using a superstoichiometric amount of TBACl actually slowed the reaction.  It is 
possible that a large amount of chloride anions forms a large amount of the corresponding 
diaryliodonium chloride, which precipitates out of solution.  Diaryliodonium chloride 
salts are highly crystalline, fairly insoluble, and react very slowly.  However, some 
chloride seems to be beneficial as it pairs strongly with sodium.  Since sodium chloride is 
nearly insoluble in organic solvents, its precipitation may drive exchange, forming the 
more soluble iodonium enolate intermediate (Scheme 2.3, structure A).  TBAOTf 
presumably does not work as well due to the lower affinity for sodium and triflate, and 
the higher solubility of sodium triflate in organic solvents.  With the addition of a phase 
transfer catalyst, the reaction can be run at lower temperature (80 ˚C), and although 
thermolysis is slower, side-products are minimized. 
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 With this methodology established, a variety of reactions were run (Table 2.2) to 
produce arylnitroesters 13–20.  The methodology was also used by a co-worker, Jordan 
Veness, toward the synthesis of a quaternary tryptophan analog.39  A slight excess of the 
sodium enolate was used (as it’s low solubility makes it easy to remove after reaction) 
and the reaction was monitored by 1H NMR, monitoring disappearance of the 
diaryliodonium salt.  After thermolysis was complete, solvent was removed.  The two 
thermolysis products, iodoarene and the arylnitroester, are moderately soluble in non-
polar solvents, such as hexanes, while other products (sodium salts, TBA salts, and 
excess enolate) are insoluble.  The polarity difference between the iodoarene and the 
arylnitroester makes separation possible by silica column chromatography.  It was later 
discovered that the iodoarene makes only a minor impact on the subsequent synthetic 
steps (nitro reduction and ester hydrolysis); chromatography could be skipped, if desired.  
As expected, the more electron-rich diaryliodonium salts reacted more slowly 
(electron-donating ligands are able to stabilize the iodine(III) center).  The most electron-
poor diaryliodonium salt, (4-methoxyphenyl)(4-nitrophenyl)iodonium 
hexafluorophosphate (12), proceeded to react at lower temperatures, so thermolyses with 
this salt were run at 35 ˚C.  Reactions with longer chain enolates (butyrate esters vs. 
propionate esters) tended to react slightly faster.  Though these enolates have a slightly 
higher solubility, presumably this is primarily due to the extra steric bulk, which 
promotes reductive elimination from the iodonium center.   
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2.2.4 Reaction Kinetics 
Isolated yields were found to be somewhat lower than yields based on NMR 
integrations (Table 2.2).  The nitroesters are volatile, and presumably some yield may be 
lost due to removing solvents and iodoarene under high vacuum.  Yields of the 
arylnitrobuyrate esters tend to be higher, attributed to a potentially lower volatility of the 
longer chain ester and slightly higher solubility in the nonpolar solvent used to extract the 
product from the reaction mixture.  As the more electron-rich diaryliodonium salts react 
more slowly, longer reaction times are required, allowing for the possibility of more side-
product formation, contributing to lower yields for the nitroesters formed from bis(4-
methoxyphenyl)iodonium triflate (1). 
 
I X
R R
1.05 eq. Na
O2N
R'
OEt
O
0.25 eq. TBACl
CD3CN, ∆
I
R
NO2
R' CO2Et
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Diaryliodonium Salt Sodium Enolate Product Time (h) 
% 
Yield 
I PF6
 
O2N
Me
OEt
O
Na  
 
4a 73% 
I PF6
 
O2N
Et
OEt
O
Na  
 
3.5a 93% 
13 
14 
NO2
Me CO2Et
NO2
Et CO2Et
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10.5a 78% 
I PF6
 
O2N
Et
OEt
O
Na  
 
12.5a 92% 
I OTf
MeO
OMe  
O2N
Me
OEt
O
Na  
 
22a 66% 
I OTf
MeO
OMe  
O2N
Et
OEt
O
Na  
 
20a 67% 
I PF6
MeO
NO2  
O2N
Me
OEt
O
Na  
 
7b 95% 
I PF6
MeO
NO2  
O2N
Et
OEt
O
Na  
 
7b 98% 
a Reaction run at 80 ˚C  b Reaction run at 35 ˚C 
 
Table 2.2: Formation of arylnitroesters 
 
 Once the arylnitroesters were synthesized, they needed to be reduced (nitro to 
amine) and hydrolyzed (ester to carboxylic acid).  As amino acids are always charged 
15 
16 
17 
18 
19 
20 
1 
1 
12 
12 
NO2
Me CO2Et
NO2
Me CO2Et
MeO
NO2
Et CO2Et
MeO
NO2
Me CO2Et
O2N
NO2
Et CO2Et
O2N
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(anionic carboxylate when basic, cationic ammonium when acidic, or zwitterionic at their 
pI), purification in the last step could be more challenging.  In my experience with the 
benzimidazole class of radiotracers (Chapter 3), I found the hydrolysis step to run more 
cleanly than the reduction step.  In addition, α-nitro carboxylic acids are prone to 
decarboxylation.40  For these reasons the nitro group reduction was run first, followed by 
ester hydrolysis. 
 Nitro groups have a fairly high reduction potential,41 and therefore are one of the 
easiest functional groups to reduce.42   Mild reductions were investigated.  Although 
Béchamp reductions (Fe0, acid)43 worked well for the benzimidazole class of radiotracers 
(Chapter 3), and there are many references for the reduction of nitroarenes, reduction on 
nitroalkanes are mentioned rarely in literature.44  Attempts to reduce arylnitroesters using 
iron in acetic acid or hydrochloric acid showed little to no conversion.  Zinc reduction 
worked quickly and was highly selective to the nitro group.  Although it requires the use 
of concentrated hydrochloric acid, it is a relatively mild reduction method that can be run 
below room temperature.  The reduction is run to completion using an excess of zinc 
metal, added in portions at 0 ˚C.  Zinc salts can be removed by neutralizing the mixture 
with aqueous sodium bicarbonate, switching to a less polar organic solvent, e.g. 
dichloromethane, filtering through a membrane filter (PTFE, 0.2 µm), and washing with 
water.  The resulting arylaminoesters can be chromatographed and characterized (e.g. 
ethyl 2-(4-methylphenyl)-2-aminopropanoate, 21), but it was found that moving forward 
without chromatography did not impact the next step. 
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 Hydrolysis was performed under basic conditions, to ensure quick and complete 
hydrolysis of the ester.  The arylaminoesters are not very soluble in aqueous media, so a 
small portion of ethanol was added to facilitate dissolution.  The mixture is stirred 
vigorously and once the arylaminoester (an oil) is fully dissolved the reaction is 
monitored by 1H NMR, observing the disappearance of ethyl ester protons.  Ethanol was 
removed in vacuo.  The resulting amino acid is moderately soluble in aqueous solution, 
so liquid-liquid extractions proved ineffective to isolate the product.  Amino acids are 
often purified by ion-exchange chromatography, though we chose not to apply that 
technique here.  Since the impurities present were found to be much more soluble in 
organic solvents than the desired amino acid product, the basic reaction mixture was 
simply washed several times with diethyl ether or dichloromethane.  Isolation of the 
amino acid was performed by crystallization out of solution at the isoelectronic point, pI.  
Under basic pH the carboxylic acid is deprotonated, increasing aqueous solubility.  Under 
acidic pH the amine is protonated, also increasing aqueous solubility.  At the 
isoelectronic point, or isoionic point, both the amine is protonated and the carboxylic acid 
is deprotonated.  This net neutral, zwitterionic species is least soluble in aqueous media 
(Figure 2.4).  The pI can be determined by placing the amino acid in an electric field and 
adjusting pH until the amino acid no longer migrates.  Natural amino acids with neutral 
side chains have isoelectronic points within a narrow range (5.5 to 6.0);45 presumably the 
pI for these unnatural amino acids does not deviate significantly from this range.  The 
solutions were carefully neutralized to about pH 5 with hydrochloric acid, concentrated in 
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vacuo, and chilled to near freezing to allow crystallization of the amino acid.  The amino 
acid products, 22–29, were isolated by filtration and washed with ice-cold water.   
 
NH2
R'
O
O
R
+ HCl
+ NaOH NH3
R'
O
O
R
+ HCl
+ NaOH NH3
R'
OH
O
R  
Figure 2.4: Amino acids at varying pH 
 
For the two amino acids generated from (4-methoxyphenyl)(4-nitrophenyl)iodonium 
hexafluorophosphate (28 and 29), the nitrophenyl is also reduced during the zinc 
reduction, as expected.  As the side chain (aniline) is no longer a neutral side chain, a 
slightly higher pH of 6 was used.   
Zinc reduction and acidic hydrolysis successfully produced the desired quaternary 
amino acids, 22–29, in good to excellent yields (Table 2.3).  The products were 
characterized by HR-MS, 1H, and 13C NMR.  Although isolation was performed at the 
predicted pI (due to the solubility being lowest at this point), characterization by NMR 
was often done at much higher pH.  During initial 13C-NMR acquisitions of the isolated 
(pH = 5–6) it was found that the quaternary carbon and even more so the adjacent carbon 
on the alkyl chain relaxed extremely slowly.  Setting relaxation delays of >15 seconds 
were required, suggesting an approximate T1 of about 3 seconds.  Basifying the NMR 
solutions with sodium hydroxide to pH 11 (pKa of the protonated amine + 2) allowed for 
significantly shorter relaxation delays (typically 2–3 times shorter). 
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1. Zn, HCl, 
    EtOH/H2O
2. NaHCO3 (aq.)Ar NO2
CO2EtR
Ar NH2
CO2EtR
1. NaOH
    EtOH/H2O
2. HCl (aq.) Ar NH2
COONaR
 
Ar R Yield (over 2 steps)  Ar R 
Yield 
(over 2 steps) 
Ph Me 88%  4-MeOPh Me 81% 
Ph Et 88%  4-MeOPh Et 85% 
4-MePh Me 87%  4-NO2Ph Me 78% 
4-MePh Et 77%  4-NO2Ph Et 76% 
 
Table 2.3: Reduction and hydrolysis of arylnitroesters 
  
2.2.5 Chirality 
 With methodology established for readily synthesizing quaternary α-alkyl α-aryl 
amino acids, we sought to develop a way to stereoselectively generate a single 
enantiomer.  One approach, utilizing the last step of the synthesis (the hydrolysis) would 
be to stereospecifically hydrolyze the ester using an esterase.  While this approach could 
work, it would be limited to a maximum yield of 50%.  We instead chose to investigate 
using a chiral directing group on the iodonium salt to selectively deliver the nitroester to 
one face of the target arene.  Based upon research developed by several former members 
of our group,46,47 [2.2]paracyclophane may be used as a regiochemical directing group in 
diaryliodonium salts.  This strategy utilizes out-of-plane steric hindrance, as well as 
electronic effects, to promote reductive elimination of iodocyclophane in iodonium salt 
thermolysis (Figure 2.5).   
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Figure 2.5: Thermolysis of a cyclophane-containing diaryliodonium salt 
 
As cyclophanes exhibit planar chirality, we sought to use this as a chiral directing group.  
In Figure 2.6, structures A and B are enantiomers.  The iodine and methoxy groups have 
been moved to the other phenyl ring of the cyclophane.  If these structures are simply 
rotated along the z-axis, A (rotated) is analogous to B, and B (rotated) is analogous to A; 
however, the ethane bridges on the cyclophanes are oriented differently.  This difference 
in the cyclophane orientation implies a difference to each face of the phenyl ring and to 
each face of the other ligand (X = OTf, PF6, nitro ester enolate). 
 
117 
 
IMeO X
IMeO X
enantiomers
rotate
OMeIX
I OMeX
 
Figure 2.6: Cyclophane phenyl iodonium salt enantiomers 
 
If the energy difference between these faces is sufficiently high during iodonium salt 
thermolysis, an excess of one of the two product enantiomers will be observed.  Isolating 
a single cyclophane enantiomer and synthesizing an enantiomerically pure 
diaryliodonium salt could potentially be used to stereoselectively generate quaternary 
α-alkyl α-aryl nitroesters, and would also be the first example of a diaryliodonium salt 
being used for enantiocontrol. 
In order to ensure thermolysis using a cyclophane and an enolate would be 
successful, a racemic diaryliodonium salt was first synthesized.  Following the approach 
used previously in our lab, 47, 48  4-methoxy-[2.2]paracyclophane (30) was synthesized 
A 
A 
(rotated) 
B 
B 
(rotated) 
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(Scheme 2.7).  Commercially available [2.2]paracyclophane was brominated to form 31.  
Lithium/halogen exchange, quenching  with trimethoxyborane, and oxidation using 
hydrogen peroxide forms 4-hydroxy-[2.2]paracyclophane (32).  Methylation with methyl 
iodide under basic conditions generates 4-methoxy-[2.2]paracyclophane (30). 
 
1. 1.1 eq nBuLi, 
    ether, -78 ˚C, 1 hr
2. 2 eq. anhydrous ZnCl2
    ether, -78 ˚C to r.t.
3. 1.5 eq. RPhI(OAc)2,
    CH3CN, -20 ˚C, 30 min
4. 2 eq. NaPF6, H2O
1.05 eq. NIS
1.05 eq. TFA
DCM, r.t., 1 h
1. 3 eq. K2CO3, MeCN, 
    80 ˚C, 30 min
2. 3 eq. MeI, 80 ˚C,
    MeCN, 3 d
1. 2.5 eq. tBuLi
   ether, -78 ˚C, 30 min
   0 ˚C, 30 min
2. 2 eq. B(OMe)3, r.t.,
    1 h
3. H2O2, NaOH, o/n
(±)(±)
Br OH
OMe I OMe
IF6P
R
(±)(±)
1.05 eq. NBS
1.05 eq. TFA
DCM, r.t.
OMe
(±)  
 
 
Scheme 2.7: Synthesis of racemic diaryliodonium salts (R=H, OMe) 
 
The previous approach utilized a brominated cyclophane (7-bromo-4-methoxy-
[2.2]paracyclophane) to synthesize the diaryliodonium salt (using lithium-halogen 
exchange).  A synthesis of an iodinated cyclophane, 7-iodo-4-methoxy-
[2.2]paracyclophane (33), was developed in an effort to improve the final synthesis step 
(generation of the diaryliodonium salt).  This could potentially open up the ability to use 
milder metalation methods (e.g. halogen-metal exchange using a Grignard reagent).  This 
route also allows recycling of the cyclophane group after thermolysis — thermolysis 
31 32 
30 47 
82% 
quantitative 
46% 84% 
R = MeO (36): 73% 
R =      H (37): 62% 
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forms the desired product and also eliminates 7-iodo-4-methoxy-[2.2]paracyclophane 
(47).   
 Formation of diaryliodonium salts can be challenging.  Intermediate salts can be 
unstable in the presence of strong nucleophiles (such as metalated arenes).  Purification is 
typically done using recrystallization (as normal phase chromatography of highly polar 
salts is impractical) and highly impure diaryliodonium salts can easily oil out of solution.  
There are a variety of methods available for synthesizing these salts, but in our 
experience most of these methods are not conducive for synthesizing cyclophane-
containing diaryliodonium salts.  A complex approach using an organozinc reagent 
(generated in situ) was previously used for this salt.  Unfortunately, this approach gave 
fairly low yields and due to several potential sources of water/oxygen contamination gave 
inconsistent results.  A variety of approaches were taken (Scheme 2.8).  Attempts to form 
the aryl stannane were previously unsuccessful (presumably due to the steric bulk of the 
large tin atom and the cyclophane).  Oxidation of iodine with Selectfluor®, using 
conditions we had previously developed for other iodoarenes,1 proved unsuccessful; ring-
opening and polymerization appeared to occur.   
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1. 1.1 eq. nBuLi, THF
   - 78 ˚C
2. 2 eq. MeOPhI(OAc)2
  THF,  -78 ˚C to r.t.
3. NaOTf, H2O/MeOH
1. 1.1 eq. nBuLi, THF
   - 78 ˚C
2. 2 eq. MgBr2, THF,
   -78 ˚C
3. 2 eq. MeOPhI(OAc)2
  THF,  -78 ˚C to r.t.
4. NaOTf, H2O/MeOH
Br
(MeO)3B
1. 2.5 eq. tBuLi, ether
   - 78 ˚C to 0 ˚C
2. 3 eq. B(OMe)3
   -78 ˚C to r.t.
unstable
1. 1.1 eq. nBuLi, THF
   - 78 ˚C
2. 2 eq. CuBr, THF,
   -78 ˚C
3. 2 eq. MeOPhI(OAc)2
  THF,  -78 ˚C to r.t.
4. NaOTf, H2O/MeOH  
Scheme 2.8: Attempts to form cyclophane salt 
 
Formation of a [2.2]paracyclophane boronate ester (34), as a model compound, was 
successful.  As trifluoroborate salts are often more shelf stable, and also more 
nucleophilic,49 the boronate ester was converted to the potassium trifluoroborate salt 
before isolation.  Presumably the salt either was formed and instantly underwent 
elimination (to form unsubstituted [2.2]paracyclophane), or presence of a proton source 
caused cleavage of the carbon-boron bond.  After thorough investigation, it was found 
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that simply stirring the boronate ester in methanol or even moderately wet acetonitrile 
promoted formation of unsubstituted [2.2]paracyclophane.  Due to this observation, it 
was suspected that the boronate ester may be reactive enough to directly couple with an 
iodonium center (e.g. bis(acetoxy)4-iodoanisole, 10).  Reaction of the crude boronate 
ester resulted only in reduction of 10 to 4-iodoanisole, presumably due to the presence of 
methoxide anions (remaining from formation of the boronate ester with 
trimethoxyborate).  However, all attempts to isolate the boronate ester from these 
methoxide salts were unsuccessful.  Washing the boronate ester with any type of aqueous 
solution (acidic or basic) showed significant formation of unsubstituted cyclophane.  
Even simply removing the solvent and isolating the desired product by dissolving the 
crude oil in non-polar solvents and filtering promoted formation of unsubstituted 
cyclophane.   
A lithiated cyclophane proved to be too reactive to couple directly – all 
bis(acetoxy)4-iodoanisole was reduced to 4-iodoanisole, and all lithiated cyclophane was 
reduced to unsubstituted [2.2]paracyclophane.  Magnesium-halogen exchange with iso-
propyl magnesium chloride on 7-iodo-4-methoxy-[2.2]paracyclophane (47) did not occur 
at room temperature or below, and when heated formation of 4-methoxy-
[2.2]paracyclophane (30) occurred nearly as fast as metalation (the aryl Grignard reagent 
could potentially abstract a proton from iso-propyl iodide).  A synthesis of 4-iodo-
[2.2]paracyclophane was developed.  This compound is only known in literature as the 
product of an iodonium salt thermolysis,46 and all attempts to directly iodinate 
[2.2]paracyclophane proved unsuccessful (presumably to the steric bulk of the 
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cyclophane and iodine, and the relatively unreactive arene).  Lithiation of 4-bromo-
[2.2]paracyclophane and substitution on NIS gave the desired iodinated product 7-iodo-
[2.2]paracyclophane (35), along with inseparable, but unreactive, [2.2]paracyclophane.  
Further studies (using other Grignard reagents for magnesium-halogen exchange, other 
solvents, and temperatures) were performed on this model compound, but abstraction of a 
proton always occurred nearly as fast or faster than metalation.  Formation of the aryl 
Grignard by lithiation followed by transmetalation with magnesium bromide showed the 
same results as directly coupling with the lithiated cyclophane.  Attempts to make an 
organocuprate and couple also gave the same results.   
I sought then to improve the existing organozinc route.  Using the original 
conditions, and monitoring after every step, it was found that lithiation was nearly 
complete (only a small amount of iodinated arene was left unreacted, presumably due to 
poor solubility in ether).  Formation of reduced iodoarene and protonated cyclophane 
accounted for nearly all of the lost yield.  After a variety of model reactions on 4-bromo-
[2.2]paracyclophane (31), it was found that several lithiating agents (n-butyl lithium, s-
butyl lithium, and t-butyl lithium) reacted well and gave similar results.  Using THF as a 
solvent in any step, even after removal of solvent in vacuo, gave very poor yields 
(resulting in nearly total formation of reduced iodoanisole and protonated cyclophane); 
using ether for the lithiation step and switching to acetonitrile for the coupling step 
provided the best results.  Initially sonicating the cyclophane in ether and warming 
slightly while stirring before slowly cooling to -78 ˚C fostered complete conversion in the 
lithiation step.  Using a larger excess of zinc chloride, and flame-drying immediately 
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before each use, gave the most consistent results.  Finally, addition of the organozinc 
reagent to the bis(acetoxy)iodoarene gave appreciably improved yields of (4-((±)-7-
methoxy-[2.2]paracyclophanyl))(4-methoxyphenyl)iodonium hexafluorophosphate (36).  
Due to the low solubility of bis(acetoxy)-4-iodoanisole (10) in acetonitrile, higher 
temperatures (-20 ˚C) were used for the coupling step.  Using a lower temperature (-25 ˚C 
or colder), by diluting 10 in a larger volume of acetonitrile did not decrease the formation 
of reduced iodoanisole, but more protonated cyclophane was observed (likely due to 
more trace moisture in the larger volume of acetonitrile).  The phenyl analog, (4-((±)-7-
methoxy-[2.2]paracyclophanyl))(phenyl)iodonium hexafluorophosphate (37), was also 
synthesized using analogous conditions. 
 
IF6P OMe
(±)
IF6P
OMe
OMe
(±)  
 
Figure 2.7: Racemic aryl-cylophanyl iodonium salts synthesized 
 
 With two racemic cyclophane iodonium salts synthesized, trial reactions were run 
to confirm thermolysis occurs similar to the symmetrical iodonium salts.  Thermolysis 
proceeded similarly to the symmetrical salts, though slightly faster.  A small amount of 
iodobenzene and 4-iodoanisole were formed, respectively, but no functionalized 
cyclophane was observed (the only discernible cyclophane species observed was 7-iodo-
36 37 
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4-methoxy-[2.2]paracyclophane (47)).  This implies that the regiochemistry of the 
reaction completely prefers elimination of the iodo-cyclophane and functionalized 
benzene or anisole; the iodobenzene or 4-iodoanisole impurities must arise from some 
other mechanism.  After thermolysis was complete the products were isolated and 
characterized.  After reduction and hydrolysis, the amino acids were purified and 
conditions were developed for separation of the two enantiomers on HPLC.  Initial 
separations were performed on a Phenomenex® Chirex 3126 chiral column (50 mm 
length, 4.6 mm diameter, 5 µm particle size), which specifically separates enantiomers of 
amino acids.  This column utilizes ligand exchange on a copper complex of (D)-
penicillamine to separate amino acid enantiomers.  Conditions were later established 
using a Phenomenex® Lux Cellulose-1 chiral column (250 mm length, 4.6 mm diameter, 
3 µm particle size), which is able to separate a variety of enantiomers by hydrogen 
bonding and π-π interactions with the cellulose phenylcarbamate stationary phase.  Using 
this column, the aryl nitroesters formed directly by the thermolysis reactions can be 
rapidly analyzed without performing the reduction and hydrolysis steps.  An Astec® 
CHIROBIOTIC® T2 chiral column (250 mm length, 4.6 mm diameter, 5 µm particle 
size) was also tried, but no conditions were found that gave any separation. 
 There are few published approaches based upon isolating single cyclophane 
enantiomers. 50 , 51   Approaches by fractional crystallization of [2.2]paracyclophanyl 
naproxen esters attempted by an undergraduate student in our lab, Anh Nguyen, proved 
unsuccessful.  An alternate approach was taken, using diastereomeric imines, based on 
work by Quici and co-workers.51 Commercially available [2.2]paracyclophane was 
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brominated using NBS to form 4-bromo-[2.2]paracyclophane (31) as previously 
described.  Conditions were developed to generate the aromatic aldehyde, 4-
formyl[2.2]paracyclophane (38), by lithiation with tBuLi and quenching with DMF 
(followed by water). 
 
Br
NBS, TFA
DCM
1. 2.5 eq. tBuLi, ether
   -78 ˚C to 0˚C
2. 3.0 eq. DMF, 
   -78 ˚C to r.t.
3. H2O
O
H
 
 
 
Scheme 2.9: Synthesis of aldehyde 38 
 
Following formation of 38, the subsequent approach of Bräse and co-workers52 was 
utilized.  Condensation with a stoichiometric amount of enantiopure (S)-2-
phenylethylamine produced two diastereomeric imines.  The reaction was monitored by 
1H NMR.  Conversion was observed by a disappearance of the aldehyde proton and 
appearance of two aldimine protons, slightly farther upfield.  It was interesting to note 
that formation of one diastereomer was slower than the other; this difference in reaction 
rate, due to planar chirality on the cyclophane, could potentially influence thermolysis 
later in the synthesis.  The crude product was recrystallized from dilute, hot hexanes.  The 
solution was allowed to cool very slowly within an insulated jacket.  After an hour or two 
crystallization began and the flask was left to cool for several hours until crystallization 
had completed, then moved to the refrigerator for several more hours before filtering and 
rinsing with cold hexanes.  This crude product, crystallizing as nearly colorless beads, 
31 38 
82% 70% 
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was only slightly enriched in one diastereomer, but contained no other impurities, by 1H 
NMR.  A second crystallization was performed, in the same manner, but using a different 
concentration.  Crystals formed from this second recrystallization were colorless and 
formed as sharp, branched needles.  In most cases only a single diastereomer was visible 
in the NMR spectrum.  This separation comes at the cost of yield.  Only 19% of the total 
initial molar amount (combination of both the desired and undesired enantiomers) was 
isolated (which equates to a recovery of 38% of (S)-4-formyl-[2.2]paracyclophane (39)).  
If necessary, a third recrystallization could be performed to improve diastereomeric 
excess, but further sacrifices yield.  All mother liquor was combined (and the imines 
cleaved on silica to recover 4-formyl-[2.2]paracyclophane).  As this mother liquor is 
enriched in the other enantiomer, refluxing with with (R)-2-phenylethylamine and 
recrystallizing in a similar manner should isolate (R)-4-formyl-[2.2]paracyclophane.  
Repeating this process, and alternating the amine used, more of the desired enantiomers 
could be isolated.  The imine, now diastereomerically pure, is easily cleaved on silica 
(due to non-deactivated silica being acidic), with the enantiopure aldehyde eluting and 
the amine remaining on silica.  Enantiomeric excess was confirmed (94%) using chiral 
HPLC on a Phenomenex® Lux chiral column (250 mm length, 4.6 mm diameter, 3 µm 
particle size). 
Dakin oxidation produces (S)-4-hydroxy-[2.2]paracyclophane (40).  Rather than 
using carbonate as a base, used previously for the racemic synthesis, sodium hydride was 
used to deprotonate the phenol.  The reaction was run in THF; since 4-hydroxy-
[2.2]paracyclophane has a much higher solubility in THF than acetonitrile, the reaction 
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was run more concentrated, allowing for a faster reaction time.  The rest of the synthesis 
was run under the same conditions as previously explained for the racemic iodonium salt.  
Though not performed for the racemic synthesis, (S)-4-methoxy-[2.2]paracyclophane 
(41) and (S)-7-iodo-4-methoxy-[2.2]paracyclophane (42) were also recrystallized after 
chromatography.  Although a racemic mixture of enantiomers cannot be separated by 
crystallization (enantiomers of the same compound have the same solubility in achiral 
solvents), the major enantiomer will preferentially crystallize with like enantiomers, 
slightly enriching the enantiopurity of the compound.53,54,55  This was confirmed by chiral 
HPLC of (S)-7-iodo-4-methoxy-[2.2]paracyclophane (42), with a further enriched 
enantiomeric excess of 97% (confirmed on the Lux chiral column). 
Using the same improved procedure as described above (4-((S)-7-methoxy-
[2.2]paracyclophanyl))(phenyl)iodonium hexafluorophosphate (43) was synthesized from 
42 and bis(acetoxy)iodobenzene.  This compound was chosen for initial studies since it 
thermolyzes relatively quickly (allowing for thermolysis at relatively low temperature in 
order to maximize any potential enantioselectivity).   
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Figure 2.8: Synthesis of enantiopure iodonium salt, 43  
 
In addition, bis(acetoxy)4-iodoanisole (10) and bis(acetoxy)-4-iodotoluene (44) 
were oxidized from the corresponding 4-iodoarenes using a periodate oxidation, and 
bis(acetoxy)-4-iodonitrobenzene (11) was oxidized from 4-iodonitrobenzene using a 
SelectfluorTM oxidation.1  Though not yet performed, these compounds could be coupled 
with 42, using the same conditions used to synthesize 43, to generate the corresponding 
enantiopure diaryliodonium salts.  With these, once conditions are established for 
thermolysis, all of previously synthesized racemic amino acids (22–29) can be 
synthesized as enantiopure amino acids. 
43 
43 
39 40 
42 41 
70% 
19% 63% 
66% 96% 77% 
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 Thermolyses using the sodium salts of ethyl 2-nitropropionate (8) and ethyl 2-
nitrobutyrate (9) were run at 60 ˚C until completion.  The aryl nitroester products were 
isolated, reduced using the zinc reduction conditions developed previously, and 
hydrolyzed under basic conditions.  The final amino acids were characterized by 1H-
NMR and HR-MS (matching the previous full characterization of the racemic products, 
22 and 23).  Unfortunately, after analysis by chiral HPLC no enantioselectivity was 
found; both sets of amino acids were completely racemic (integrations of the two 
enantiomers deviated by up to 1%, but repeated injections gave an average ratio of 
50.05/49.95).   
Ratios of each reagent were altered (substoichiometric, equal, and 
superstoichiometric amounts of the enolate (8 and 9) relative to the iodonium salt (43)) 
and concentration of the reaction mixture was varied, but all reactions gave racemic 
products.  Based on kinetic data, the reaction appears to be pseudo first order.  As the 
solubility of the enolate is low (until the end of the reaction some enolate visibly appears 
to always stay out of solution, even at reaction temperature), the reaction rate appears to 
be solely dependent on the concentration of the iodonium salt.  No matter if there is a 
substoichiometric, equal, and superstoichiometric amount of enolate to iodonium salt, the 
low solubility seems to limit the amount of dissolved enolate to effectively be 
substoichiometric. 
Presumably formation of the iodonium salt occurs quickly (with the enolate that is 
currently in solution) and the resulting inorganic salt (sodium triflate or sodium 
hexafluorophosphate) likely precipitates out of solution, making the exchange effectively 
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irreversible.  Collision of the enolate and the iodonium center likely occurs statistically, 
with little preference, forming an equal, or nearly equal, mixture of both diastereomers: S 
(on the cyclophane), R (on the carbon attached to the iodine); and S (on the cyclophane), 
S (on the carbon attached to the iodine).  If exchange does not readily occur, rather than 
finding the thermodynamic minimum of the two intermediates, there may always be an 
equal mixture, which will thermolyze to an equal mixture of both product enantiomers.   
We theorized that if an excess of enolate were in solution, exchange may occur 
more readily, and the thermodynamically favorable intermediate would dominate.  
Computational methods were employed to investigate the energy differences between 
these two intermediates.  Simplified intermediates were used (removing the methoxy 
group from the cyclophane, using the propionate-based enolate, and using a methyl ester; 
Figure 2.9).  Three rotamers of each of these simplified intermediates were drawn and 
optimized using GAMESS.24,25 
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Figure 2.9: Initial structures used for ground state geometry optimizations 
 
In our experience empirical calculations often perform poorly on T-shaped iodonium 
salts (instead generating nearly tetrahedral structures), so ab initio calculations were 
started directly.  Ground state geometry optimizations were performed using B3LYP/3-
21G.  After Hessian analysis of each structure, to incorporate vibrational energies, a zero-
point energy corrected ∆G of 1.517 kcal/mol at 298.15 K was found between the lowest 
energy rotamer of each intermediate (Figure 2.10).   
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Figure 2.10: Initial ground state energy calculations  
 
Presumably the intermediates could undergo ligand exchange (the two diastereomers are 
not distinctly visible in 1H NMR), and at equilibrium there would be an excess of the 
lower energy compound (13 to 1 at 298.15 K).  This distribution may be even higher with 
the ethyl ester (9).  Presumably the difference in steric bulk between the alkoxy group 
and the alkyl group (ethyl ester vs. methyl group in 8; ethyl ester vs. ethyl group in 9) 
dictates the energy difference between the intermediate structures.  In the lower energy 
structure, the sterically smaller group on the enolate aligns with the side closest to 
cyclophane bridge, so that the sterically larger group may align farther from the 
cyclophane bridge.  Higher level calculations, for each of the lowest energy rotamers, 
were initiated to obtain a more accurate ground state energy difference. A mixed basis 
set, B3LYP/DZVP56 for the iodine center and B3LYP/6-311G for all other atoms, was 
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used for the higher level ground state optimizations.  Unfortunately, neither calculation 
would converge, despite multiple attempts using varied input geometries.  In all cases the 
enolate would rearrange to bond to the iodine center at one of the nitro group’s oxygens 
(Figure 2.11).  Since the reaction does not progress with oxygen-carbon bond formation 
these did not seem like reasonable structures along the reaction coordinate. 
 
 
Figure 2.11: Example structure generated from higher level calculation 
 
Despite the lack of higher level energy values, the energy differences in the low-level 
calculations was promising.  Each of these intermediates should undergo reductive 
elimination to a different aryl nitroester enantiomer.  The ratio of these ground state 
intermediates does not translate directly to an enantiomeric excess; an analysis of the 
transition state (along the reaction coordinate from each ground state compound above to 
the appropriate product enantiomer) would be necessary.  However, for compounds with 
this many atoms, especially heavy atoms, the computational time required is often not 
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practical (each low-level ground state optimization took about two weeks).  Based on the 
difference in ground state energies we were hopeful there would be a similar energy 
difference between the transition states.  We sought to find a way to bring an excess of 
enolate into solution, in an attempt to promote exchange, and take advantage of the 
energy difference between the two ground states.  Despite historically worse yields found 
in our lab using more polar solvents for iodonium thermolysis reactions, thermolysis 
reactions were attempted in DMSO.  Using DMSO-d6, all reagents dissolved at room 
temperature.  Thermolysis was monitored at room temperature, but no reaction took 
place.  Once the temperature was raised to 40 ˚C thermolysis began to take place.  
Though complete thermolysis takes nearly two full days at this temperature, the lower 
temperature should promote better selectivity.  No noticeable side-products were visible 
in the NMR (compared to reactions in benzene or acetonitrile).  Conditions were also 
established in DMF (with 20% acetonitrile-d3 to allow for 1H NMR analysis).  
Thermolysis also began at 40 ˚C and no noticeable side-products were visible.   
 In order to more quickly analyze results, conditions were established for direct 
separation of enantiomers of the aryl nitroesters by chiral HPLC without performing a 
two-step reduction/hydrolysis first.  Using the Lux chiral column, the two enantiomers 
were analyzed, after initial aqueous work-up to remove DMSO or DMF (which are not 
compatible with the Lux column).  As a general-purpose chiral column, separation is not 
as clean as with the Chirex chiral column (Figure 2.12), but the two enantiomers are 
separable for an initial analysis.  An Astec CHIROBIOTIC® chiral column was also used, 
but no separation was found regardless of the conditions used. 
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Figure 2.12: Chiral HPLC separations of ethyl 2-nitro-2-phenylpropionate (13)  
(top: Chirex 3126; bottom: Lux Cellulose-1) 
 
After initial analysis of the aryl nitroesters on the Lux column, reduction and hydrolysis 
can still be run, and the product mixture can be analyzed on the Chirex chiral column — 
this column provides a much larger baseline separation of the amino acid enantiomers 
than the Lux column provides for the aryl nitroesters.  With the Lux column, 
enantiomeric purity of the aryl nitroester product mixture can be analyzed before the 
reduction or hydrolysis steps, allowing aliquots, taken from the reaction mixture before 
and at completion, to be analyzed to investigate potential kinetic resolution.  If one 
enantiomer of the aryl nitroester forms more quickly than the other during thermolysis of 
43, allowing the reaction to run to completion would give an equal mix of enantiomers; 
halting the reaction before completion would give an enriched mixture of enantiomers. 
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Thermolysis reactions were performed with superstoichiometric as well as 
substoichiometric amounts of the enolate to the iodonium salt.  Several aliquots were 
taken throughout the course of the reaction, worked up initially by liquid-liquid 
extraction to remove DMSO or DMF, and analyzed by chiral HPLC using the Lux 
column.  In DMSO-d6, regardless of conditions, all results were racemic (within 
instrumental error).  Even an aliquot taken at 2% conversion showed only 2.4% 
enantiomeric excess (48.8% to 51.2%), which likely stems from instrumental error (due 
to the very low amount of product at 2% completion) rather than any actual selectivity.  
Using DMF (with 30% acetonitrile-d3 added for NMR), most results showed no 
selectivity (within instrumental error), but one run, using 80 mol% of the sodium salt of 
ethyl 2-nitrobutyrate at 40 ˚C, showed some enantioselectivity.  At 66% conversion, after 
about a day of thermolysis, 26.6% enantiomeric excess was found (63.3% to 36.7%).  
When taken to completion (at 45 ˚C), 6.4% enantiomeric excess was found (53.2% to 
46.8%).  However, due to deviations in the baseline of this HPLC trace, the enantiomeric 
excess could be attributed to an impurity lying under one of the enantiomer peaks.  The 
partially converted aliquot was concentrated in vacuo, dissolved in benzene, and filtered.  
This should remove any polar contaminants, such as excess enolate and others.  The 
sample was concentrated in vacuo again, dissolved in methanol, and filtered.  Less polar 
components, such as (S)-7-iodo-4-methoxy-[2.2]paracyclophane (42) are sparingly 
soluble in methanol.  HPLC analysis of this sample was performed and showed a nearly 
equal distribution of enantiomers (45.0% to 55.0%).  Subsequent runs provided similar 
results, suggesting either a very small enantiomeric excess, that rapidly decreases with 
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reaction progress, or simply integration error due to overlapping impurities in the HPLC 
trace. 
We theorized that the intermediate complex (Scheme 2.3, structure A) did not 
undergo exchange, and initial collision of the enolate and the iodonium center occurs 
statistically, with little to no preference.  A secondary chiral element was introduced.  By 
adding a chiral ammonium salt to the reaction mixture, the sodium enolate, as a soft base, 
can bind to the soft chiral ammonium salt.  This complex, when exchanging with the 
cyclophane iodonium salt (43), should have a higher preference for one face.  
Commercially available (R)- and (S)-1-phenylethylamine were methylated with methyl 
iodide and ion-exchanged with a hexafluorophosphate anion (45 and 46).  Generation of 
45, using potassium carbonate in acetonitrile, only provided 13% of the desired product, 
presumably due to Hoffman elimination.  For generation of 46, milder conditions, sodium 
bicarbonate in methanol, were used and provided 61% of the desired product. 
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Scheme 2.10: Synthesis of enantiopure N,N,N-trimethyl-1-phenylethylammonium 
hexafluorophosphate salts (45 and 46) 
 
Thermolysis reactions in DMF were run under the same conditions as before, but with an 
excess (3 eq.) of 45 or 46 added; aliquots were taken as the reaction progressed.  NMR 
45 
46 
13% 
61% 
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analysis showed that thermolysis occurred at the same rate as previous reactions, with no 
other by-products formed.  Unfortunately, HPLC analysis still showed an equal mixture 
of both enantiomers. 
 After these results we theorized that at 40 ˚C, the amount of steric bulk on the 
cyclophane or the nitro ester did not provide a large enough energy difference to provide 
stereoselectivity.  We sought to design an analogous tert-butyl ester to impart more steric 
bulk on one side of the nitro ester as it approached the iodonium salt.  The shorter ester, 
ethyl 2-nitropropionate (5), should provide the most sterically disparate effect.   All 
attempts to hydrolyze ethyl 2-nitropropionate to the corresponding carboxylic acid 
proved ineffective.  Since the a-position is fairly acidic, typical basic methods could not 
be used.  After several attempts, it appeared that under acidic conditions, hydrolysis took 
place, but decomposition quickly occurred.  In the 1H NMR spectrum, acetic acid, 
ethanol, and ethyl acetate (presumably an esterification product of the acetic acid and 
ethanol) were identified along with residual starting material.  An alternate route was 
taken, starting with the more stable a-bromo ester. 
 
H3C Br
O
BrH
H3C O
O
BrH
1. NEt3, neat
    0 ˚C
2. tBuOH
    0 ˚C to r.t.
NaNO2, phloroglucinol
DMSO, 0 ºC to r.t.
H3C O
O
NO2
H
 
 
Scheme 2.11: Synthesis of tert-butyl 2-nitropropionate (48) 
 
Commercially available 2-bromopropionyl bromide was carefully esterified with tert-
butanol to form tert-butyl 2-bromopropionate (47).57  Using the same type of reaction 
48 47 
76% 49% 
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used to generate the ethyl esters, 5 and 6, tert-butyl 2-bromopropionate was converted to 
tert-butyl 2-nitropropionate (48).28  Unlike nitro esters 5 and 6, the enolate of 48 could 
not be generated using sodium ethoxide without risk of transesterification.  Attempts 
using potassium tert-butoxide in either THF or tert-butanol generated the product, but 
also introduced a sticky yellow impurity that could not be removed.   As this ester should 
be much less soluble in water than the analogous ethyl esters, aqueous sodium carbonate 
was utilized.  Unfortunately, very little product was formed.  The neat ester was stirred 
with a substoichiometric amount of powdered sodium hydride (added slowly in portions) 
to form the enolate (49). 
 Thermolysis reactions were attempted with the more sterically disparate enolate.  
Thermolysis began at 40 ˚C and proceeded in a similar manner, but at a slightly faster 
rate.  A small amount of racemic product was produced using the racemic iodonium salt, 
37, to use for HPLC standards.  HPLC conditions were developed and separation was 
found to be improved with the tert-butyl ester product enantiomers.  Thermolysis was run 
with the enantiopure iodonium salt, 43.  Several aliquots were taken over the course of 
the reaction and analyzed by HPLC.  Unfortunately, results were consistent with the ethyl 
esters; no enantioselectivity was observed. 
 
2.2.6 Future Directions 
Increasing the steric hindrance on the ester did not provide enantioselectivity, but 
it may be worthwhile to rather increase the steric bulk on the cyclophane itself.  Rather 
than using a p-methoxy group to make the cyclophane more electron-rich (ensuring full 
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regioselectivity), an o-methoxy group could be used instead.  Our group has developed a 
synthesis for this compound to avoid benzyne formation by abstraction of the ortho-
cyclophane proton by fluoride.47  This compound could be synthesized by utilizing the 
existing strategy for synthesizing (S)-4-hydroxy-[2.2]paracyclophane (40), and 
continuing with the existing strategy for synthesizing (5-(4-
methoxy[2.2]paracyclophanyl))(4’-methoxyphenyl)iodonium hexafluorophosphate.  
Once this compound is synthesized, thermolysis reactions could be run with the existing 
enolate salts (ethyl and tert-butyl) and HPLC analysis could be performed using the same 
conditions.   
 
2.3 Conclusion 
 Although a route to stereoselectively produce quaternary a-alkyl a-aryl amino 
acids was not discovered, a simple procedure for producing quaternary a-alkyl a-aryl 
amino acids was developed.  The convergent nature of the synthesis of these compounds 
makes this route attractive for screening a variety of unnatural amino acids.   
After completion of this work, but before publication of this dissertation, 
Olofsson and co-workers independently developed a method of delivering nitro esters to 
arenes using diaryliodonium salts.58  The conditions developed are similar to the initial 
conditions described in this work, but the protic nitro ester is added along with cesium 
carbonate, to form the enolate salt in situ, before thermolysis was performed.  No 
reduction or hydrolysis are performed to make these compounds into amino acids.   
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 We have presented a methodology to rapidly generate quaternary a-alkyl a-aryl 
amino acids.  Using methods such as enzymatic hydrolysis, or separation of enantiomers 
by chiral HPLC, this approach could be used to synthesize a variety of unnatural amino 
acids for screening.  Stereoselectively generating these compounds, directly from 
iodonium salt thermolysis, would be ideal, and the methods outlined in this work could 
be useful for developing a future solution. 
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2.5 Experimental 
 
Bis(4-methoxyphenyl)iodonium triflate (1): 
 
In a flame-dried 25 mL Schlenk flask charged with N2, bis(acetoxy)iodoanisole (753 mg, 
2.13 mmol) was dissolved in 7 mL dry methylene chloride. With stirring, anisole (0.93 
mL, 8.52 mmol) was added by syringe. The solution was cooled to -10 ˚C in a sodium 
chloride-ice bath. To this solution, triflic acid (0.21 mL, 2.34 mmol) was added dropwise 
over the course of 10 minutes by syringe. A deep blue color was immediately observed 
upon addition. After addition, the solution was allowed to warm slowly to room 
temperature overnight. The solution was reduced to dryness in vacuo. The crude solid 
was recrystallized from methylene chloride by layering with a 10% solution of ether in 
hexanes to yield a colorless solid (729.6 mg, 69.5%): 1H NMR (CD3CN, 400 MHz, 298 
K): δ 7.98 (d, J = 9.1 Hz, 4H), 7.04 (d, J = 9.1 Hz, 4H), 3.83 (s, 6H); 19F NMR (CD3CN, 
376 MHz, 298 K): δ -79.24 (s, OTf); 13C NMR (CD3CN, 100 MHz, 298 K): δ 164.26, 
138.28, 119.07, 103.38, 56.77; HRMS (HRFAB): calcd. for C14H14O2I [M-OTf]+ 
341.0038 found 341.0036. 
 
Wang, B.; Cerny, R.L.; Uppaluri, S.; Kempinger, J.J.; DiMagno, S.G. J. Fluor. Chem. 
2010, 131, 1113–1121. 
I OTfO
O
 151 
 
Dimethyl methylmalonate (2): 
 
In a flame-dried 100 mL Schlenk flask, dimethyl malonate (3.96 g, 0.030 mmol) was 
dissolved in dry benzene (20 mL).  The solution was cooled to -78 ˚C and lithium 
diisopropylamide (16.5 mL, 2.0 M in THF/heptane/ethylbenzene, 0.033 mmol) was 
added dropwise.  The solution was stirred for 30 min at -78 ˚C and methyl iodide (2.2 
mL, 0.036 mmol) was added dropwise.  The solution was allowed to warm to r.t. 
overnight.  The sufficiently pure product was isolated under high dynamic vacuum as a 
colorless oil (1.85 g, 42.3%): 1H NMR (CD3CN, 500 MHz, 298 K): δ 3.68 (s, 6H), 3.49 
(q, J = 7.2 Hz, 1H), 1.33 (d, J = 7.3 Hz, 3H). 
 
Sodium 1,3-dimethoxy-2-methyl-3-oxopropenolate (3): 
 
Dry methanol (10 mL) was transferred to a flame-dried 50 mL Schlenk tube by syringe, 
under nitrogen, and chilled in an ice bath.  Freshly cut sodium metal (32.2 mg, 1.1 mmol) 
was rinsed with dry pentane, and added to the Schlenk tube in portions, slowly.  After the 
sodium had fully reacted, the solution was allowed to warm to room temperature and 
dimethyl methylmalonate (200.6 µL, 2.3 mmol), dried over 4 Å molecular sieves, was 
added dropwise.  The solution was stirred for 30 minutes.  Methanol was removed in 
O
MeO
O
OMe
HMe
CH3
ONa
OMe
O
MeO
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vacuo. The colorless solid was triturated three times, using sonication, with hexanes and 
dried in vacuo (126.8 mg, 52.5%): 1H NMR (CD3OD, 400 MHz, 298 K): δ 3.35 (s, 6H), 
1.36 (s, 3H); 13C NMR (CD3OD, 100 MHz, 298 K): δ 172.36, 50.00, 14.01. 
 
Dimethyl 2-(4-methoxyphenyl)-2-methylmalonate (4): 
 
Bis(4-methoxyphenyl)iodonium triflate (0.030 g, 0.030 mmol), sodium 1,3-dimethoxy-2-
methyl-3-oxopropenolate (0.011 g, 0.033 mmol) were added to an sealed	 NMR	 tube	fitted	with	 a	 Teflon	 screw	 cap	 closure. Benzene-d6 (0.6 mL) was added to the tube. The 
tube was sealed, sonicated for 5 minutes, and heated to 140 ˚C, in the dark. The product 
was analyzed without isolation: 1H NMR (C6D6, 400 MHz, 298 K): δ 7.39 (d, J = 8.9 Hz, 
2H), 6.76 (d, J = 8.9 Hz, 2H), 3.32 (s, 6H), 3.26 (s, 3H). 
 
Ethyl 2-nitropropanoate (5): 
 
In a 25 mL round bottom flask anhydrous phloroglucinol (267.5 mg, 1.74 mmol) and 
anhydrous sodium nitrite (207.0 mg, 3.16 mmol) were suspended in DMSO (1.25 mL) 
with stirring. Ethyl 2-bromobutyrate (210 µL, 1.58 mmol) was added dropwise. The flask 
OMe
O
O
MeO
O
Me OEt
O
NO2
H
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was loosely stoppered, covered in foil, and the suspension was stirred for 1.5 hours. The 
suspension was poured into ice water (10 mL). The mixture was extracted 5 times with 
diethyl ether. The organic layers were washed with brine, dried over sodium sulfate, and 
filtered. Ether was removed in vacuo at 100 Torr. The oil was diluted with chloroform (5 
mL) and filtered. The solution was chromatographed on silica with ethyl acetate/hexanes 
(15:85 v/v) to yield a colorless oil (168 mg, 76.1%): 1H NMR (CDCl3, 500 MHz, 298 K): 
δ 5.19 (q, J = 7.2 Hz, 1H), 4.27 (q, J = 7.3 Hz, 2H), 1.77 (d, J = 7.3 Hz, 3H), 1.29 (t, J = 
7.2 Hz, 3H); 13C NMR (CDCl3, 126 MHz, 298 K): δ 165.30, 83.37, 63.16, 15.81, 13.97; 
HRMS: (ESI) calcd. for C5H8NNa2O4 [M-H+2Na]+ 192.0249 found 192.0253. 
 
Kornblum, N.; Blackwood, R. K. Org. Synth. 1957, 37, 44. 
 
Ethyl 2-nitrobutanoate (6): 
 
In a 500 mL round bottom flask anhydrous phloroglucinol (20.0 g, 0.16 mol) and 
anhydrous sodium nitrite (18.0 g, 0.26 mol) were suspended in DMSO (300 mL) with 
stirring. Ethyl 2-bromobutyrate (20.19 mL, 0.15 mol) was added dropwise. The flask was 
loosely stoppered, covered in foil, and the suspension was stirred for 2.5 hours. The 
suspension was poured into ice water (600 mL). Diethyl ether was added (150 mL) and 
separated. The aqueous layer was extracted 4 times with diethyl ether (50 mL). The 
organic layers were washed with brine (50 mL), dried over sodium sulfate, and filtered. 
Et OEt
O
NO2
H
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Ether was removed in vacuo at 100 Torr. The solution was chromatographed on silica 
with MTBE/hexanes (15:85 v/v) to yield a colorless oil (18.1 g, 74.9%): 1H NMR 
(CDCl3, 300 MHz, 298 K): δ 5.03 (dd, J = 9.2 Hz, J = 5.6 Hz, 1H), 4.28 (q, J = 7.2 Hz, 
2H), 2.42–2.07 (m, 2H), 1.30 (t, J = 7.2 Hz, 3H), 1.04 (t, J = 7.4 Hz, 3H); 13C NMR 
(CDCl3, 75 MHz, 298 K): δ 164.69, 89.61, 63.11, 24.09, 14.07, 10.35; HRMS: (ESI) 
calcd. for C6H10NNa2O4 [M-H+2Na]+ 206.0411 found 206.0405; HRMS: (EI+) calcd. for 
C6H11NNaO4 [M+Na]+ 184.0586 found 184.0587. 
 
Kornblum, N.; Blackwood, R. K. Org. Synth. 1957, 37, 44. 
 
Sodium 1-ethoxy-2-nitroethenolate (7): 
 
Dry ethanol (60 mL) was transferred to a flame-dried 100 mL Schlenk tube by syringe, 
under nitrogen, and chilled in an ice bath.  Freshly cut sodium metal (455.4 mg, 19.8 
mmol) was rinsed with dry pentane, and added to the Schlenk tube in portions, slowly.  
After the sodium had fully reacted, the solution was allowed to warm to room 
temperature and ethyl nitroacetate (2.3 mL, 20.8 mmol), dried over 4 Å molecular sieves, 
was added dropwise.  A colorless precipitate formed and the mixture was stirred for 30 
minutes.  Ethanol was removed in vacuo. The colorless solid was triturated three times, 
using sonication, with ether and dried in vacuo (2.9463 g, 95.9%): 1H NMR (CD3OD, 
OEt
ONa
H
NO2
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400 MHz, 298 K): δ 4.10 (q, J = 7.1 Hz, 2H), 1.23 (t, J = 7.1 Hz, 3H); 13C NMR 
(CD3OD, 100 MHz, 298 K): δ 166.12, 60.17, 14.92. 
 
Sodium 1-ethoxy-2-nitropropenolate (8): 
 
Dry ethanol (60 mL) was transferred to a flame-dried 100 mL Schlenk tube by syringe, 
under nitrogen, and chilled in an ice bath.  Freshly cut sodium metal (551.8 mg, 24.0 
mmol) was rinsed with dry pentane, and added to the Schlenk tube in portions, slowly.  
After the sodium had fully reacted, the solution was allowed to warm to room 
temperature and ethyl 2-nitropropanoate (3.30 mL, 25.3 mmol), dried over 4 Å molecular 
sieves, was added dropwise.  A colorless precipitate formed and the mixture was stirred 
for 30 minutes.  Ethanol was removed in vacuo. The colorless solid was triturated three 
times, using sonication, with ether and dried in vacuo (4.0255 g, 99.2 %):  1H NMR 
(CD3OD, 400 MHz, 298 K): δ 4.15 (q, J = 7.1 Hz, 2H), 2.13 (s, 3H), 1.27 (t, J = 7.1 Hz, 
3H); 13C NMR (CD3OD, 100 MHz, 298 K): δ 166.38, 113.06, 61.03, 15.20, 14.89. 
 
Sodium 1-ethoxy-2-nitrobutenolate (9): 
 
Dry ethanol (60 mL) was transferred to a flame-dried 100 mL Schlenk tube by syringe, 
under nitrogen, and chilled in an ice bath.  Freshly cut sodium metal (551.8 mg, 24.0 
OEt
ONa
Me
NO2
OEt
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Et
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mmol) was rinsed with dry pentane, and added to the Schlenk tube in portions, slowly.  
After the sodium had fully reacted, the solution was allowed to warm to room 
temperature and ethyl 2-nitrobutyrate (3.7 mL, 25.2 mmol), dried over 4 Å molecular 
sieves, was added dropwise.  A colorless precipitate formed and the mixture was stirred 
for 30 minutes.  Ethanol was removed in vacuo. The colorless solid was triturated three 
times, using sonication, with ether and dried in vacuo (4.207 g, 95.7 %):  1H NMR 
(CD3OD, 400 MHz, 298 K): δ 4.16 (q, J = 7.1 Hz, 2H), 2.64 (q, J = 7.3 Hz, 2H), 1.27 (t, 
J = 7.1 Hz, 3H), 1.06 (t, J = 7.3 Hz, 3H); 13C NMR (CD3OD, 100 MHz, 298 K): δ 
166.33, 118.59, 60.86, 23.25, 14.93, 11.65. 
 
Bis(acetoxy)iodoanisole (10): 
 
Sodium periodate (11.000g, 51.5 mmol) and sodium acetate (9.000 g, 110.0 mmol) were 
added to a 100 mL Schlenk storage tube with a stirbar. Acetic acid (50 mL) and acetic 
anhydride (7.5 mL) were added. 4-iodoanisole (sublimed under vacuum) (11.700 g, 50.0 
mmol) was suspended in 25 mL acetic acid and added to the tube with stirring. The tube 
was sealed and heated to 115 ˚C for 2.5 hours, stirring vigorously. The mixture was 
cooled to room temperature and diluted with water (300 mL) and dichloromethane (100 
mL). The layers were separated and the aqueous layer was extracted twice with 
dichloromethane (100 mL). The combined organic layers were dried over sodium sulfate 
and dichloromethane was removed in vacuo. The pale yellow oil was diluted with 200 
mL hexanes, triturated, and sonicated until the oil had solidified. The mixture was filtered 
O I(OAc)2
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and the solid was triturated twice with hexanes. The solid was transferred to a 250 mL 
Schlenk flask along with 100 mL hexanes and 1 mL acetic acid. The mixture was heated 
to 35 ˚C under vacuum overnight to yield a colorless solid (16.139 g, 91.7%). 1H NMR 
(CD3CN, 400 MHz, 298 K): δ 8.05 (d, J = 9.1 Hz, 2H), 7.05 (d, J = 9.1 Hz, 2H), 3.86 (s, 
3H), 1.90 (s, 6H); 13C NMR (CD3CN, 100 MHz, 298 K) δ 177.7, 163.7, 138.7, 118.0, 
112.0, 56.8, 20.8; HRMS: (HRFAB) calcd. for C14H13NO4I [M-2OAc+(3-NBA)]+ 
385.9889 found 385.9885. 
 
K. P. Landge, K. S. Jang, S. Y. Lee, D. Y. Chi, J. Org. Chem. 2012, 77, 5705. 
 
Bis(acetoxy)-4-nitrobenzene (11): 
 
In a nitrogen charged glovebox, 4-iodonitrobenzene (2.34 g, 9.40 mmol) and 1-
chloromethyl-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane bis(tetrafluoroborate) (4.33 g, 
12.22 mmol) were suspended in 200 mL acetonitrile in a 500 mL Schlenk storage flask. 
Trimethylsilyl acetate (3.7 mL, 24.44 mmol) was added with agitation. The flask was 
sealed and heated to 50 ˚C for 18 hours in the dark.  The reaction was allowed to cool to 
r.t. and solvent was removed in vacuo. The oil was diluted with DCM and washed three 
times with aqueous acetate buffer (0.5 M sodium acetate, 0.5 M acetic acid) and once 
with water. The organic layers were dried over sodium sulfate and solvent was removed 
in vacuo. The solid was dissolved in minimal DCM and added to a solution of ether in 
hexanes (10% v/v). The precipitate was allowed to stand for 30 minutes, and then filtered 
I(OAc)2O2N
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through a 0.2 µm PTFE membrane filter.  The solid was dried overnight, under high 
dynamic vacuum (2.93 g, 85.0%). 1H NMR (400 MHz, CDCl3, 298 K) δ 8.32 (d, J = 8.8 
Hz, 2H), 8.28 (d, J = 9.2 Hz, 2H), 2.03 (s, 6H); 13C NMR (100 MHz, CDCl3, 298 K) δ 
175.0, 147.8, 134.4, 125.1, 124.0, 18.7; HRMS: (ESI) calcd. for C10H10NO6INa [M+Na]+ 
389.9451 found 389.9455. 
 Qin,	L.;	Hu,	B.;	Neumann,	K.;	Linstad,	E.	 J.;	McCauley,	K.;	Veness,	 J.;	Kempinger,	 J.	 J.;	DiMagno,	S.	G.	Eur.	J.	Org.	Chem.	2015,	2015,	5919–5924. 
 
(4-Methoxyphenyl)(4-nitrophenyl)iodonium hexafluorophosphate (12): 
 
1-(Diacetoxyiodo)-4-nitrobenzene 1a (3.00 g, 8.17 mmol) was suspended in 30 mL 
acetonitrile in a 100 mL Schlenk flask. Potassium 4-methoxyphenyltrifluoroborate (1.83 
g, 8.58 mmol) was added. With stirring, a solution of trimethylsilyl trifluoroacetate (1.4 
mL, 8.17 mmol) in 3 mL acetonitrile was added dropwise over the course of 15 minutes. 
The mixture was stirred for 1 hour. Solvent was removed in vacuo and the crude oil was 
dissolved in DCM. The solution was washed three times with aqueous acetate buffer (0.5 
M sodium acetate, 0.5 M acetic acid) and once with water. The organic layer was dried 
over sodium sulfate, filtered, and solvent was removed in vacuo. The crude oil was 
triturated three times, using sonication, with 10 mL 10% diethyl ether in hexanes. The 
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solid was dissolved in acetonitrile and a solution of sodium hexafluorophosphate (13.8 g, 
81.7 mmol) was added dropwise with stirring. The mixture was reduced in vacuo, and 
extracted three times with DCM. The organic layers were washed once with water and 
dried over sodium sulfate. Solvent was removed in vacuo, and the solid was suspended, 
using sonication, in 100 mL distilled benzene, chilled to 10 ˚C for 30 minutes, and 
immediately filtered to yield a colorless solid (3.15 g, 76.2%): 1H NMR (CD3CN, 400 
MHz, 298 K): δ 8.26 (d, J = 9.2 Hz, 2H), 8.20 (d, J = 9.2 Hz, 2H), 8.07 (d, J = 9.2 Hz, 
2H), 7.10 (d, J = 9.2 Hz, 2H), 3.85 (s, OMe); 19F NMR (CD3CN, 376 MHz, 298 K): δ -
74.14 (d, J = 707.2 Hz, PF6); 13C NMR (CD3CN, 100 MHz, 298 K): δ 164.88, 151.42, 
139.39, 136.89, 127.79, 120.18, 119.59, 101.91, 56.91; HRMS: (ESI) calcd. for 
C13H11INO3 [M-PF6]+ 355.9784, found: 355.9772.  
 
Ethyl 2-nitro-2-phenylpropanoate (13): 
 
Bis(phenyl)iodonium hexafluorophosphate (2.0000 g, 4.69 mmol), sodium 1-ethoxy-2-
nitropropenolate (0.8335 g, 4.92 mmol), and tetra n-butylammonium chloride (0.3261 g, 
1.17 mmol) were added to a 100 mL Schlenk tube with stirbar. Acetonitrile (50 mL) was 
added to the tube. The tube was sealed, sonicated for 5 minutes, and heated to 80 ˚C, in 
the dark. Solvent was removed in vacuo. The sticky yellow solid was extracted three 
times with hexanes (3 x 30 mL), using sonication, and hexanes were removed in vacuo.  
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The pale yellow oil was concentrated under high dynamic vacuum to remove 
iodobenzene. The oil was chromatographed through a short silica column with ethyl 
acetate/hexanes (5:95 v/v) to yield a colorless oil (0.7637 g, 72.9%): 1H NMR (CDCl3, 
400 MHz, 298 K): δ 7.50–7.39 (m, 5H), 4.35 (q, J = 7.1 Hz, 2H), 2.27 (s, 3H), 1.32 (t, J = 
7.1 Hz, 3H); 13C NMR (CDCl3, 100 MHz, 298 K): δ 167.40, 134.29, 130.06, 128.79, 
127.68, 95.28, 63.40, 23.32, 14.02; HRMS (ESI): calcd. for C11H13NNaO4 [M+Na]+ 
246.0742 found 246.0750; HRMS (EI+): calcd. for C11H13NNaO4 [M+Na]+ 246.0742 
found 246.0737. 
 
Ethyl 2-nitro-2-phenylbutanoate (14): 
 
Bis(phenyl)iodonium hexafluorophosphate (2.0000 g, 4.69 mmol), sodium 1-ethoxy-2-
nitrobutenolate (0.9026 g, 4.92 mmol), and tetra n-butylammonium chloride (0.3261 g, 
1.17 mmol) were added to a 100 mL Schlenk tube with stirbar. Acetonitrile (50 mL) was 
added to the tube. The tube was sealed, sonicated for 5 minutes, and heated to 80 ˚C, in 
the dark. Solvent was removed in vacuo. The sticky yellow solid was extracted three 
times with hexanes (3 x 30 mL), using sonication, and hexanes were removed in vacuo.  
The pale yellow oil was concentrated under high dynamic vacuum to remove 
iodobenzene. The oil was chromatographed through a short silica column with ethyl 
acetate/hexanes (5:95 v/v) to yield a colorless oil (1.0365 g, 93.2%): 1H NMR (CDCl3, 
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400 MHz, 298 K): δ 7.52–7.45 (m, 2H), 7.45–7.38 (m, 3H), 4.33 (q, J = 7.1 Hz, 2H), 
2.81–2.63 (m, 2H), 1.31 (t, J = 7.1 Hz, 3H), 1.03 (t, J = 7.4 Hz, 3H); 13C NMR (CDCl3, 
100 MHz, 298 K): δ 166.61, 133.51, 129.77, 128.67, 128.15, 99.05, 63.06, 29.41, 14.01, 
9.18; HRMS (ESI): calcd. for C12H15NNaO4 [M+Na]+ 260.0899 found 260.0897. 
 
Ethyl 2-(4-methylphenyl)-2-nitropropanoate (15): 
 
Bis(4-methylphenyl)iodonium hexafluorophosphate (2.1299 g, 4.69 mmol), sodium 1-
ethoxy-2-nitropropenolate (0.8335 g, 4.92 mmol), and tetra n-butylammonium chloride 
(0.3261 g, 1.17 mmol) were added to a 100 mL Schlenk tube with stirbar. Acetonitrile 
(50 mL) was added to the tube. The tube was sealed, sonicated for 5 minutes, and heated 
to 80 ˚C, in the dark. Solvent was removed in vacuo. The sticky yellow solid was 
extracted three times with hexanes (3 x 30 mL), using sonication, and hexanes were 
removed in vacuo.  The pale yellow oil was concentrated under high dynamic vacuum at 
30˚C to remove 4-iodotoluene. The oil was chromatographed through a short silica 
column with ethyl acetate/hexanes (7:93 v/v) to yield a colorless oil (0.8713 g, 78.3%): 
1H NMR (CDCl3, 400 MHz, 298 K): δ 7.36 (d, J = 7.8 Hz, 2H), 7.24 (d, J = 7.8 Hz, 2H), 
4.35 (q, J = 7.1 Hz, 2H), 2.39 (s, 3H), 2.26 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H); 13C NMR 
(CDCl3, 100 MHz, 298 K): δ 167.55, 140.25, 131.31, 129.46, 127.63, 95.12, 63.30, 23.19, 
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21.32, 14.00; HRMS (ESI): calcd. for C12H15NNaO4 [M+Na]+ 260.0899 found 260.0905; 
HRMS (EI+): calcd. for C12H15NNaO4 [M+Na]+ 260.0899 found 260.0894. 
 
Ethyl 2-(4-methylphenyl)-2-nitrobutanoate (16): 
 
Bis(4-methylphenyl)iodonium hexafluorophosphate (2.1299 g, 4.69 mmol), sodium 1-
ethoxy-2-nitrobutenolate (0.9026 g, 4.92 mmol), and tetra n-butylammonium chloride 
(0.3261 g, 1.17 mmol) were added to a 100 mL Schlenk tube with stirbar. Acetonitrile 
(50 mL) was added to the tube. The tube was sealed, sonicated for 5 minutes, and heated 
to 80 ˚C, in the dark. Solvent was removed in vacuo. The sticky yellow solid was 
extracted three times with hexanes (3 x 30 mL), using sonication, and hexanes were 
removed in vacuo.  The pale yellow oil was concentrated under high dynamic vacuum to 
remove 4-iodotoluene. The oil was chromatographed through a short silica column with 
ethyl acetate/hexanes (7:93 v/v) to yield a colorless oil (1.0862 g, 92.2%): 1H NMR 
(CDCl3, 400 MHz, 298 K): δ 7.37 (d, J = 7.8 Hz, 2H), 7.23 (d, J = 7.8 Hz, 2H), 4.33 (q, J 
= 7.1 Hz, 2H), 2.80–2.60 (m, 2H), 2.38 (s, 3H), 1.31 (t, J = 7.1 Hz, 3H), 1.03 (t, J = 7.3 
Hz); 13C NMR (CDCl3, 100 MHz, 298 K): δ 166.82, 139.97, 130.55, 129.40, 128.15, 
98.96, 63.02, 29.29, 21.33, 14.06, 9.23; HRMS (ESI): calcd. for C13H17NNaO4 [M+Na]+ 
274.1055 found 274.1053; HRMS (EI+): calcd. for C13H17NNaO4 [M+Na]+ 274.1055 
found 274.1043. 
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Ethyl 2-(4-methoxyphenyl)-2-nitropropanoate (17): 
 
Bis(4-methoxyphenyl)iodonium triflate (1.2746 g, 2.60 mmol), sodium 1-ethoxy-2-
nitropropenolate (0.4617 g, 2.73 mmol), and tetra n-butylammonium chloride (0.1807 g, 
0.65 mmol) were added to a  50 mL Schlenk tube with stirbar. Acetonitrile (25 mL) was 
added to the tube. The tube was sealed, sonicated for 5 minutes, and heated to 80 ˚C, in 
the dark. Solvent was removed in vacuo. The sticky orange solid was extracted three 
times with hexanes (3 x 15 mL), using sonication, and hexanes were removed in vacuo.  
The pale orange oil was concentrated under high dynamic vacuum at 60 ˚C to remove 4-
iodoanisole. The oil was chromatographed through a short silica column with ethyl 
acetate/hexanes (10:90 v/v) to yield a colorless oil (0.6585 g, 65.9%): 1H NMR (CDCl3, 
400 MHz, 298 K): δ 7.42 (d, J = 7.9 Hz, 2H), 6.94 (d, J = 7.9 Hz, 2H), 4.34 (q, J = 7.1 Hz, 
2H), 3.84 (s, 3H), 2.25 (s, 3H), 1.32 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 100 MHz, 298 
K): δ 167.70, 160.83, 129.35, 126.08, 114.07, 94.85, 63.30, 55.53, 23.07, 14.03; HRMS 
(ESI): calcd. for C12H15NNaO5 [M+Na]+ 276.0848 found 276.0855. 
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Ethyl 2-(4-methoxyphenyl)-2-nitrobutanoate (18): 
 
Bis(4-methoxyphenyl)iodonium triflate (1.2746 g, 2.60 mmol), sodium 1-ethoxy-2-
nitrobutenolate (0.5000 g, 2.73 mmol), and tetra n-butylammonium chloride (0.1807 g, 
0.65 mmol) were added to a  50 mL Schlenk tube with stirbar. Acetonitrile (25 mL) was 
added to the tube. The tube was sealed, sonicated for 5 minutes, and heated to 80 ˚C, in 
the dark. Solvent was removed in vacuo. The sticky orange solid was extracted three 
times with hexanes (3 x 15 mL), using sonication, and hexanes were removed in vacuo.  
The pale orange oil was concentrated under high dynamic vacuum at 60 ˚C to remove 4-
iodoanisole. The oil was chromatographed through a short silica column with ethyl 
acetate/hexanes (10:90 v/v) to yield a colorless oil (0.4636 g, 66.7%): 1H NMR (CDCl3, 
400 MHz, 298 K): δ 7.43 (d, J = 7.7 Hz, 2H), 6.93 (d, J = 7.7 Hz, 2H), 4.33 (q, J = 7.1 Hz, 
2H), 3.83 (s, 3H), 2.80–2.60 (m, 2H), 1.30 (t, J = 7.1 Hz, 3H), 1.02 (t, J = 7.3 Hz, 3H); 
13C NMR (CDCl3, 100 MHz, 298 K): δ 166.93, 160.60, 129.84, 125.29, 114.01, 98.68, 
62.99, 55.51, 29.06, 14.06, 9.21; HRMS (ESI): calcd. for C13H17NNaO5 [M+Na]+ 
290.1004 found 290.1007; HRMS (EI+): calcd. for C13H17NNaO5 [M+Na]+ 290.1004 
found 290.1017. 
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Ethyl 2-(4-nitrophenyl)-2-nitropropanoate (19): 
 
(4-Methoxyphenyl)(4-nitrophenyl)iodonium hexafluorophosphate (0.2000 g, 0.2765 
mmol), sodium 1-ethoxy-2-nitropropenolate (0.0708 g, 0.2903 mmol), and tetra n-
butylammonium chloride (0.0276 g, 0.06913 mmol) were added to a 25 mL Schlenk flask 
with stirbar. Acetonitrile (3 mL) was added to the flask. The flask was sealed, sonicated 
for 5 minutes, and heated to 35 ˚C, in the dark. Solvent was removed in vacuo at 35 ˚C. 
The sticky yellow solid was chromatographed through a silica column with ethyl 
acetate/hexanes (10:90 v/v) to yield a pale yellow oil (0.0707 g, 95.3%): 1H NMR 
(CDCl3, 400 MHz, 298 K): δ 8.29 (d, J = 9.0 Hz, 2H), 7.66 (d, J = 9.0 Hz, 2H), 4.38 (q, J 
= 7.1 Hz, 2H), 2.30 (s, 3H), 1.33 (t, J = 7.1 Hz, 3H); 13C NMR (CDCl3, 700 MHz, 298 K): 
δ 166.33, 148.74, 140.61, 129.02, 123.89, 94.47, 64.05, 23.39, 14.00. 
NO2
O2N
Me O
O
 166 
 
Ethyl 2-(4-nitrophenyl)-2-nitrobutanoate (20): 
 
(4-Methoxyphenyl)(4-nitrophenyl)iodonium hexafluorophosphate (0.2000 g, 0.2765 
mmol), sodium 1-ethoxy-2-nitrobutenolate (0.0767 g, 0.2903 mmol), and tetra n-
butylammonium chloride (0.0276 g, 0.06913 mmol) were added to a 25 mL Schlenk flask 
with stirbar. Acetonitrile (3 mL) was added to the flask. The flask was sealed, sonicated 
for 5 minutes, and heated to 35 ˚C, in the dark. Solvent was removed in vacuo at 35 ˚C. 
The sticky yellow solid was chromatographed through a silica column with ethyl 
acetate/hexanes (10:90 v/v) to yield a pale yellow oil (0.0765 g, 98.0%): 1H NMR 
(CDCl3, 400 MHz, 298 K): δ 8.28 (d, J = 9.0 Hz, 2H), 7.69 (d, J = 9.0 Hz, 2H), 4.36 (dq, 
J = 7.1 Hz, J = 1.0 Hz, 2H), 2.73 (q, J = 7.4 Hz, 2H), 1.32 (t, J = 7.1 Hz), 1.03 (t, J = 7.4 
Hz); 13C NMR (CDCl3, 700 MHz, 298 K): δ 165.62, 148.52, 139.93, 129.47, 123.77, 
98.29, 63.75, 29.74, 14.02, 9.02. 
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Ethyl 2-(4-methylphenyl)-2-aminopropanoate (21): 
 
Ethyl 2-(4-methylphenyl)-2-nitropropanoate (0.1482 g, 0.625 mmol) was dissolved in 
200 proof ethanol (6.25 mL). Concentrated aqueous HCl (1.0 mL) was added dropwise 
with stirring. Zinc dust (1.6345 g, 25 mmol) was added slowly, in portions, with stirring. 
The suspension was stirred vigorously for 3 hours, covered loosely. The suspension was 
neutralized with saturated aqueous sodium bicarbonate, filtered by syringe through a 0.2 
µm PTFE membrane filter, and washed twice with 200 proof ethanol (2 x 2 mL).  The 
solution was extracted three times with dichloromethane. The combined organic layers 
were washed twice with saturated aqueous sodium bicarbonate and then brine. The 
organic layer was dried over sodium sulfate and concentrated in vacuo.  The oil was 
dissolved in acetonitrile (5 mL) and washed 5 times with hexanes (5 x 2 mL). 
Acetonitrile was removed in vacuo and the crude oil was used without further 
purification. (0.1049 g, 81.0%): 1H NMR (CD3CN, 400 MHz, 298 K): δ 7.36 (d, J = 8.2 
Hz, 2H), 7.15 (d, J = 8.2 Hz, 2H), 4.09 (q, J = 7.1 Hz, 2H), 2.31 (s, 3H), 2.05 (br s, NH2), 
1.55 (s, 3H), 1.16 (t, J = 7.1 Hz, 3H). 
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2-Ammonio-2-phenylpropanoate (22): 
 
Ethyl 2-phenyl-2-nitropropanoate (0.1395 g, 0.625 mmol) was dissolved in 200 proof 
ethanol (6 mL). Concentrated aqueous HCl (1.0 mL) was added dropwise with stirring. 
Zinc dust (1.6345 g, 25 mmol) was added slowly, in portions, with stirring. The 
suspension was stirred vigorously for 3 hours, covered loosely. The suspension was 
neutralized with saturated aqueous sodium bicarbonate, filtered through a 0.2 µm PTFE 
membrane filter, and washed twice with dichloromethane (2 x 5 mL).  The layers were 
separated and the aqueous layer was extracted two times with dichloromethane (2 x 5 
mL). The combined organic layers were washed twice with saturated aqueous sodium 
bicarbonate (2 x 5 mL). Dichloromethane was removed in vacuo, the oil was diluted with 
200 proof ethanol (2 mL), and concentrated to half the volume to remove trace 
dichloromethane.  The oil was diluted with 2.0 M aqueous sodium hydroxide (2 mL) and 
stirred for 2 hours.  The solution as acidified to pH 5 with 2.0 M aqueous HCl. Ethanol 
and water were removed in vacuo. The solid was dissolved in minimal water, at r.t., and 
chilled in the refrigerator.  The colorless solid was collected by vacuum filtration and 
washed with cold water (0.0903 g, 87.5%): 1H NMR (10% CD3OD in D2O+NaOH, pH 
12, 500 MHz, 298 K): δ 7.32 (d, J = 7.3 Hz, 2H), 7.24 (t, J = 7.3 Hz, 2H), 7.16 (t, J = 7.3 
Hz, 1H), 1.46 (s, 3H); 13C NMR (10% CD3OD in D2O+NaOH, pH 12, 125 MHz, 298 K): 
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δ 184.47, 147.09, 129.59, 128.00, 126.28, 62.58, 26.98; HRMS (ESI): calcd. for 
C9H10NNa2O2 [M-H+2Na]+ 210.0512 found 210.0509. 
 
2-Ammonio-2-phenylbutanoate (23): 
 
Ethyl 2-phenyl-2-nitrobutanoate (0.1482 g, 0.625 mmol) was dissolved in 200 proof 
ethanol (6 mL). Concentrated aqueous HCl (1.0 mL) was added dropwise with stirring. 
Zinc dust (1.6345 g, 25 mmol) was added slowly, in portions, with stirring. The 
suspension was stirred vigorously for 3 hours, covered loosely. The suspension was 
neutralized with saturated aqueous sodium bicarbonate, filtered through a 0.2 µm PTFE 
membrane filter, and washed twice with dichloromethane (2 x 5 mL).  The layers were 
separated and the aqueous layer was extracted two times with dichloromethane (2 x 5 
mL). The combined organic layers were washed twice with saturated aqueous sodium 
bicarbonate (2 x 5 mL). Dichloromethane was removed in vacuo, the oil was diluted with 
200 proof ethanol (2 mL), and concentrated to half the volume to remove trace 
dichloromethane.  The oil was diluted with 2.0 M aqueous sodium hydroxide (2 mL) and 
stirred for 2 hours.  The solution as acidified to pH 5 with 2.0 M aqueous HCl. Ethanol 
and water were removed in vacuo. The solid was dissolved in minimal water, at r.t., and 
chilled in the refrigerator.  The colorless solid was collected by vacuum filtration and 
washed with cold water (0.0990 g, 88.4%): 1H NMR (D2O+NaOH, pH 10, 700 MHz, 298 
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K): δ 7.40 (d, J = 7.6 Hz, 2H), 7.32 (t, J = 7.6 Hz, 2H), 7.24 (t, J = 7.6 Hz, 1H), 2.12–
2.00 (m, 1H), 2.00–1.86 (m, 1H), 0.80 (t, J = 7.3 Hz, 3H); 13C NMR (10% CD3OD in 
D2O+NaOH, pH 10, 176 MHz, 298 K): δ183.61, 146.36, 129.49, 127.97, 126.72, 66.22, 
32.39, 9.25; HRMS (ESI): calcd. for C10H12NNa2O2 [M-H+2Na]+ 224.0669 found 
224.0656. 
 
2-Ammonio-2-(4-methylphenyl)propanoate (24): 
 
Ethyl 2-(4-methylphenyl)-2-aminopropanoate (0.1049 g, 0.506 mmol) was dissolved in 
200 proof ethanol (0.5 mL). 2.0 M aqueous sodium hydroxide (2 mL) was added 
dropwise with stirring. An oily precipitate formed, but after 2 hours was homogeneous.  
The solution as acidified to pH 5 with 2.0 M aqueous HCl. Ethanol and water were 
removed in vacuo. The solid was dissolved in minimal water, at r.t., and chilled in the 
refrigerator.  The colorless solid was collected by vacuum filtration and washed with cold 
water (0.0792 g, 87.3%). 
 
Alternate method: ethyl 2-(4-methylphenyl)-2-nitropropanoate (0.1482 g, 0.625 mmol) 
was dissolved in 200 proof ethanol (6 mL). Concentrated aqueous HCl (1.0 mL) was 
added dropwise with stirring. Zinc dust (1.6345 g, 25 mmol) was added slowly, in 
portions, with stirring. The suspension was stirred vigorously for 3 hours, covered 
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loosely. The suspension was neutralized with saturated aqueous sodium bicarbonate, 
filtered through a 0.2 µm PTFE membrane filter, and washed twice with dichloromethane 
(2 x 5 mL).  The layers were separated and the aqueous layer was extracted two times 
with dichloromethane (2 x 5 mL). The combined organic layers were washed twice with 
saturated aqueous sodium bicarbonate (2 x 5 mL). Dichloromethane was removed in 
vacuo, the oil was diluted with 200 proof ethanol (2 mL), and concentrated to half the 
volume to remove trace dichloromethane.  The oil was diluted with 2.0 M aqueous 
sodium hydroxide (2 mL) and stirred for 2 hours.  The solution as acidified to pH 5 with 
2.0 M aqueous HCl. Ethanol and water were removed in vacuo. The solid was dissolved 
in minimal water, at r.t., and chilled in the refrigerator.  The colorless solid was collected 
by vacuum filtration and washed with cold water (0.0861 g, 76.9%): 1H NMR 
(D2O+NaOH, pH 10, 700 MHz, 298 K): δ 7.37 (d, J = 7.7 Hz, 2H), 7.25 (d, J = 7.7 Hz, 
2H), 2.33 (s, 3H), 1.61 (s, 3H); 13C NMR (10% CD3OD in D2O+NaOH, pH 10, 176 MHz, 
298 K): δ 184.49, 144.18, 137.9, 130.05, 126.23, 62.30, 27.00, 21.11; HRMS (ESI): 
calcd. for C10H12NNa2O2 [M-H+2Na]+ 224.0669 found 224.0766. 
 
2-Ammonio-2-(4-methylphenyl)butanoate (25): 
 
Ethyl 2-(4-methylphenyl)-2-nitrobutanoate (0.1571 g, 0.625 mmol) was dissolved in 200 
proof ethanol (6 mL). Concentrated aqueous HCl (1.0 mL) was added dropwise with 
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stirring. Zinc dust (1.6345 g, 25 mmol) was added slowly, in portions, with stirring. The 
suspension was stirred vigorously for 3 hours, covered loosely. The suspension was 
neutralized with saturated aqueous sodium bicarbonate, filtered through a 0.2 µm PTFE 
membrane filter, and washed twice with dichloromethane (2 x 5 mL).  The layers were 
separated and the aqueous layer was extracted two times with dichloromethane (2 x 5 
mL). The combined organic layers were washed twice with saturated aqueous sodium 
bicarbonate (2 x 5 mL). Dichloromethane was removed in vacuo, the oil was diluted with 
200 proof ethanol (2 mL), and concentrated to half the volume to remove trace 
dichloromethane.  The oil was diluted with 2.0 M aqueous sodium hydroxide (2 mL) and 
stirred for 2 hours.  The solution as acidified to pH 5 with 2.0 M aqueous HCl. Ethanol 
and water were removed in vacuo. The solid was dissolved in minimal water, at r.t., and 
chilled in the refrigerator.  The colorless solid was collected by vacuum filtration and 
washed with cold water (0.0930 g, 77.0%): 1H NMR (D2O, pH 5, 500 MHz, 298 K): δ 
7.07 (d, J = 8.0 Hz, 2H), 7.70 (d, J = 8.0 Hz, 2H), 2.03 (s, 3H), 1.88–1.76 (m, 1H), 1.76–
1.64 (m, 1H), 0.58 (t, J = 7.3 Hz, 3H); 13C NMR (10% CD3OD in D2O+NaOH, pH 12, 
100 MHz, 298 K): δ 184.12, 143.45, 138.17, 130.21, 126.81, 66.03, 32.33, 21.26, 9.34; 
HRMS (ESI): calcd. for C11H14NNa2O2 [M-H+2Na]+ 238.0825 found 238.0811. 
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2-Ammonio-2-(4-methoxyphenyl)propanoate (26): 
 
Ethyl 2-(4-methoxyphenyl)-2-nitropropanoate (0.1577 g, 0.625 mmol) was dissolved in 
200 proof ethanol (6 mL). Concentrated aqueous HCl (1.0 mL) was added dropwise with 
stirring. Zinc dust (1.6345 g, 25 mmol) was added slowly, in portions, with stirring. The 
suspension was stirred vigorously for 3 hours, covered loosely. The suspension was 
neutralized with saturated aqueous sodium bicarbonate, filtered through a 0.2 µm PTFE 
membrane filter, and washed twice with dichloromethane (2 x 5 mL).  The layers were 
separated and the aqueous layer was extracted two times with dichloromethane (2 x 5 
mL). The combined organic layers were washed twice with saturated aqueous sodium 
bicarbonate (2 x 5 mL). Dichloromethane was removed in vacuo, the oil was diluted with 
200 proof ethanol (2 mL), and concentrated to half the volume to remove trace 
dichloromethane.  The oil was diluted with 2.0 M aqueous sodium hydroxide (2 mL) and 
stirred for 2 hours.  The solution as acidified to pH 5 with 2.0 M aqueous HCl. Ethanol 
and water were removed in vacuo. The solid was dissolved in minimal water, at r.t., and 
chilled in the refrigerator.  The colorless solid was collected by vacuum filtration and 
washed with cold water (0.1580 g, 81.0%): 1H NMR (D2O, pH 5, 700 MHz, 298 K): δ 
7.40 (d, J = 8.7 Hz, 2H), 6.98 (d, J = 8.7 Hz, 2H), 3.76 (s, 3H), 1.89 (s, 3H); 13C NMR 
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(D2O, pH 5, 176 MHz, 298 K): δ 174.68, 159.45, 128.48, 127.34, 114.47, 61.73, 55.30, 
21.01; HRMS (ESI): calcd. for C10H12NNa2O3 [M-H+2Na]+ 240.0618 found 240.0609. 
 
2-Ammonio-2-(4-methoxyphenyl)butanoate (27): 
 
Ethyl 2-(4-methoxyphenyl)-2-nitrobutanoate (0.1671 g, 0.625 mmol) was dissolved in 
200 proof ethanol (6 mL). Concentrated aqueous HCl (1.0 mL) was added dropwise with 
stirring. Zinc dust (1.6345 g, 25 mmol) was added slowly, in portions, with stirring. The 
suspension was stirred vigorously for 3 hours, covered loosely. The suspension was 
neutralized with saturated aqueous sodium bicarbonate, filtered through a 0.2 µm PTFE 
membrane filter, and washed twice with dichloromethane (2 x 5 mL).  The layers were 
separated and the aqueous layer was extracted two times with dichloromethane (2 x 5 
mL). The combined organic layers were washed twice with saturated aqueous sodium 
bicarbonate (2 x 5 mL). Dichloromethane was removed in vacuo, the oil was diluted with 
200 proof ethanol (2 mL), and concentrated to half the volume to remove trace 
dichloromethane.  The oil was diluted with 2.0 M aqueous sodium hydroxide (2 mL) and 
stirred for 2 hours.  The solution as acidified to pH 4 with 2.0 M aqueous HCl. Ethanol 
and water were removed in vacuo. The solid was dissolved in minimal water, at r.t., and 
chilled in the refrigerator.  The colorless solid was collected by vacuum filtration and 
washed with cold water (0.0954 g, 85.2%): 1H NMR (D2O, pH 4, 700 MHz, 298 K): δ 
H3N
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7.53 (d, J = 8.2 Hz, 2H), 7.12 (d, J = 8.2 Hz, 2H), 3.96 (s, 3H), 2.25–2.16 (m, 1H), 2.15–
2.06 (m, 1H), 0.98 (t, J = 7.3 Hz, 3H); 13C NMR (10% CD3OD in D2O, pH 4, 176 MHz, 
298 K): δ 183.24, 157.71, 138.14, 127.26, 114.10, 64.74, 56.16, 55.60, 8.47; HRMS 
(ESI): calcd. for C12H17NNaO3 [M-H+2Na]+ 254.0775 found 254.0763. 
 
2-Ammonio-2-(4-aminophenyl)propanoate (28): 
 
Ethyl 2-(4-nitrophenyl)-2-nitropropanoate (0.0394 g, 0.1469 mmol) was dissolved in 200 
proof ethanol (2 mL). Concentrated aqueous HCl (0.3 mL) was added dropwise with 
stirring. Zinc dust (0.5450 g, 8.336 mmol) was added slowly, in portions, with stirring. 
The suspension was stirred vigorously for 3 hours, covered loosely. The suspension was 
neutralized with saturated aqueous sodium bicarbonate, filtered through a 0.2 µm PTFE 
membrane filter, and washed twice with dichloromethane (2 x 2 mL).  The layers were 
separated and the aqueous layer was extracted two times with dichloromethane (2 x 2 
mL). The combined organic layers were washed twice with saturated aqueous sodium 
bicarbonate (2 x 2 mL). Dichloromethane was removed in vacuo, the oil was diluted with 
200 proof ethanol (2 mL), and concentrated to half the volume to remove trace 
dichloromethane.  The oil was diluted with 2.0 M aqueous sodium hydroxide (2 mL) and 
stirred for 2 hours.  The solution as acidified to pH 6 with 2.0 M aqueous HCl. Ethanol 
and water were removed in vacuo. The solid was dissolved in minimal water and 
NH2
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chromatographed on a reverse phase Waters Sep-Pack (C18 Plus) using 100% water.  
Solvent was evaporated in vacuo to yield a colorless solid (0.0207 g, 78.1%): 1H NMR 
(D2O+NaOH, pH 10, 700 MHz, 298 K): δ 6.64 (d, J = 7.8 Hz, 2H), 6.19 (d, J = 7.8 Hz, 
2H), 0.93 (s, 3H); 13C NMR (D2O+NaOH, pH 10, 176 MHz, 298 K): δ 183.49, 168.24, 
168.23, 144.64, 135.58, 125.75, 125.71, 115.80, 60.39; HRMS (ESI): calcd. for 
C9H11N2Na2O2 [M-H+2Na]+ 225.0616 found 225.0613. 
 
2-Ammonio-2-(4-aminophenyl)butanoate (29): 
 
Ethyl 2-(4-nitrophenyl)-2-nitrobutanoate (0.0406 g, 0. 1469 mmol) was dissolved in 200 
proof ethanol (2 mL). Concentrated aqueous HCl (1.0 mL) was added dropwise with 
stirring. Zinc dust (0.5450 g, 8.336 mmol) was added slowly, in portions, with stirring. 
The suspension was stirred vigorously for 3 hours, covered loosely. The suspension was 
neutralized with saturated aqueous sodium bicarbonate, filtered through a 0.2 µm PTFE 
membrane filter, and washed twice with dichloromethane (2 x 2 mL).  The layers were 
separated and the aqueous layer was extracted two times with dichloromethane (2 x 2 
mL). The combined organic layers were washed twice with saturated aqueous sodium 
bicarbonate (2 x 2 mL). Dichloromethane was removed in vacuo, the oil was diluted with 
200 proof ethanol (2 mL), and concentrated to half the volume to remove trace 
dichloromethane.  The oil was diluted with 2.0 M aqueous sodium hydroxide (2 mL) and 
NH2
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stirred for 2 hours.  The solution as acidified to pH 5 with 2.0 M aqueous HCl. Ethanol 
and water were removed in vacuo. The solid was dissolved in minimal water and 
chromatographed on a reverse phase Waters Sep-Pack (C18 Plus) using 100% water.  
Solvent was evaporated in vacuo to yield a colorless solid (0.0223 g, 76.0%): 1H NMR 
(D2O, pH 5, 400 MHz, 298 K): δ 7.36 (d, J = 8.3 Hz, 2H), 6.96 (d, J = 8.3 Hz, 2H), 2.47–
2.28 (m, 2H), 1.10 (t, J = 7.4 Hz, 3H); 13C NMR (D2O, pH 5, 150.9 MHz, 298 K): δ 
176.44, 147.19, 129.05 (br), 127.76, 116.77, 67.58, 28.44, 8.27; HRMS (ESI): calcd. for 
C10H13N2Na2O2 [M-H+2Na]+ 239.0772 found 239.0777. 
 
(±)-4-Methoxy-[2.2]paracyclophane (30): 
 
In a 100 mL Schlenk storage tube potassium carbonate (14.15 g, 102.39 mmol) and (±)-
4-hydroxy[2.2]paracyclophane (7.420 g, 33.02 mmol) were dissolved in acetonitrile (60 
mL) and heated to 80 ˚C for 30 minutes. Iodomethane (6.35 mL, 102.39 mmol) was 
added dropwise, the tube was sealed, and the mixture was stirred at 80 ˚C for 3 days. 
Solvent was removed in vacuo, and the solid was dissolved in ethyl acetate, and water 
was added. The mixture was neutralized with aqueous hydrochloric acid (0.1 M) and the 
layers were separated. The organic layer was dried over sodium sulfate, filtered, and 
solvent was removed in vacuo. The solid was chromatographed on silica, loaded using 
hot hexanes, and eluted as a gradient from 0% ethyl acetate/hexanes (v/v) to 3% to yield 
OMe
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a colorless solid (3.639 g, 46.3%). 1H NMR (CDCl3, 400 MHz, 298 K): δ 6.76 (dd, J = 
7.8 Hz, J = 1.8 Hz, 1H), 6.38–6.55 (m, 4H), 6.28 (dd, J =  7.5 Hz, J = 1.4 Hz, 1H), 5.67 
(d, J = 1.3 Hz, 1H), 3.71 (s, 3H), 3.42–3.48 (m, 1H), 2.99–3.13 (m, 6H), 2.59–2.66 (m, 
1H); 13C NMR (CDCl3, 100 MHz, 298 K): δ 157.6, 142.1, 140.3, 138.8, 135.0, 133.7, 
133.1, 131.5, 128.4, 127.5, 124.4, 116.7, 54.3, 35.5, 35.4, 34.1, 31.7; HRMS (EI+): calcd. 
for C17H18O [M]+ 238.1358 found 238.1358. 
 
Cram, D. J.; Day, A. C. J. Org. Chem. 1966, 31, 1227-32. 
 
(±)-4-Bromo-[2.2]paracyclophane (31): 
 
In a 4 L amber bottle, [2.2]paracyclophane (20.00 g, 95.18 mmol) was dissolved in 
dichloromethane (1.6 L).  In a separate beaker, N-bromosuccinamide (17.28 g, 97.08 
mmol) and trifluoroacetic acid (7.48 mL, 97.08 mmol) were dissolved in 
dichloromethane (0.8 L) with stirring. Once fully dissolved, this solution was poured into 
the 4 L amber bottle. The solution was stirred for 2 days, then transferred to a separatory 
funnel. The solution was washed 3 times with a solution of saturated aqueous sodium 
bicarbonate in water (1:1 v/v), and once with brine. The organic layer was dried over 
sodium sulfate, filtered, and solvent was removed in vacuo to yield the crude product 
(carried forward without further purification) as a nearly colorless powder (29.09 g, 
Br
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82.2%): 1H NMR (CDCl3, 400 MHz, 298 K): δ 7.18 (dd, J = 7.8 Hz, J = 1.9 Hz, 1H), 
6.45–6.61 (m, 6H), 3.45–3.52 (m, 1H), 2.80–3.26 (m, 7H); 13C NMR (CDCl3, 100 MHz, 
298 K): δ 141.61, 139.33, 139.11, 137.25, 135.05, 133.31, 133.02, 132.91, 132.25, 
131.46, 128.69, 126.97, 35.85, 35.48, 34.82, 33.47; HRMS (EI+): calcd. for C16H15Br 
[M]+ 286.0357, 288.0337 found 286.0344, 288.0339. 
 
Cram, D. J.; Day, A. C. J. Am. Chem. Soc. 1966, 31, 1227–1232. 
 
(±)-4-Hydroxy-[2.2]paracyclophane (32): 
 
In a flame-dried 1L Schlenk flask with a stirbar, (±)-4-bromo-[2.2]paracyclophane (9.500 
g, 33.31mmol) was dissolved in dry ether (300 mL). The solution was cooled to -78 ˚C 
and tert-butyl lithium (1.7 M in pentane, 45 mL, 76.62 mmol) was added dropwise. The 
suspension was stirred at -78 ˚C for 20 minutes, warmed to 0 ˚C, and held at 0 ˚C for 20 
minutes. Trimethylborate (7.36 mL, 66.62 mmol) was added dropwise and the solution 
was allowed to warm to r.t. over the course of an hour. To this suspension, a solution of 
hydrogen peroxide (30% v/v in water, 12.4 mL) and sodium hydroxide (0.5 M in water, 
16.5 mL) was added dropwise and the mixture was stirred overnight. Additional sodium 
hydroxide ((0.5 M in water, 33 mL) was added. The mixture was neutralized with 
saturated aqueous sodium bicarbonate and hydrochloric acid (1 M), and extracted three 
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times with ether. The organic layers were washed with dilute sodium bisulfite, dried over 
sodium sulfate, filtered, and solvent was removed in vacuo. The crude pale orange solid 
was used without further purification (7.42 g, quantitative): 1H NMR (CDCl3, 400 MHz, 
298 K): δ 7.01 (dd, J = 7.8 Hz, J = 1.9 Hz, 1H), 6.56 (dd, J = 7.8 Hz, J = 1.9 Hz, 1H), 
6.46 (dd, J = 7.8 Hz, 1.9 Hz, 1H), 6.38–6.42 (m, 2H), 6.27 (dd, J = 7.7 Hz, J = 1.6 Hz, 
1H), 5.55 (d, J = 1.6 Hz, 1H), 4.45 (s, 1H), 3.29–3.39 (m, 1H), 2.87–3.16 (m, 6H), 2.62–
2.73 (m, 1H); 13C NMR (CDCl3, 100 MHz, 298 K): δ 153.7, 142.0, 139.6, 138.8, 135.5, 
133.0, 132.8, 131.9, 127.9, 125.4, 125.0, 122.6, 35.3, 34.8, 33.8, 31.1; HRMS (EI+): 
calcd. for C16H16O [M]+ 224.1201 found 224.1198. 
 
Krohn, K.; Rieger, H.; Hopf, H.; Barrett, D.; Jones, P. G.; Döring, D. Chem. Ber. 1990, 
123 1729. 
 
(±)-7-Iodo-4-methoxy-[2.2]paracyclophane (33): 
 
In a 100 mL round bottom flask, (±)-4-methoxy-[2.2]paracyclophane (1.2461 g, 5.27 
mmol) was dissolved in dichloromethane (50 mL). In an addition funnel, N-
iodosuccinimide (1.259g, 5.54 mmol) and trifluoracetic acid (0.43 mL, 5.54 mmol) were 
dissolved in dichloromethane (50 mL) with swirling and added to the round bottom flask 
over 5 minutes. The solution was stirred, in the dark, for 1.5 hours before being 
I OMe
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neutralized by saturated aqueous sodium bicarbonate. The mixture was transferred to a 
separatory funnel and the layers were separated. The organic layer was washed once with 
saturated aqueous sodium bicarbonate, a solution of sodium metabisulfite in brine (5 
g/L), then brine. The organic layer was dried over sodium sulfate, filtered, and solvent 
was removed in vacuo. The crude solid was dissolved from minimal boiling hexanes (~60 
mL), chilled to -20 ˚C, filtered, and washed with cold hexanes to yield a pale brown solid 
(1.605 g, 83.8%): 1H NMR (CDCl3, 400 MHz, 298 K): δ 7.13 (dd, J = 7.9 Hz, J = 1.8, 
1H), 6.75 (dd, J = 7.9 Hz, J = 1.8 Hz, 1H), 6.71 (s, 1H), 6.46 (dd, J = 7.9 Hz, J = 1.8, 
1H), 6.40 (dd, J = 7.8 Hz, J = 1.8 Hz, 1H), 5.69 (s, 1H), 3.68 (s, 3H), 2.82–3.37 (m, 7H), 
2.43–2.53 (m, 1H); 13C NMR (CDCl3, 100 MHz, 298 K): δ 157.9, 144.7, 143.9, 139.9, 
138.5, 132.9, 131.5, 129.9, 129.6, 128.9, 117.7, 91.9, 54.3, 39.3, 33.6, 33.2, 31.1; HRMS 
(EI+): calcd. for C17H17IO [M]+ 364.0324 found 364.0330. 
 
(4-((±)-7-Methoxy-[2.2]paracyclophanyl))(4-methoxyphenyl)iodonium 
hexafluorophosphate (36): 
 
In a flame-dried 50 mL Schlenk tube, (±)-7-iodo-4-methoxy-[2.2]paracyclophane (0.1250 
g, 0.3432 mmol) was dissolved, with stirring, in warm ether (10 mL), under N2. The 
OMeIF6P
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solution was gradually cooled, with vigorous stirring, to -78 ˚C.  To this mixture, n-butyl 
lithium (2.5 M in hexanes, 0.16 mL, 0.3775 mmol) was added, dropwise. The mixture 
was stirred at -78 ˚C for 30 minutes. In a separate 50 mL Schlenk tube, anhydrous zinc 
chloride (0.300 g, 2.059 mmol) was gently flame-dried until bubbling subsided. An oven-
dried stirbar was added. After cooling to r.t., dry ether (12 mL) was added, under N2, and 
the solid was dissolved using sonication and vigorous stirring. A portion of this solution 
(4 mL, 0.6864 mmol zinc chloride) was added dropwise to the first Schlenk tube.  The 
suspension was allowed to warm to room temperature and ether was removed under high 
dynamic vacuum to yield a foam. Dry acetonitrile (3 mL) was added with stirring to 
dissolve the foam.  In a separate flame-dried 50 mL Schlenk tube, bis(acetoxy)-4-
iodoanisole (0.1813 g, 0.5148 mmol) was dissolved in dry acetonitrile (10 mL). Both 
solutions were chilled to -20 ˚C and the organozinc chloride solution was added, 
dropwise, over the course of 5 min to the bis(acetoxy)-4-iodoanisole solution.  The 
resulting solution was held at -20 ˚C for 30 minutes before warming to r.t.  Deionized 
water and sodium hexafluorophosphate (0.1441g, 0.8580 mmol) were added, with 
stirring, and the mixture was concentrated in vacuo. The mixture was extracted three 
times with dichloromethane. The combined organic layers were dried over sodium 
sulfate, filtered, and solvent was removed in vacuo. The crude solid was dissolved in 
minimal dichloromethane and slowly dripped into a stirring solution of ether in hexanes 
(10% v/v).  Stirring was stopped, and after standing for an hour, the mixture was filtered 
and the solid rinsed three times with hexanes to yield a colorless powder (0.1546 g, 
73.2%): 1H NMR (CD3CN, 400 MHz, 298 K): δ 8.01 (d, J = 9.2 Hz, 2H), 7.25 (s, 1H), 
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7.07 (d, J = 9.2 Hz, 2H), 6.81 (dd, J = 7.8 Hz, J = 1.8 Hz, 1H), 6.62 (dd, J = 7.9 Hz, J = 
1.9 Hz, 1H), 6.29 (dd, J = 7.9 Hz, J = 1.6 Hz, 1H), 6.12 (dd, J = 8.0 Hz, J = 2.0 Hz, 1H), 
6.02 (s, 1H), 3.83 (s, 3H), 3.74 (s, 3H), 3.31 (ddd, J = 11.6 Hz, J = 9.8 Hz, J = 1.7 Hz, 
1H), 3.26 (dd, J = 8.4 Hz, J = 5.7 Hz, 1H), 3.23 (dd, J = 13.9 Hz, J = 4.3 Hz, 1H), 3.18 
(dd, J = 12.9 Hz, J = 4.1 Hz, 1H), 3.15 (dd, J = 8.3 Hz, J = 3.0 Hz, 1H), 3.05 (ddd, J = 
12.8 Hz, J = 9.9 Hz, J = 6.4 Hz, 1H), 3.02 (ddd, J = 12.8 Hz, J = 9.9 Hz, J = 6.4 Hz, 1H), 
2.68 (ddd, J = 13.1 Hz, J = 10.5 Hz, J = 6.4 Hz, 1H); 13C NMR (CD3CN, 400 MHz, 298 
K): δ 163.3, 161.6, 146.4, 140.5, 139.9, 137.9, 137.4, 133.2, 132.4, 131.4, 131.3, 128.8, 
119.8, 118.2, 107.4, 101.1, 55.8, 54.9, 37.2, 34.5, 32.9, 30.7; 19F NMR (CD3CN, 376 
MHz, 298 K): δ -72.7 (d, J = 706.7 Hz, 6F); HRMS: (HRFAB) calcd. for C24H24IO2 [M]+ 
471.08210 (100%), 472.08454 (26%) found 471.08221 (100%), 472.08561 (23%). 
 
Wang, B.; Graskemper, J. W.; Qin, L.; DiMagno, S. G. Angew. Chem. Int. Ed. 2010, 49, 
4079–4083. 
 
(4-((±)-7-Methoxy-[2.2]paracyclophanyl))(phenyl)iodonium hexafluorophosphate 
(37): 
 
In a flame-dried 50 mL Schlenk tube, (±)-7-iodo-4-methoxy-[2.2]paracyclophane (0.1250 
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g, 0.3432 mmol) was dissolved, with stirring, in warm ether (10 mL), under N2. The 
solution was gradually cooled, with vigorous stirring, to -78 ˚C.  To this mixture, n-butyl 
lithium (2.5 M in hexanes, 0.16 mL, 0.3775 mmol) was added, dropwise. The mixture 
was stirred at -78 ˚C for 30 minutes. In a separate 50 mL Schlenk tube, anhydrous zinc 
chloride (0.300 g, 2.059 mmol) was gently flame-dried until bubbling subsided. An oven-
dried stirbar was added. After cooling to r.t., dry ether (9 mL) was added, under N2, and 
the solid was dissolved using sonication and vigorous stirring. A portion of this solution 
(3 mL, 0.6864 mmol zinc chloride) was added dropwise to the first Schlenk tube.  The 
suspension was allowed to warm to room temperature and ether was removed under high 
dynamic vacuum to yield a foam. Dry acetonitrile (3 mL) was added with stirring to 
dissolve the foam.  In a separate flame-dried 50 mL Schlenk tube, 
bis(acetoxy)iodobenzene (0.1658 g, 0.5148 mmol) was dissolved in dry acetonitrile (10 
mL). Both solutions were chilled to -20 ˚C and the organozinc chloride solution was 
added, dropwise, over the course of 5 min to the bis(acetoxy)iodobenzene solution.  The 
resulting solution was held at -20 ˚C for 30 minutes before warming to r.t.  Deionized 
water and sodium hexafluorophosphate (0.1441g, 0.8580 mmol) were added, with 
stirring, and the mixture was concentrated in vacuo. The mixture was extracted three 
times with dichloromethane. The combined organic layers were dried over sodium 
sulfate, filtered, and solvent was removed in vacuo. The crude solid was dissolved in 
minimal dichloromethane and slowly dripped into a stirring solution of ether in hexanes 
(10% v/v).  Stirring was stopped, and after standing for an hour, the mixture was filtered 
and the solid rinsed three times with hexanes to yield a colorless powder (0.1255 g, 
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62.3%): 1H NMR (CD3CN, 400 MHz, 298 K): δ 8.03 (d, J = 7.9 Hz, 2H), 7.70 (t, J = 7.5 
Hz, 1H), 7.54 (t, J = 7.9 Hz, 2H), 7.29 (s, 1H), 6.82 (dd, J = 7.8 Hz, J = 1.8 Hz, 1H), 6.63 
(dd, J = 7.8 Hz, J = 1.8 Hz, 1H), 6.34 (dd, J = 7.9 Hz, J = 1.9 Hz, 1H), 6.19 (dd, J = 7.9 
Hz, J = 1.9 Hz, 1H), 6.04 (s, 1H), 3.74 (s, 3H), 3.37–2.99 (m, 7H), 2.74–2.64 (m, 1H); 
19F NMR (CD3CN, 400 MHz, 298 K): δ -72.88 (d, J = 708.0 Hz, 6F); HRMS (ESI): 
calcd. for C23H22IO [M-PF6]+ 441.0710 found 441.0730. 
 
(±)-4-Formyl-[2.2]paracyclophane (38): 
 
In a flame-dried 500 mL Schlenk flask, (±)-4-bromo-[2.2]paracyclophane (4.296 g, 15.07 
mmol) was dissolved in warm ether (150 mL), under N2, with stirring. The solution was 
chilled to -78 ˚C and tert-butyl lithium (1.7 M in pentane, 22.2 mL, 37.69 mmol) was 
added dropwise.  The mixture was held at -78 ˚C for 30 min, warmed to 0 ˚C, and held at 
0 ˚C for 30 min.  The mixture was chilled to -78 ˚C and N,N-dimethylformamide (3.5 
mL, 45.22 mmol) was added, dropwise. The mixture was held at -78 ˚C for 15 minutes, 
then allowed to warm to r.t. overnight. Solvent was removed in vacuo and the solid was 
dissolved in dichloromethane, washed three times with deionized water. The aqueous 
layer was extracted with dichloromethane. The organic layers were combined and washed 
with brine. The organic layers were dried over sodium sulfate, filtered, and solvent was 
removed in vacuo. The crude solid was chromatographed, loaded dry. 
O
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[2.2]paracyclophane was removed by flushing the column with hexanes. The product was 
eluted as a gradient from 5% ethyl acetate/hexanes (v/v) to 10% to yield an off-white 
solid (2.465 g, 69.8%): 1H NMR (CDCl3, 400 MHz, 298 K): δ 9.95 (s, 1H), 7.02 (s, 1H), 
6.74 (d, J = 7.8 Hz, 1H), 6.60 (d, J = 7.8 Hz, 1H), 6.57 (d, J = 7.7 Hz, 1H), 6.50 (d, J = 
7.7 Hz, 1H), 6.44 (d, J = 7.9 Hz, 1H), 6.38 (d, J = 7.9 Hz, 1H), 4.11 (t, J = 11.1 Hz, 1H), 
3.23–2.90 (m, 7H); 13C NMR (CDCl3, 100 MHz, 298 K) δ 192.11, 143.41, 140.84, 
139.69, 139.63, 138.26, 136.78, 136.53, 136.30, 133.44, 133.10, 132.55, 132.34, 35.45, 
35.33, 35.17, 33.80; HRMS (EI+): calcd. for C17H16O [M]+ 236.1201 found 236.1204. 
 
(S)-4-Formyl-[2.2]paracyclophane (39): 
 
In a 1 L round bottom flask with a stirbar, (±)-4-hydroxy-[2.2]paracyclophane (16.111 g, 
68.76 mmol) was dissolved in benzene (0.4 L). (R)-1-phenethylamine (8.80 mL, 68.76 
mmol) was added dropwise and the solution was heated at reflux overnight.  Solvent was 
removed in vacuo and the crude oil was placed under high dynamic vacuum. The crude 
solid was dissolved in gently boiling hexanes (410 mL). The flask was insulated and 
allowed to cool slowly to room temperature and then chilled to 0 ˚C.  The mixture was 
filtered and the solid was washed with cold hexanes. The solid was dissolved in gently 
boiling hexanes (200 mL).  The flask was insulated and allowed to cool slowly to room 
temperature and then chilled to 0 ˚C.  The mixture was filtered and the solid was washed 
O
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with cold hexanes.  Diastereomeric purity was confirmed by 1H NMR.  The solid was 
dissolved in dichloromethane and passed down a short silica plug to cleave the imine, 
yielding the product as a colorless powder (2.988 g, 18.5%): 1H NMR (CDCl3, 400 MHz, 
298 K): δ 9.95 (s, 1H), 7.02 (s, 1H), 6.74 (d, J = 7.8 Hz, 1H), 6.60 (d, J = 7.8 Hz, 1H), 
6.57 (d, J = 7.7 Hz, 1H), 6.50 (d, J = 7.7 Hz, 1H), 6.44 (d, J = 7.9 Hz, 1H), 6.38 (d, J = 
7.9 Hz, 1H), 4.11 (t, J = 11.1 Hz, 1H), 3.23–2.90 (m, 7H); 13C NMR (CDCl3, 100 MHz, 
298 K) δ 192.11, 143.41, 140.84, 139.69, 139.63, 138.26, 136.78, 136.53, 136.30, 
133.44, 133.10, 132.55, 132.34, 35.45, 35.33, 35.17, 33.80; HRMS (EI+): calcd. for 
C17H16O [M]+ 236.1201 found 236.1204; HPLC (Phenomenex® Lux chiral column (250 
mm length, 4.6 mm diameter, 3 µm particle size), methanol:water (90:10 v/v), 1.0 
mL/min, 254 nm): 19.74 min (R); 24.48 min (S); ee 94.0%. 
 
Banfi, S.; Manfredi, A.; Montanari, F.; Pozzi, G.; Quici, S. J. Mol. Catal. A: Chem. 1996, 
113, 77–86. 
 
(S)-4-Hydroxy-[2.2]paracyclophane (40): 
 
In a 250 mL round bottom flask, (S)-4-formyl-[2.2]paracyclophane (2.988 g, 12.72 
mmol) was dissolved in dichloromethane (60 mL) and methanol (60 mL). Concentrated 
sulfuric acid (0.7 mL) was added dropwise. Hydrogen peroxide (35% aqueous, 1.5 mL) 
OH
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was added dropwise. The solution was stirred, loosely capped, for 16 hours. Solvents 
were removed in vacuo. The crude oily solid was diluted with dichloromethane, and 
washed two times with deionized water.  The organic layer was dried over sodium 
sulfate, filtered, and solvent was removed in vacuo. The crude solid was 
chromatographed on silica, loading in hot dichloromethane, and eluting as a gradient 
from 100% hexanes to 15% ethyl acetate in hexanes (v/v) to yield a pale orange solid 
(1.789 g, 63.1%): 1H NMR (CDCl3, 400 MHz, 298 K): δ 7.01 (dd, J = 7.8 Hz, J = 1.9 
Hz, 1H), 6.56 (dd, J = 7.8 Hz, J = 1.9 Hz, 1H), 6.46 (dd, J = 7.8 Hz, 1.9 Hz, 1H), 6.38–
6.42 (m, 2H), 6.27 (dd, J = 7.7 Hz, J = 1.6 Hz, 1H), 5.55 (d, J = 1.6 Hz, 1H), 4.45 (s, 1H), 
3.29–3.39 (m, 1H), 2.87–3.16 (m, 6H), 2.62–2.73 (m, 1H); 13C NMR (CDCl3, 100 MHz, 
298 K): δ 153.7, 142.0, 139.6, 138.8, 135.5, 133.0, 132.8, 131.9, 127.9, 125.4, 125.0, 
122.6, 35.3, 34.8, 33.8, 31.1; HRMS (EI+): calcd. for C16H16O [M]+ 224.1201 found 
224.1198. 
 
Friedmann, C. J.; Ay, S.; Bräse, S.  J. Org. Chem., 2010, 13, 4612–4614. 
 
(S)-4-Methoxy-[2.2]paracyclophane (41): 
 
In a nitrogen-charged glove box, (S)-4-hydroxy-[2.2]paracyclophane (1.780 g, 7.94 
mmol) was dissolved in tetrahydrofuran (20 mL). Sodium hydride (0.210 g, 8.73 mmol) 
OMe
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was added in portions, with stirring, waiting for fizzing to subside between additions. The 
mixture was stirred for an additional 10 minutes, sealed, and removed from the glove 
box. Under N2, iodomethane (1.0 mL, 15.88 mmol) was added dropwise. The solution 
was sealed and heated to 80 ˚C for 40 hours. Solvent was removed in vacuo. The solid 
was dissolved in ether, washed twice with water, three times with aqueous potassium 
hydroxide (2.0 M), and once with brine. The organic layers were dried over sodium 
sulfate and solvent was removed in vacuo. The solid was chromatographed on silica, 
loaded using hot hexanes, and eluted as a gradient from 0% ethyl acetate/hexanes (v/v) to 
3% to yield a colorless solid (1.246 g, 66.4%): 1H NMR (CDCl3, 400 MHz, 298 K): δ 
6.76 (dd, J = 7.8 Hz, J = 1.8 Hz, 1H), 6.38–6.55 (m, 4H), 6.28 (dd, J =  7.5 Hz, J = 1.4 
Hz, 1H), 5.67 (d, J = 1.3 Hz, 1H), 3.71 (s, 3H), 3.42–3.48 (m, 1H), 2.99–3.13 (m, 6H), 
2.59–2.66 (m, 1H); 13C NMR (CDCl3, 100 MHz, 298 K): δ 157.6, 142.1, 140.3, 138.8, 
135.0, 133.7, 133.1, 131.5, 128.4, 127.5, 124.4, 116.7, 54.3, 35.5, 35.4, 34.1, 31.7; 
HRMS (EI+): calcd. for C17H18O [M]+ 238.1358 found 238.1358. 
 
(S)-7-Iodo-4-methoxy-[2.2]paracyclophane (42): 
 
In a 100 mL round bottom flask, (S)-4-methoxy-[2.2]paracyclophane (2.000 g, 8.46 
mmol) was dissolved in dichloromethane (25 mL). In a 125 mL Erlenmeyer, N-
iodosuccinimide (2.000 g, 8.89 mmol) and trifluoracetic acid (0.69 mL, 8.89 mmol) were 
I OMe
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dissolved in dichloromethane (40 mL) with swirling and added to the round bottom flask, 
in 2 mL portions. The solution was stirred, in the dark, for 1 hour before being 
neutralized by saturated aqueous sodium bicarbonate. The mixture was transferred to a 
separatory funnel and the layers were separated. The organic layer was washed once with 
saturated aqueous sodium bicarbonate, a solution of sodium metabisulfite in brine (5 
g/L), then brine. The organic layer was dried over sodium sulfate, filtered, and solvent 
was removed in vacuo. The crude solid was dissolved from minimal boiling hexanes 
(~100 mL), chilled to –20 ˚C, filtered, and washed with cold hexanes to yield a pale 
brown solid (2.964 g, 96.4%): 1H NMR (CDCl3, 400 MHz, 298 K): δ 7.13 (dd, J = 7.9 
Hz, J = 1.8, 1H), 6.75 (dd, J = 7.9 Hz, J = 1.8 Hz, 1H), 6.71 (s, 1H), 6.46 (dd, J = 7.9 Hz, 
J = 1.8, 1H), 6.40 (dd, J = 7.8 Hz, J = 1.8 Hz, 1H), 5.69 (s, 1H), 3.68 (s, 3H), 2.82–3.37 
(m, 7H), 2.43–2.53 (m, 1H); 13C NMR (CDCl3, 100 MHz, 298 K): δ 157.9, 144.7, 143.9, 
139.9, 138.5, 132.9, 131.5, 129.9, 129.6, 128.9, 117.7, 91.9, 54.3, 39.3, 33.6, 33.2, 31.1; 
HRMS (EI+): calcd. for C17H17IO [M]+ 364.0324 found 364.0330; HPLC (Phenomenex® 
Lux chiral column (250 mm length, 4.6 mm diameter, 3 µm particle size), 
methanol:water (95:5 v/v), 1.0 mL/min, 254 nm): 20.01 min (R); 23.54 min (S); ee 
96.5%. 
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(4-((S)-7-Methoxy-[2.2]paracyclophanyl))(phenyl)iodonium hexafluorophosphate 
(43): 
 
In a flame-dried 100 mL Schlenk tube, (S)-7-iodo-4-methoxy-[2.2]paracyclophane 
(0.5000 g, 1.3728 mmol) was dissolved, with stirring, in warm ether (40 mL), under N2. 
The solution was gradually cooled, with vigorous stirring, to -78 ˚C.  To this mixture, n-
butyl lithium (2.5 M in hexanes, 0.64 mL, 1.510 mmol) was added, dropwise. The 
mixture was stirred at -78 ˚C for 30 minutes. In a separate 50 mL Schlenk tube, 
anhydrous zinc chloride (0.800 g, 5.491 mmol) was gently flame-dried until bubbling 
subsided. An oven-dried stirbar was added. After cooling to r.t., dry ether (20 mL) was 
added, under N2, and the solid was dissolved using sonication and vigorous stirring. A 
portion of this solution (10 mL, 2.746 mmol zinc chloride) was added dropwise to the 
first Schlenk tube.  The suspension was allowed to warm to room temperature and ether 
was removed under high dynamic vacuum to yield a foam. Dry acetonitrile (10 mL) was 
added with stirring to dissolve the foam.  In a separate flame-dried 100 mL Schlenk tube, 
bis(acetoxy)iodobenzene (0.6632 g, 5.491 mmol) was dissolved in dry acetonitrile (40 
mL). Both solutions were chilled to -20 ˚C and the organozinc chloride solution was 
added, dropwise, over the course of 5 min to the bis(acetoxy)iodobenzene solution.  The 
OMeIF6P
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resulting solution was held at -20 ˚C for 30 minutes before warming to r.t.  Deionized 
water and sodium hexafluorophosphate (0.5764 g, 3.432 mmol) were added, with stirring, 
and the mixture was concentrated in vacuo. The mixture was extracted three times with 
dichloromethane. The combined organic layers were dried over sodium sulfate, filtered, 
and solvent was removed in vacuo. The crude solid was dissolved in minimal 
dichloromethane and slowly dripped into a stirring solution of ether in hexanes (10% 
v/v).  Stirring was stopped, and after standing for an hour, the mixture was filtered and 
the solid rinsed three times with hexanes to yield a colorless powder (0.6228 g, 77.3%): 
1H NMR (CD3CN, 400 MHz, 298 K): δ 8.03 (d, J = 7.9 Hz, 2H), 7.70 (t, J = 7.5 Hz, 1H), 
7.54 (t, J = 7.9 Hz, 2H), 7.29 (s, 1H), 6.82 (dd, J = 7.8 Hz, J = 1.8 Hz, 1H), 6.63 (dd, J = 
7.8 Hz, J = 1.8 Hz, 1H), 6.34 (dd, J = 7.9 Hz, J = 1.9 Hz, 1H), 6.19 (dd, J = 7.9 Hz, J = 
1.9 Hz, 1H), 6.04 (s, 1H), 3.74 (s, 3H), 3.37–2.99 (m, 7H), 2.74–2.64 (m, 1H); 19F NMR 
(CD3CN, 400 MHz, 298 K): δ -72.88 (d, J = 708.0 Hz, 6F); HRMS (ESI): calcd. for 
C23H22IO [M-PF6]+ 441.0710 found 441.0730. 
 
(S)-N,N,N-Trimethyl-1-phenylethanaminium hexafluorophosphate (45): 
 
In a 100 mL Schlenk storage tube, potassium carbonate (31.0 mmol, 4.29g) was 
suspended in acetonitrile (50 mL) and heated to 80 ˚C with vigorous stirring. (S)-1-
phenylethylamine (7.76 mmol, 1.0 mL) was added dropwise. The mixture was stirred at 
80 ˚C for 15 minutes, cooled to r.t., and iodomethane (46.6 mmol, 2.89 mL) was added. 
CH3
NMe3F6P
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The tube was sealed and heated to 80 ˚C overnight.  Solvent was removed in vacuo, 
diluted with water (75 mL) and extracted three times with dichloromethane (3 x 25 mL). 
Solvent was removed in vacuo, and the solid was dissolved in minimal methanol and 
aqueous sodium hexafluorophosphate (1 M, 10 mL) was added with stirring. The mixture 
was concentrated in vacuo, extracted three times with dichloromethane (3 x 25 mL). The 
organic layers were washed once with deionized water, dried over sodium sulfate, and 
solvent was removed in vacuo. The crude solid was recrystallized from boiling methanol 
(10 mL), chilled to -20 ˚C, filtered, and rinsed with cold methanol to yield the product as 
colorless plates (308 mg, 12.8%): 1H NMR (CD3CN, 400 MHz, 298 K): δ 7.51 (m, 5H), 
4.57 (q, J = 7.0 Hz, 1H), 2.95 (s, 9H), 1.75 (dt, J = 1.9 Hz, J = 7.0 Hz, 3H); 19F NMR 
(CD3CN, 376 Hz, 298 K): δ -72.74 (d, J = 706.5 Hz, 6F); 13C NMR (CD3CN, 100 MHz, 
298 K): δ 133.90, 131.69, 131.54, 130.19, 75.29, 52.05 (t, J = 8.1 Hz), 15.43; HRMS 
(ESI): calcd. for C11H18N [M-PF6]+ 164.1439 found 164.1439. 
 
(R)-N,N,N-Trimethyl-1-phenylethanaminium hexafluorophosphate (46): 
 
In a 100 mL Schlenk storage tube, sodium bicarbonate (31.0 mmol, 2.61 g) was 
suspended in methanol (40 mL) and (R)-1-phenylethylamine (7.76 mmol, 1.0 mL) and 
iodomethane (46.6 mmol, 2.89 mL) were added. The mixture was stirred for 15 minutes, 
then sealed and heated to 70 ˚C overnight.  Solvent was removed in vacuo, diluted with 
dichloromethane (50 mL) and washed three times with aqueous sodium 
CH3
NMe3F6P
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hexafluorophosphate (1 M, 10 mL) and once with deionized water. The organic layers 
were dried over sodium sulfate, and solvent was removed in vacuo. The crude solid was 
recrystallized from boiling methanol (10 mL), chilled to room temperature, filtered, and 
rinsed with cold methanol to yield the product as colorless plates (1.460 g, 60.8%): 1H 
NMR (CD3CN, 400 MHz, 298 K): δ 7.51 (m, 5H), 4.57 (q, J = 7.0 Hz, 1H), 2.95 (s, 9H), 
1.75 (dt, J = 1.9 Hz, J = 7.0 Hz, 3H); 19F NMR (CD3CN, 376 Hz, 298 K): δ -72.74 (d, J 
= 706.5 Hz, 6F); 13C NMR (CD3CN, 100 MHz, 298 K): δ 133.90, 131.69, 131.54, 130.19, 
75.29, 52.05 (t, J = 8.1 Hz), 15.43; HRMS (ESI): calcd. for C11H18N [M-PF6]+ 164.1439 
found 164.1439. 
 
tert-Butyl 2-bromopropionate (47): 
 
Under nitrogen, 2-bromopropionyl bromide (4.85 mL, 46.30 mmol) was dissolved in 20 
mL dry DCM with stirring. The solution was cooled to 0 ˚C and triethylamine (6.5 mL, 
46.30 mmol), dried over KOH, was added by syringe. tert-Butanol (5.15 g, 69.48 mmol) 
was dissolved in 5 mL dry DCM and added dropwise by syringe.  A colorless precipitate 
forms. After addition the solution was allowed to warm to room temperature and stirred 
for an additional hour. The mixture was transferred to a separatory funnel, washed once 
with water, once with saturated aqueous sodium bicarbonate, and once with brine. The 
organic layer was dried over sodium sulfate, filtered, and concentrated to a colorless oil 
in vacuo. The crude product was used without further purification (7.378 g, 76.2%): 1H 
H3C O
O
Br
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NMR (CDCl3, 400 MHz, 298 K): δ 4.27 (q, J = 6.9 Hz, 1H), 1.78 (d, J = 6.9 Hz, 3H), 
1.48 (s, 9H). 
 
Linton, R. B.; Reutershan, H. M.; Aderman, M. C.; Richardson, A. E.; Brownell, R. K.; 
Ashley, W. C.; Evans, A. C.; Miller, J. S. Tetrahedron. Lett. 2007, 11, 1993–1997. 
 
tert-Butyl 2-nitropropionate (48): 
 
In a 250 mL round bottom flask anhydrous phloroglucinol (4.71 g, 38.86 mmol) and 
anhydrous sodium nitrite (4.23 g, 70.58 mmol) were suspended in DMSO (70 mL) with 
stirring. tert-Butyl 2-bromopropionate (7.38 g, 35.29 mmol) was added dropwise. The 
flask was loosely stoppered, covered in foil, and the suspension was stirred for 3 hours. 
The suspension was poured into ice water and extracted 5 times with diethyl ether. The 
organic layers were washed with brine, dried over sodium sulfate, and filtered. Ether was 
removed in vacuo. The oil was chromatographed on silica with dichloromethane to yield 
a colorless oil (3.011 g, 48.7%): 1H NMR (CDCl3, 400 MHz, 298 K): δ 5.11 (q, J = 7.1 
Hz, 1H), 1.75 (d, J = 7.1 Hz, 3H), 1.50 (s, 9H); 13C NMR (CD3CN, 100 MHz, 298 K): δ 
164.25, 84.70, 84.21, 27.89, 15.90; HRMS (ESI): calcd. for C7H12NNa2O4 [M-H+2Na]+ 
220.0562 found 220.0563; HRMS (EI+): calcd. for C7H13NNaO4 [M+Na]+ 198.0742 
found 198.0745. 
 
H3C O
O
NO2
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Kornblum, N.; Blackwood, R. K. Org. Synth. 1957, 37, 44. 
 
Sodium 1-tert-butoxy-2-nitropropenolate (49): 
 
In a flame-dried 50 mL Schlenk tube, tert-butyl 2-nitropropionate (0.5000 g, 2.85 mmol) 
was added under N2. The tube was chilled to 0 ˚C. Sodium hydride (0.0650 g, 2.71 
mmol) was added in portions under N2 with vigorous stirring. Once bubbling had 
subsided, the mixture was diluted with ethyl acetate. The mixture was washed once with 
minimal deionized water.  The organic layer was dried over sodium sulfate and solvent 
was removed in vacuo. The solid was sonicated in ether, filtered, and washed three times 
with ether to yield a colorless powder (0.4570 g, 81.2%): 1H NMR (CD3OD, 400 MHz, 
298 K): δ 2.11 (s, 3H), 1.51 (s, 9H); 13C NMR (CD3OD, 100 MHz, 298 K): δ 164.26, 
112.81, 79.51, 27.25, 14.14. 
  
H3C O
ONa
NO2
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2.6 NMR Spectra 
 
1H NMR (CDCl3, 500 MHz, 298 K) spectrum of ethyl 2-nitropropanoate (5) 
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13C NMR (CDCl3, 125 MHz, 298 K) spectrum of ethyl 2-nitropropanoate (5) 
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1H NMR (CD3OD, 400 MHz, 298 K) spectrum of sodium 1-ethoxy-2-nitropropenolate 
(8) 
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13C NMR (CD3OD, 100 MHz, 298 K) spectrum of sodium 1-ethoxy-2-nitropropenolate 
(8) 
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1H NMR (CDCl3, 400 MHz, 298 K) spectrum of ethyl 2-(4-methylphenyl)-2-
nitropropanoate (15) 
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13C NMR (CDCl3, 100 MHz, 298 K) spectrum of ethyl 2-(4-methylphenyl)-2-
nitropropanoate (15) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of ethyl 2-(4-methylphenyl)-2-
aminopropanoate (21) 
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1H NMR (D2O, 700 MHz, 298 K) spectrum of 2-ammonio-2-(4-
methylphenyl)propanoate (24) 
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13C NMR (D2O, 176 MHz, 298 K) spectrum of 2-ammonio-2-(4-
methylphenyl)propanoate (24) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of (4-methoxyphenyl)(4-
nitrophenyl)iodonium hexafluorophosphate (12) 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of (4-methoxyphenyl)(4-
nitrophenyl)iodonium hexafluorophosphate (12) 
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13C NMR (CD3CN, 100 MHz, 298 K) spectrum of (4-methoxyphenyl)(4-
nitrophenyl)iodonium hexafluorophosphate (12) 
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1H NMR (CDCl3, 700 MHz, 298 K) spectrum of (S)-4-formyl-[2.2]paracyclophane (39) 
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13C NMR (CDCl3, 100 MHz, 298 K) spectrum of (S)-4-formyl-[2.2]paracyclophane (39) 
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1H NMR (CDCl3, 700 MHz, 298 K) spectrum of (S)-4-hydroxy-[2.2]paracyclophane (40) 
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13C NMR (CDCl3, 176 MHz, 298 K) spectrum of (S)-4-hydroxy-[2.2]paracyclophane 
(40) 
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1H NMR (CDCl3, 400 MHz, 298 K) spectrum of (S)-4-methoxy-[2.2]paracyclophane (41) 
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13C NMR (CDCl3, 100 MHz, 298 K) spectrum of (S)-4-methoxy-[2.2]paracyclophane 
(41) 
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1H NMR (CDCl3, 400 MHz, 298 K) spectrum of (S)-7-iodo-4-methoxy-
[2.2]paracyclophane (42) 
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13C NMR (CDCl3, 100 MHz, 298 K) spectrum of (S)-7-iodo-4-methoxy-
[2.2]paracyclophane (42) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of (4-((±)-7-methoxy-
[2.2]paracyclophanyl))(4-methoxyphenyl)iodonium hexafluorophosphate (36) 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of (4-((±)-7-methoxy-
[2.2]paracyclophanyl))(4-methoxyphenyl)iodonium hexafluorophosphate (36) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of (4-((S)-7-methoxy-
[2.2]paracyclophanyl))(phenyl)iodonium hexafluorophosphate (43) 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of (4-((S)-7-methoxy-
[2.2]paracyclophanyl))(phenyl)iodonium hexafluorophosphate (43) 
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1H NMR (CDCl3, 300 MHz, 298 K) spectrum of tert-butyl 2-nitropropionate (48) 
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13C NMR (CDCl3, 75 MHz, 298 K) spectrum of tert-butyl 2-nitropropionate (48) 
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1H NMR (CD3OD, 700 MHz, 298 K) spectrum of sodium 1-tert-butoxy-2-
nitropropenolate (49) 
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13C NMR (CD3OD, 700 MHz, 298 K) spectrum of sodium 1-tert-butoxy-2-
nitropropenolate (49) 
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CHAPTER 3 
SYNTHESIS OF A VARIETY OF 2-ARYL-5-FLUOROBENZIMIDAZOLES 
 
3.1 Introduction 
In recent years there has been an interest in synthesizing substituted 
benzimidazoles, particularly 2-arylbenzimidazoles.1  Benzo-fused imidazoles, oxazoles, 
and thiazoles have shown a broad range of biological activities.2–4  This includes anti-
tumor,5–8 anti-viral,9–13 anti-microbial,14–17 anti-fungal,1 anti-ulcer,1 anti-histaminic,1 and 
anti-inflammatory agents.18,19 
 
6
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Figure 3.1: Numbering convention for benzimidazole (left)20 and some 
2-arylbenzimidazoles used as biological agents (right) 
 
For material applications, these compounds are useful as nonlinear optics (NLO).21–24  
NLOs can be used for frequency doubling, optical phase conjugation (wavefront 
Exhibits cytotoxicity and apoptotic  
activity toward human breast cancer cells8 
Anti-inflammatory  
and analgesic19 
Anti-bacterial against 
Chlamydia pneumoniae16 
Anti-microbial against 
Leishmania donovani17 
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reversal), etc.  More recently these compounds have also found application as organic 
light-emitting diodes (OLED) and liquid crystals.25–30 
We are mostly interested in this class of compounds for their biological 
application.  Given their broad range of activity, radio-labeled 2-arylbenzimidazoles 
could be useful for imaging.  These compounds could potentially be used for diagnosing 
and monitoring cancer patients, studying inflammatory response, and as a diagnostic 
method for Alzheimer’s disease.  These compounds are structurally related to 
benzothiazole and benzoxazole compounds currently used for positron emission 
tomography (PET) imaging of ß-amyloid plaques (Figure 3.2).   
 
N
SHO
N
11CH3
H
N
SHO
N
CH3
H
18F
N
SHO
N
N
11CH3
H
O
HO
N
N
H
CH3
18F
[11C]PiB [11C]AZD2184
[18F]Flutemetamol [18F]AZD4694  
Figure 3.2: Some current PET radiotracers used for imaging ß-amyloid plaques  
 
Also, several studies suggest that long-term use of anti-inflammatory drugs may protect 
patients against the onset of Alzheimer’s disease.31  The mechanism for this protection is 
not well understood, and subsequent studies have not found improvement in patients 
taking standard NSAIDs.32  As these compounds have found use as anti-inflammatory 
agents, they may be useful as imaging agents as well. 
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We sought to develop a synthesis of 2-arylbenzimidazoles that could be used as 
radiotracers for PET.  We chose to substitute these compounds with fluoride-18 for the 
same reasons as discussed previously in relation to the synthesis of Flutemetamol 
(Chapter 1).  Its half-life of about 2 hours is convenient for relatively complex radiotracer 
synthesis, long enough to synthesize the radiotracer at a lab with an on-site cyclotron and 
transport it to nearby satellite PET centers (that lack a full radiochemical lab and 
cyclotron).  Its half-life is also short enough to collect kinetic data in a reasonable time 
period (provided the unbound radiopharmaceutical is metabolized quickly); radioactivity 
in the patient is short-lived, allowing the PET scan to be an outpatient procedure.  The 
low positron kinetic energy of fluorine-18 ensures a short range in tissue, which provides 
a high resolution PET scan.  The decay of fluorine-18 yields innocuous 18O as the product 
atom.  The nuclear reaction for formation of fluorine-18 from oxygen-18, 18O(p,n)18F on 
18O-enriched water (H218O), can yield several Curie (Ci) amounts of fluorine-18 from a 
single cyclotron run, allowing for many PET scans from a single cyclotron run.  Fluorine 
substitution of drugs often leads to improved pharmacological profiles.33,34  The high 
electronegativity and small atomic radius of the fluorine atom, along with the short C–F 
bond length, cause relatively small structural perturbations compared to other functional 
group substitutions, but drastically alter the electronic properties, and often improve the 
bioavailability of the compound. 35 , 36   These features make fluorine-18 an attractive 
radionuclide to incorporate into 2-arylbenzimidazoles. 
As with the synthesis of Flutemetamol (Chapter 1) we chose to use hypervalent 
iodine complexes, specifically diaryliodonium triflates and diaryliodonium 
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hexafluorophosphates, to introduce fluorine-18 onto the target molecule.  A synthesis of 
diaryliodonium salts, using a variety of substituted benzenes at the 2-position of 
benzimidazole, was started.  We chose to introduce the fluorine atom at the 5-position, as 
a large variety of 2-arylbenzimidazoles of interest have substitution at the 5-position.2–4 
  
3.2 Results and Discussion 
 
3.2.1 Direct Synthesis of 2-Aryl-5-[19F]Fluorobenzimidazoles 
 We began by synthesizing [19F]-fluorinated benzimidazoles directly, without 
using iodonium salts.  A total of 11 2-aryl-5-fluorobenzimidazoles were produced in 
sufficient purity.  These compounds would be useful later in the project as fluorine-19 
standards for NMR analysis and HPLC standards for radiochemistry.  This shorter 
synthesis also worked as a model synthesis for the first portion of the subsequent 
synthesis with iodonium salts.  Oakridge National Labs (ORNL) expressed interest in 
screening these 2-aryl-5-[19F]fluorobenzimidazoles, so a variety of compounds were 
synthesized (ORNL subcontract 4000089408). 
There is a broad array of methods for synthesizing benzimidazoles. 37 – 48   A 
retrosynthesis was designed (Scheme 3.1).  We chose a route that built up the 
benzimidazole by coupling a nitro aniline and substituted benzoyl chloride, followed by 
reduction and ring closure.  This route was chosen as the precursors were inexpensive in 
large quantities, the synthetic steps generally did not require harsh conditions, and the 
final step did not require toxic catalysts which could pose issues if used in vivo.   
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Scheme 3.1: Retrosynthesis of 2-aryl-5-fluorobenzimidazoles 
 
Starting with commercially available 4-bromoaniline, the benzene ring was 
nitrated.  Electrophilic aromatic substitution is not directly possible on anilines due to the 
extremely activated arene and the easily oxidized amine.  Small scale trials rapidly 
became highly exothermic and turned jet black.  The amine was protected using acetic 
anhydride to form 4-fluoroacetanilide (1).49,50  This arene was nitrated using fuming 
nitric acid to yield 4-fluoro-2-nitroacetanilide (2). 
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Scheme 3.2: General forward synthesis of 2-aryl-5-fluorobenzimidazoles 
 
Conditions were also established for nitration using milder reagents (Scheme 3.3).  At -8 
˚C, the nitronium cation forms from the combination of concentrated nitric and sulfuric 
1 2 3 
7a–l 
6a–l 5a–l 
4a–l 
90% 
15–86% 
(46% avg.) 
22–59% 
(42% avg.) 
18–91% 
(52% avg.) 
 
quantitative 
97% 
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acids and addition occurs.  At lower temperatures the reaction did not progress at a 
reasonable rate, and higher temperatures promoted a second nitration (to form 4-fluoro-
2,6-dinitroacetanilide) and formation of 4-fluoro-3-nitroacetanilide. 
 
NH
F
NH
F NO2
O O
conc. HNO3
conc. H2SO4
-8 ˚C
 
Scheme 3.3: Milder nitration conditions 
 
Yields tended to be lower with these reaction conditions, and temperature control proved 
more difficult.  Fuming nitric acid, while more hazardous to use, provided better yields.  
Due to the stronger conditions, temperatures could be lowered to -40 ˚C, which greatly 
minimized formation of side-products.  It was found that scaling up the reaction above 2 
grams of 1 made temperature control more difficult (presumably due to slower 
temperature diffusion through the larger solution volume).  Since nitration was complete 
in only 10 minutes, this step was effectively scaled up by repeated nitration on a 2 g 
scale.  Deprotection was performed under acidic conditions to form 4-fluoro-2-
nitroaniline (3); deprotection with hydroxide also proved effective.  Recrystallization was 
performed after each step for compound characterization; however, it was found that 
recrystallization after deprotection provided pure product, even if recrystallization was 
not performed for the acetate protection and nitration steps.  Although the route without 
individual crystallizations gave a poorer yield for the hydrolysis step (to form 3), the 
overall yield after three steps was similar. 
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Amides were generated using acid chlorides (4a–l).  A variety of acid chlorides 
could be purchased commercially or readily synthesized; twelve were chosen (Figure 
3.3). 
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Figure 3.3: Acid chlorides used 
 
Amide formation proved more challenging.  Initial reactions, using a 1:1 ratio of aniline 
(3) to acid chloride (4a–l) and an excess of triethylamine, went only partially to 
completion (typically 30–60%).  Addition of more acid chloride (1:1.5 3 to 4a–l)  made 
little change in the amount of product.  Even with the addition of 4-
(dimethylamino)pyridine (DMAP), the reaction did not progress further.  Changing the 
solvent from dichloromethane to acetonitrile, a more polar and higher boiling solvent, 
increased reaction rate, but did not change the amount of product produced.  Using 
a b 
c d 
e f g h 
i j k 
l 
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rigorously dry 3, acetonitrile, and triethylamine made no noticeable change.  Fortunately 
the amide product (5a–l) was separable from 3 and the acid chloride (4a–l) by 
recrystallization or column chromatography.  Using vacuum sublimation, 3 could be 
recovered from the impure mother liquor, and further purified using recrystallization. 
 Reduction of the aryl nitro and ring closure could potentially be performed by a 
reductive imination.  However, we chose to take a two-step approach instead to better 
study each step.  Reduction was performed using hydrogen gas and a metal catalyst.51 
Initially platinum oxide was used with 400 psi H2 to reduce 5a to 6a.  Reaction was found 
to be complete by TLC, but even after purification, NMR showed what seemed to be 
significant impurities in the aliphatic region.  After further analysis we realized that not 
only was the nitro group reduced to the amine, but the phenyl ring was also reduced to a 
cyclohexyl ring (Scheme 3.4), exclusively forming N-cyclohexyl-4-fluoro-2-aminoaniline 
(6m). 
 
NH
F
O
NO2
10 mol% PtO2
400 psi H2
2-propanol, r.t.
NH
F
O
NH2
 
Scheme 3.4: Formation of N-cyclohexyl-4-fluoro-2-aminoaniline (6m). 
 
Though not the intended outcome, this was fortuitous as it offered a simple route to an 
additional 2-aryl-5-fluorobenzimidazole.  The reaction was run again using lower 
pressure (200 psi H2) and palladium over carbon (Pd/C).  These conditions (Scheme 3.5) 
exclusively produced N-phenyl-4-fluoro-2-aminoaniline (6a).   
6m 5a 
75% 
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Scheme 3.5: Formation of N-phenyl-4-fluoro-2-aminoaniline (6a). 
 
It was found that 100 psi was also sufficient hydrogen pressure to reduce the nitro group.  
The rest of the amides were reduced using these milder conditions to produce 6b–l. 
 Ring closure was performed under acidic conditions.52,53  This step presumably 
occurs in a similar fashion to imine formation (Figure 3.4).     
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Figure 3.4: Proposed mechanism of ring closure 
 
The added aromatic stability from a 10-electron fused ring system (rather than a single 
ring 6-electron system) makes this process favorable.  The addition of molecular sieves 
also helps to drive the reaction by removing the water that is eliminated.  Neutralization 
of excess acid and purification by recrystallization or column chromatography provides 
the 2-aryl-5-fluorobenzimidazoles (7a–m).  These compounds are fairly insoluble in most 
organic solvents, and NMR spectra can be complicated due to fast tautomerization 
5a 6a 
42% 
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(Figure 3.5); in most cases several of the benzimidazole ring protons are highly 
broadened or not visible. 
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Figure 3.5: Proposed mechanism of tautomerization 
 
We were unable to fully purify compounds 7h and 7j, but sent the remaining 11 
compounds to ORNL for screening. 
 
3.2.2 Synthesis of 2-Aryl-5-[18F]Fluorobenzimidazoles Precursors 
With fluorine-19 standards completed, synthesis was started toward 
diaryliodonium salts that could be used as precursors for 2-aryl-5-
[18F]fluorobenzimidazoles.  Compounds with tight binding and long half-lives in vivo are 
typically unsuitable for therapeutic use due to their extended duration of effect.  
However, since the dosage of a radiotracer for PET is typically well below the level of 
physiological effect, compounds that bind tightly to the target (e.g. tumor cells) are often 
useful as imaging agents.  Regardless of the results ORNL might publish, we decided to 
proceed toward synthesizing the same set of compounds using diaryliodonium salts, 
which could be used in a radiosynthesis and evaluated as radiotracers for positron 
emission tomography (PET).  Two of these compounds were successfully fluorinated, 
using conditions suitable for radiofluorination.  An additional eight 2-aryl-5-
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bromobenzimidazoles were produced and partially carried forward toward production of 
the analogous PET precursors.   
We have developed a wide variety of methods to make diaryliodonium salts,54–56 
but at the onset of this project we had only developed a few (Figure 3.6): (1) an aryl 
iodonium diacetate could be directly coupled with an arene, activated toward 
electrophilic aromatic substitution (EAS), in the presence of an acid (typically p-
toluenesulfonic acid57,58) or a Lewis acid (trimethylsilyl p-toluenesulfonate (TMS-OTs), 
trimethylsilyl trifluoromethanesulfonate (TMS-OTf), etc), (2) an aryl iodonium diacetate 
could be coupled with an aryl trifluoroborate salt in the presence of a Lewis acid, (3) an 
aryl iodonium diacetate could be coupled with an aryl stannane in the presence of an 
acid59 or a Lewis acid. 
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Figure 3.6: Methods for synthesizing diaryliodonium salts 
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The first route was not practical for synthesizing a broad scope of 2-arylbenzimidazoles, 
as many of the compounds have electron-rich arenes at the 2-position of the 
benzimidazole; rather than add to the 5-position of the benzimidazole ring, bis(acetoxy)-
4-methoxybenzene could instead add to the other arene.  Both the second and third 
methods could be used with a 2-aryl-5-bromobenzimidazole precursor.  A synthesis for 
2-aryl-5-bromobenzimidazoles was developed.  The same, or similar, synthetic steps 
from the first synthesis could presumably be used to make brominated (rather than 
fluorinated) analogs (Scheme 3.6).   
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Scheme 3.6: General forward synthesis of 2-aryl-5-bromobenzimidazoles 
 
Acetylation proceeded with similar results; 4-bromoacetanilide (8) was somewhat 
less soluble than 4-fluoroacetanilide (1), which led to slightly improved yields.  Nitration 
was performed with fuming nitric acid to produce 4-bromo-2-nitroacetanilide (9).  It was 
found that this reaction could be scaled to 6 grams of 8 without a significant loss in purity 
or yield, unlike the synthesis of 4-fluoro-2-nitroacetanilide which provided lower yields 
8 9 10 
11a–l 
13a–l 
4a–l 
98% 92% 89% 
20–87% 
(49% avg.) 
49–89% 
(73% avg.) 
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above 2 grams of 1 (due to side-reactions).  Presumably this is due to bromine being 
slightly more deactivating than fluorine,60 , 61  and also that 4-bromoacetanilide (8) is 
slightly less soluble in nitric acid than 4-fluoroacetanilide (1), which may slow the 
reaction slightly.  A larger scale batch of 9 was produced by repeated nitration on a 6 g 
scale.  Removal of the acetyl protecting group was performed under the same conditions 
to produce 4-bromo-2-nitroaniline (10). 
Once again, amide formation proved challenging.  We theorized that a 
complicated equilibrium existed between the aniline and the amide product (11a–l); an 
unreacted aniline could attack the product, cleaving the amide to generate another amide 
(11a–l) and free aniline (10).  After further investigation it was discovered that in some 
reactions (e.g. formation of 11a, h, k, l), the imide (caused by a second addition of the 
acid chloride onto the product amide, 11) was predominantly formed.  Presumably the 
electron-deficient amide (11) was sufficiently acidic to be deprotonated by triethylamine 
and react with a second equivalent of the acid chloride (4).  It may be possible for this 
imide to exist as an intermediate in the equilibrium, even though it was not readily 
observed in all reactions.  Under this assumption, conditions were modified for some 
compounds, using pyridine instead of triethylamine and a stoichiometric amount of acid 
chloride.  Using this method, yields were significantly improved (in most cases).  Some 
imides (12a, 12e, 12l) were isolated by recrystallization and hydrolyzed to the 
corresponding amide (11a, 11e, 11l) by hydrolysis with a suitable amount of sodium 
hydroxide (determined using several small-scale trial reactions, plotting the amount of 
remaining imide, and projecting an optimum amount of hydroxide to use). 
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 Rather than take a two-step approach as with the previous synthesis, a mild 
reduction, run under acidic conditions, was performed to both reduce the nitro group and 
close the ring to form the 2-aryl-5-bromobenzimidazoles (13a–l).  Since aromatic nitro 
groups have a high reduction potential,51 a variety of conditions could be used.62  Tin, 
zinc, and iron reductions were investigated.  It was found that a Béchamp reduction, 
using iron filings in acetic acid, was able to reduce the nitro group and exact ring-
closure.63,64  Typically Béchamp reductions are run in hydrochloric acid, but it was found 
that acetic acid, at 110 ˚C was sufficient.  This reaction is fairly selective to nitro groups 
(selective even to aromatic nitro groups and tertiary aliphatic nitro groups over other 
aliphatic nitro groups65), so there was little worry of side-reactions on the other aromatic 
ring.  Finally, iron is relatively non-toxic.  Due to this mild approach, 5-bromo-2-
cyclohexylbenzimdazole (the brominated analog of 7m) was not synthesized.  Slow 
reaction rate is a drawback to this approach; reaction times varied from overnight to a 
week.  Performing the reaction in a sealed tube removed the concern of evaporation of 
solvent.  Reactions could be easily monitored by color — the initial reaction mixtures are 
brightly colored due to the vibrantly yellow to orange amides (11a–l), and the completed 
reaction mixtures were a pale rust color, from the oxidized iron.  Once the initial yellow 
color had faded, analysis of the solution by TLC was used to more conclusively gauge 
reaction progress.  Despite long reaction times, there were rarely side-reactions, and the 
product could be isolated by liquid-liquid extraction and, if necessary, a short silica 
column.  It was later found that the reaction time could be shortened using iron powder 
rather than iron filings; presumably the larger surface area increases the rate of reduction. 
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Compound 11j gave surprising results.  In theory the nitro group on both rings 
would be reduced (Scheme 3.7); however, after purification, the predominant product 
was 2-(4-nitrophenyl)-5-bromobenzimidazole (13m) 
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Scheme 3.7: Formation of 2-(4-nitrophenyl)-5-bromobenzimidazole (13m) 
 
Compound 13j was formed (confirmed by EI+ MS of the crude reaction mixture, showing 
[M]+ 287.0047 m/z), but only as a very minor product (not observed by NMR).  In the 1H 
NMR spectrum of the isolated product, 13m, protons on the aromatic ring at the 2-
position of the benzimidazole (8.9 Hz doublet at 8.40 ppm, 8.9 Hz doublet at 8.23 ppm) 
were shifted only slightly from those in the 1H NMR spectrum of 11j (8.9 Hz doublet at 
8.42 ppm, 8.9 Hz doublet at 8.16 ppm). 
 In total, ten 2-aryl-5-bromobenzimdazoles were produced.  We began to carry 
these compounds forward to produce the analogous diaryliodonium salts.  Before 
formation of the diaryliodonium salt, the acidic NH (pKa of benzimidazole in DMSO is 
16.466) needed to be protected.  Boc was chosen as the protecting group due to its ease of 
11j 13j 
13m 
58% 
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introduction and ease of removal (after the fluorination step).  Also, the lower polarity of 
the tert-butyl group would hopefully increase solubility of 13 in organic solvents.  We 
have incorporated Boc protecting groups into diaryliodonium salts several times with 
good success.  Boc protection proceeded smoothly with triethylamine in acetonitrile, 
using DMAP as a catalyst.   
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Scheme 3.8: Boc protection of 13 
 
Due to the rapid equilibrium between the two benzimidazole tautomers, Boc protection 
gave a nearly equal mixture of two regioisomers of each compound (14).  Initially, for a 
few of the set of Boc protections that were run, each regioisomer was isolated separately 
for characterization.  However, these fractions were recombined for the next synthetic 
steps.  For the remainder of the set of compounds 14 produced (eight compounds in all), 
both regioisomers were isolated as a mixture.  Once fluorination is complete and the Boc 
group is removed, tautomerization will occur again; each regioisomer will yield the same 
tautomers after deprotection. 
 Next, 14 were converted to the corresponding aryl tributylstannanes (15).  This 
reaction was chosen initially as we had a good deal of experience with these compounds.  
13 14 
81–92% 
(88% avg.) 
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Though organotin compounds may be toxic, the amount present after formation and 
purification of the diaryliodonium salt should be minimal, and the PET dosage is very 
low.  The tributyltin group was chosen as it is far less volatile and less toxic than 
trimethyltin; the longer chain alkanes should also help to improve compound solubility as 
did the Boc protecting group.  Given the somewhat fragile nature of the Boc protecting 
group, lithiation or formation of a Grignard reagent could not be used, so a palladium-
catalyzed transformation was used (Scheme 3.9).67     
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Scheme 3.9: Stannylation of 14 
 
Reaction progress was monitored by concurrently running a small scale reaction in 
benzene-d6 and monitoring by 1H NMR.  Since naturally occurring 115Sn, 117Sn, and 119Sn 
all have nuclear spin ½, the stannylated products are relatively easy to identify; protons 
near the tin atom appear with tin satellites.  The stannylated products were isolated as a 
mixture of regioisomers.  Once again, for a few of the set of stannylations that were run, 
each regioisomer was isolated separately for characterization.  These fractions were 
recombined for the next synthetic steps.  For the remainder of the set of compounds 15 
14 15 
43–52% 
(49% avg.) 
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produced (four compounds in all were produced in sufficient yield and purity), both 
regioisomers were isolated as a mixture.   
 Iodonium salts were synthesized from all of the set of compounds 15 (Scheme 
3.10).  The diaryliodonium triflates (16) formed were isolated as a mixture of 
regioisomers. 
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Scheme 3.10: Synthesis of diaryliodonium salts 16 
 
Purification proved challenging.  Even small amounts of residual tin (Bu3SnOAc is a 
stoichiometric by-product) caused the salts to oil rather than crystallize.  The crude salt 
could be precipitated from a more polar solvent (THF, ethyl acetate, dichloromethane, 
etc) with pentane.  Repeating this process several times usually yielded a solid.  Some 
compounds were only isolated as a sticky solid, even after repeated precipitations.  A 
number of crystallization methods were attempted: chilling a multiple-solvent solution 
near the cloud point, layering, vapor diffusion, or slow evaporation.  In all cases no 
crystallization was observed; only an oil was produced.  Residual tin compounds are 
15 
16 
32–81% 
(53% avg.) 
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often removed by stirring with a fluoride salt (e.g. potassium fluoride in ethanol); 
unfortunately, this strategy would not be practical as it could leave residual fluoride-19 
impurities (even minor amounts could compete with fluoride-18 during radiochemistry).  
Chromatography can also be used, but no solvent conditions could be established; 16 
remained at the baseline on TLC using silica or alumina.  Repeated trituration with 
pentane did remove small amounts of residual tin.  Soxhlet extraction using pentane did 
further purify the salt, but did not remove all of the tin impurity.  Performing a liquid-
liquid extraction by dissolving compounds 16 in acetonitrile and washing with pentane 
also removed some, but not all, tin impurity. 
 We sought to find another strategy to convert 14 to 16 without using tin.  Miyaura 
borylation (Scheme 3.11) was attempted.68  Regardless of the conditions used (solvent, 
base, ligand), the borylation reaction cleaved the Boc protecting group and did not appear 
to achieve conversion of the carbon-bromine bond to carbon-boron.  Boc protection of 
the crude product mixture recovered 14, confirming that borylation did not occur. 
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Scheme 3.11: Miyaura borylation example 
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Despite the potential for undesired iodoarylation of the aromatic ring at the 2-
position rather than the benzimidazole aromatic ring, direct addition of p-
methoxyphenyliodonium diacetate by electrophilic aromatic substitution was tested.  
Commercially available 2-phenylbenzimidazole was protected with a Boc protecting 
group to produce  17 (Scheme 3.12). 
 
N
H
N
Boc2O, NEt3
cat. DMAP
MeCN, r.t. N
N
Boc
 
 
Scheme 3.12: Boc protection of 2-phenylbenzimidazole 
 
Since there is no substitution on the benzimidazole ring, only one regioisomer is 
produced.  An excess of p-methoxyphenyliodonium diacetate (18) was combined with 17 
in acetonitrile-d3 (Scheme 3.13).  A variety of Lewis acid catalysts were added:  TMS-
OTs, TMS-OMs, and TMS-OTf. 
 
N
N
Boc MeO
I(OAc)2
TMS-X N
N
Boc
IX
MeO  
Scheme 3.13: Direct iodoarylation of 17 
 
Initially 1 equivalent was used; if no reaction occurred, a second equivalent was added.  
Presumably these Lewis acids undergo exchange with one or both of the acetates on p-
methoxyphenyliodonium diacetate.  The more electron-withdrawing anion(s) decreases 
17 
17 
96% 
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electron density on the iodonium center, increasing the electrophilicity of the compound.  
With the addition of TMS-OTs, the least electron-withdrawing anion (i.e. the weakest), 
no reaction occurred on 17.  A second equivalent made no change, and neither did 
heating the reaction mixture.  With the addition of TMS-OMs, no reaction occurred on 
17, with one or two equivalents.  Once heated, reduction of p-methoxyphenyliodonium 
diacetate to p-iodoanisole was observed.  Analysis of 17 was inconclusive as many 
products were formed.  With the addition of 1 equivalent of TMS-OTf, at room 
temperature, reduction of p-methoxyphenyliodonium diacetate to p-iodoanisole occurred 
immediately (visible by a vibrant color change and confirmed by 1H NMR).  Analysis of 
17 was again inconclusive; other than the sharp peaks for p-iodoanisole protons, several 
very broad peaks were present in the aromatic region.   
At this point we had begun to develop another technique for synthesizing 
diaryliodonium salts, oxidation of aryl iodides to aryl iodonium diacetates using 
SelectfluorTM and TMS-OAc.69  As this reaction only occurs on aryl iodides, a Boc 
protected 2-aryl-5-iodobenzimidazole needed to be produced.  Direct iodination of 17 did 
not provide the desired aryl iodide.  Aniline was iodinated with elemental iodine under 
basic conditions to selectively give 4-iodoaniline (19).  Acetyl protection proceeded 
smoothly using the same conditions as above to produce 4-iodoacetanilide (20). 
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Scheme 3.14: Initial steps toward synthesis of 2-aryl-5-iodobenzimidazoles 
 
Unfortunately, nitration produced less than 10% 4-iodo-2-nitroacetanilide (21), instead 
generating 4-nitroacetanilide as the major product (~90%).  Nitration reactions run as 
cold as possible (fuming nitric acid began to freeze below -45 ˚C) still produced primarily 
4-nitroacetanilide.  Rather than redesigning the synthesis at this point, we decided to 
continue forward and test fluorination of the diaryliodonium triflates (16) produced by 
the previous route using tin. 
 Although none of the set of compounds 16 could not be recrystallized after a 
variety of attempts, for some compounds repeated trituration or Soxhlet extraction was 
successful at removing the tin impurities below the level of detection by 1H NMR.  Tin 
impurities may still remain at levels that could be problematic for radiochemistry, but 
presumably should not cause issues with fluorination on a larger scale (NMR scale) with 
fluorine-19.  Three diaryliodonium triflates (16d, 16e, and 16f) were produced and 
purified as a mixture of regioisomers for analysis (Figure 3.7). 
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Figure 3.7: Diaryliodonium triflates (16) analyzed 
 
Since tin impurities were not observed in the 1H NMR spectrum, we theorized that issues 
with recrystallization may be due to the mixture of two regioisomers rather than the 
presence of a stannane.  Compound 16d was produced as a set of single regioisomers by 
isolating each regioisomer of 15d by column chromatography and synthesizing each 
regioisomer of 16d in a separate reaction.  Unfortunately, neither regioisomer of 16d 
could be crystallized, suggesting that residual tin may be preventing crystallization. 
 Fluorination proceeded smoothly, though regiochemical issues arose.  To avoid 
aryl swapping,55 a substoichiometric amount of fluoride, as tetra methylammonium 
fluoride (TMAF), was added.  No aryl swapping was observed in acetonitrile-d3.  Since 
thermolysis of diaryliodonium salts in more polar solvents tend to provide lower yield 
(presumably more polar solvents promote disproportionation), acetonitrile-d3 was 
removed and benzene-d6 was added.  In benzene-d6, compounds 16 are sparingly soluble, 
so analysis by 1H NMR proved difficult.  However, after heating at 140 ˚C thermolysis 
proceeded and the fluorinated products could be easily identified by 19F NMR.  Two 
regioisomers were expected as each arises from thermolysis of the respective regioisomer 
of 16.  The desired Boc protected 2-aryl-5-fluorobenzimidazole products (22) were 
16d 
16e 16f 
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observed as multiplets around -116 and -117 ppm.  For comparison, 2-aryl-5-
fluorobenzimidazoles (7), lacking a Boc group, appear around -120 ppm.  Unfortunately, 
in addition to the desired products, a significant portion of 4-fluoroanisole (-124 ppm) 
was also observed.  This was confirmed by doping the NMR sample with commercially 
available 4-fluoroanisole. 
 
N
N
Ar
I
BocF
MeO
N
N
Ar
I
Boc
MeO
F
∆ ∆
N
N
Ar
Boc
MeO
I
F
N
N
Boc
MeO
F
I
Ar
 
Figure 3.8: Two regiochemical pathways for thermolysis of diaryliodonium salts 
  
This product forms due to a thermolysis pathway which eliminates Boc protected 2-aryl-
5-iodobenzimidazoles.  The intermediate diaryliodonium fluorides undergo rapid 
equilibrium between several T-shaped conformations (AX3E2 in AXE notation; two 
shown in Figure 3.8).  The anion (fluoride in this case) and arene can only combine when 
one is axial (A) and one is equatorial (E).  Elimination of the most electron-rich arene is 
typically preferred.  Presumably this is due to a build-up of negative charge on the 
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electron-poor arene in a Meisenheimer-like transition state (Figure 3.9); the more 
electron-poor arene is better able to stabilize the negative charge.   
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Figure 3.9: Meisenheimer-like transition state 
 
When both arenes (A and B) are similar in electron density, a mixture of products occurs: 
A–F + B–I and A–I + B–F.  In the 19F NMR, both Boc protected 2-aryl-5-
fluorobenzimidazole regioisomers (A–F) and 4-fluoroanisole (B–F) were observed.  At 
140 ˚C, thermolysis of compound 16e provided only 37.3% A–F and 62.7% B–F.  At 80 
˚C, thermolysis of compound 16f provided a more favorable 67.7% A–F and 32.3% B–F.  
Below 80 ˚C thermolysis was not observed.  For compound 16f, the products were 
isolated by Preparative Thin Layer Chromatography (Prep TLC).  Both Boc protected 2-
(4-methylphenyl)-5-fluorobenzimidazole regioisomers (22f) and both Boc protected 2-(4-
methylphenyl)-5-iodobenzimidazole regioisomers (23f) were isolated in 52% yield.  For 
compound 16e, the four 2-(4-tert-butylphenyl)-5-halobenzimidazole products (22e and 
23e) could not be fully separated by Prep TLC.  From these results it is likely that both 
anisole and the corresponding 2-arylbenzimdazole are similar in electron density.  
Thermolysis at lower temperature utilizes the minor difference in electron density to 
provide better regioselectivity. 
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 The isolated fluorinated products (22f) were deprotected under acidic conditions 
with trifluoroacetic acid.70  The Boc protecting group was removed and the product was 
characterized.  Without the Boc protecting group the two regioisomers were now free to 
equilibrate by tautomerization.  By 1H NMR, 19F NMR, and HR-MS, the compound was 
confirmed to be 2-(4-methylphenyl)-5-fluorobenzimidazole (7f), as synthesized 
previously. 
 
3.2.3 Future Directions 
There are other methods that could potentially be used to purify compounds 16.  
Though costly, reverse phase chromatography could be used.  We have used ion-
exchange resins, specifically Amberlite quaternary ammonium resin (previously 
equilibrated with sodium triflate), to ensure full ion-exchange of diaryliodonium 
hexafluorophosphates to diaryliodonium triflates (since fluoride-19 atoms in 
hexafluorophosphate can exchange with fluoride-18).  It may be possible to treat 
compounds 16 with sodium hexafluorophosphate or pass compounds 16 down a 
dedicated ion-exchange column in an effort to exchange the anion on residual tin salts 
(such as Bu3SnOAc) in the hopes that the exchanged salt will bind less tightly and allow 
crystallization of 16.  Because of the difficulty in removing all traces of residual tin, it 
may be ideal to redesign the synthesis using an alternate synthetic route.  Borylation was 
not successful, solely removing the Boc protecting group, but it could be worthwhile to 
attempt a Miyaura borylation on a 2-aryl-5-bromobenzimidazole before Boc protection.  
As we later discovered with synthesis of cylophanyl-containing iodonium salts,71–73 an 
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aryl zinc halide may be coupled with a bis(acetoxy)iodoarene to produce a 
diaryliodonium salt.  Although these compounds are synthesized by lithiation of an aryl 
halide, which would likely be incompatible with the Boc protecting group, a Negishi 
coupling could be attempted.  More recently we have developed methodology using 
magnesium-halogen exchange on aryl iodides (see Chapter 1) and in some cases aryl 
bromides.  Designing a synthesis to produce 2-aryl-5-iodobenzimidazoles may be 
worthwhile.  There are many different routes to making benzimidazoles, and since the 
beginning of this project a number of additional methods have been published.37–48  
Nitration under milder conditions, using a combination of nitric and sulfuric acids 
(Scheme 3.3), may provide the desired 5-iodo-2-nitroacetanilide.  Oxidation of the 2-aryl-
5-iodobenzimidazole to iodonium diacetates using SelectfluorTM may be possible. 
Poor regioselectivity is an issue we have faced before.54,74  For example, due to 
poor regioselectivity, 2-fluoro-17ß-estradioldimethylether was only able to be produced 
in 42% yield.  This issue could be overcome by using a directing group that employs not 
only electronic effects, but also steric effects.   
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Scheme 3.15: Potential route to regioselectively generate compounds 22 
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By replacing the 4-iodoanisole synthon with a methoxy-substituted cyclophane (e.g. 7-
iodo-4-methoxy-[2.2]paracyclophane or 5-iodo-4-methoxy-[2.2]paracyclophane), 
stereoelectronic control generally affords full regioselectivity, elimination of the 
corresponding iodocyclophane and fluorination of the desired arene (Scheme 3.15).71–73 
 
3.3 Conclusion 
 Eleven 2-aryl-5-fluorobenzimidazoles (7) were successfully produced.  Using 
these compounds as NMR standards, and using this synthesis as a model synthesis, ten 2-
aryl-5-bromobenzimidazoles (13) were successfully produced.  Although some 
compounds could only be partially carried forward toward synthesis of 16, three 
diaryliodonium triflates (16) were generated from these compounds.  Poor 
regioselectivity hindered yields, but fluorination by thermolysis was successful in 
providing 22.  Deprotection of one compound using trifluoroacetic acid showed this 
compound was identical to the 2-aryl-5-bromobenzimidazole (13) produced without 
using iodonium salt thermolysis.  Given the poor regioselectivity, and potential issues 
with even trace amounts of residual tin, the methodology outlined in this chapter may not 
be ideal for testing fluorine-18 analogs of these compounds in vivo; however, this 
methodology would be suitable for initial testing.  As 2-aryl-5-[18F]fluorobenzimidazoles 
are not reported in the literature, this would be the first example.  Given the interest in 
these compounds in literature,2–30 access to radio-fluorinated radiotracers may be useful 
in cancer diagnosis, monitoring, and treatment, as well as studying inflammatory 
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pathways, Alzheimer’s disease, anti-microbial properties, etc.  The work outlined in this 
chapter provides a methodology for accessing these compounds. 
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3.5 Experimental 
 
4-Fluoroacetanilide (1): 
 
In an oven-dried 100 mL round bottom flask equiped with a stirbar, acetic anhydride (25 
mL) was added and cooled to 0 ˚C.  4-fluoroaniline (5 mL) was added dropwise with 
stirring.  Several drops of concentrated sulfuric acid were added until precipitation began.  
The mixture was allowed to warm to room temperature over the course of an hour.  The 
mixture was cooled to 0 ˚C and cautiously neutralized with aqueous sodium bicarbonate.  
The solid was filtered, washed with cold water, and dried in vacuo.  The crude solid was 
recrystallized from hot 85% aqueous ethanol to yield 4-fluoroacetanilide as a dull 
colorless solid (7.8 g, 96.8%): 1H NMR (CDCl3, 400 MHz, 298 K) δ 7.45 (s, NH), 7.34 
(dd, 2H, J = 6.8 Hz, J = 2.0 Hz), 6.89 (t, 2H, J = 8.8 Hz), 2.05 (s, 3H); 19F NMR (CDCl3, 
376 MHz, 298 K) δ -117.96 (ddd, J = 13.1 Hz, J = 8.3 Hz, J = 4.7 Hz); 13C NMR (CDCl3, 
100 MHz, 298 K) δ 168.52 (s), 160.60 (s), 158.18 (s), 133.89 (d, J = 3.0 Hz), 121.87 (d, J 
= 8.0 Hz), 115.59 (d, J = 22.1 Hz), 24.34 (s). 
 Mohan,	 J.	 “Confirmatory	Tests	and	Derivatization	of	Common	Organic	Compounds,	Their	Derivatization	and	Classified	Tables	 including	Melting	and	Boiling	Points”	 in	“Organic	 Analytical	 Chemistry:	 Theory	 and	 Practice”;	 Alpha	 Science	 Int’l	 Ltd.:	Oxford,	United	Kingdom,	2003.	
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4-Fluoro-2-nitroacetanilide (2): 
 
Fuming nitric acid (25 mL) was dispensed into a 50 mL Erlenmyer flask and cooled to –
40 °C by means of a saturated CaCl2/water slurry (cooled by dry ice).  4-
Fluoroacetanilide (2.00 g) was added directly (in portions) to the cold acid and the flask 
was swirled to help dissolve the organic material.  After the addition was complete the 
flask was allowed to stand in the bath (with occasional manual swirling) for 15 min.  The 
mixture was poured onto 100 g of ice and neutralized with saturated aqueous sodium 
bicarbonate solution.  The precipitated solid was filtered, washed with cold water, and 
dried in vacuo to yield 4-fluoro-2-nitroacetanilide as an essentially pure pale yellow solid 
(2.34 g, 90.2%): 1H NMR (CDCl3, 400 MHz, 298 K) δ 10.19 (s, NH), 8.80 (dd, 1H, J = 
4.2 Hz, J = 9.5 Hz), 7.93 (dd, 1H, J = 3.0 Hz, J = 8.5 Hz), 7.42 (ddd, 1H, J = 9.2 Hz, J = 
7.0 Hz, J = 4.0 Hz), 2.30 (s, 3H); 19F NMR (CDCl3, 376 MHz, 298 K) δ -115.97 (ddd, J = 
8.4 Hz, J = 7.0 Hz, J = 5.2 Hz); 13C NMR (CDCl3, 100 MHz, 298 K) δ 169.17 (s), 158.41 
(s), 155.95 (s), 131.59 (s), 124.34 (d, J = 7.0), 123.68 (d, J = 22.1 Hz), 112.47 (d, J = 
27.2), 25.69 (s). 
 
Hay, M. P.; Hicks, K. O.; Pchalek, K.; Lee, H. H.; Blaser, A.; Pruijn, F. B.; Anderson, R. 
F.; Shinde, S. S.; Wilson, W. R.; Denny, W. A. J. Med. Chem., 2008, 51, 6853–6865. 
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4-Fluoro-2-nitroaniline (3): 
 
In a 250 mL round bottom flask 4-fluoro-2-nitroacetanilide (4.68 g) dissolved in 10 mL 
THF was treated with 50 mL of aqueous HCl (2 M) and heated at reflux overnight.  The 
solution was neutralized with saturated aqueous sodium bicarbonate and extracted with 
ethyl acetate.  The combined organic layers were dried over sodium sulfate, filtered, and 
evaporated to yield 4-fluoro-2-nitroaniline compound as an orange solid (3.66 g, 99.7%): 
1H NMR (CDCl3, 500 MHz, 298 K) δ 7.81 (dd, 1H, J = 3.0 Hz, J = 9.1 Hz), 7.18 (ddd, 
1H, J = 3.0 Hz, J = 7.1 Hz, J = 9.3 Hz), 6.82 (dd, 1H, J = 9.2 Hz, J = 4.5 Hz), 6.02 (s, 
NH2); 19F NMR (CDCl3, 376 MHz, 298 K) δ -125.93 (ddd, J = 4.7 Hz, J = 7.2 Hz, J = 
9.1 Hz); 13C NMR (CDCl3, 126 MHz, 298 K) δ 154.46 (s), 152.56 (s), 141.75 (s), 124.81 
(d, J = 24.0 Hz), 120.22 (d, J = 7.3 Hz), 111.42 (d, J = 26.1 Hz). 
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4-Nitrobenzoyl chloride (4j): 
 
In an oven-baked 250 mL Schlenk flask, dry 4-nitrobenzoic acid (20.0 g, 0.120 mmol) 
was suspended in thionyl chloride (50 mL), under N2, at 0 ˚C.  The mixture was brought 
to reflux until the mixture became homogeneous (6 hours).  Unreacted thionyl chloride 
was removed by distillation under vacuum, with gentle heating as needed.  The solid was 
dried overnight under high dynamic vacuum to yield the product as pale yellow crystals 
(21.34 g, 96.1%): 1H NMR (CDCl3, 500 MHz, 298 K): δ 8.38 (d, J = 8.8 Hz, 2H), 8.32 
(d, J = 8.8 Hz, 2H); 13C NMR (CDCl3, 126 MHz, 298 K): δ 167.26, 138.25, 132.45, 
131.57, 124.27. 
 
Mohsin, M. A.; Akhter, Z.; Bolte, M.; Butt, M. S.; Khan, M. S. U.; Siddiqi, H. M. J 
Mater Sci, 2009, 44, 4796–4805. 
 
General procedure for the preparation of N-arylcarbonyl-5-fluoro-2-nitroanilines 
(5a–l) with solid acid chlorides: 4-Fluoro-2-nitroaniline (468 mg, 3.00 mmol), the 
appropriate acid chloride (3.30 mmol), and triethylamine (1 mL) were dissolved in 10 mL 
of dry acetonitrile.  The reaction was heated at 80 °C for 12 hours.  The reaction mixture 
was diluted with 50 mL dichloromethane and washed with 30 mL aqueous sodium 
bicarbonate diluted in deionized water (1:1 v/v).  The aqueous layer was extracted with 
O2N
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15 mL dichloromethane.  The combined organic layers were dried over sodium 
sulfate, evaporated, and purified by column chromatography or recrystallization using the 
solvent(s) indicated. 
 
General procedure for the preparation of N-arylcarbonyl-5-fluoro-2-nitroanilines 
(5a–l) with liquid acid chlorides: 4-Fluoro-2-nitroaniline (468 mg, 3.00 mmol), and 
triethylamine (1 mL) were dissolved in 10 mL of dry acetonitrile.  The appropriate acid 
chloride (3.30 mmol) was added dropwise by syringe and the reaction was heated at 80 
°C for 12 hours.  The reaction mixture was diluted with 50 mL dichloromethane and 
washed with 30 mL aqueous sodium bicarbonate diluted in deionized water (1:1 v/v).  
The aqueous layer was extracted with 15 mL dichloromethane.  The combined organic 
layers were dried over sodium sulfate, evaporated, and purified by column 
chromatography or recrystallization using the solvent(s) indicated. 
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N-Benzoyl-4-fluoro-2-nitroaniline (5a): 
 
This compound (640 mg, 82%) was obtained as a brilliant yellow solid after 
recrystallization from hot 95% aqueous ethanol: 1H NMR (CD2Cl2, 400 MHz, 298 K) δ 
11.21 (s, NH), 9.04 (dd, 1H, J = 5.2 Hz, J = 9.3 Hz), 8.00 (dd, 1H, J = 2.9 Hz, J = 8.1 
Hz), 7.99 (d, 2H, 7.0 Hz), 7.62 (t, 1H, J = 7.0 Hz), 7.55 (t, 2H, J = 8.3 Hz), 7.47 (ddd, 
1H, J = 3.2 Hz, J = 7.0 Hz, J = 9.8 Hz); 19F NMR (CD2Cl2, 376 MHz, 298 K) δ -117.66 
(ddd, J = 5.2 Hz, J = 6.9 Hz, J = 8.1 Hz); 13C NMR (CDCl3, 126 MHz, 298 K) δ 165.68 
(s), 158.02 (s), 156.05 (s), 133.78 (s), 132.79 (s), 131.96 (d, J = 2.6 Hz), 129.11 (s), 
127.35 (s), 124.03 (d, J = 7.4 Hz), 123.74 (d, J = 22.4 Hz), 112.45 (d, J = 27.4 Hz). 
 
N-(4-Methoxybenzoyl)-4-fluoro-2-nitroaniline (5b): 
 
This compound (391 mg, 44.9%) was obtained as yellow needles after recrystallization 
from 60 mL of hot hexane/ethyl acetate (4:1).  Additional crops of crystals could be 
obtained by concentrating the filtrate: 1H NMR (CDCl3, 400 MHz, 298 K) δ 11.13 (s, 
NH), 9.02 (dd, 1H, J = 5.3 Hz, J = 9.6 Hz), 7.97 (dd, 1H, J = 3.1 Hz, J = 8.6 Hz), 7.93 (d, 
2H, J = 8.9 Hz), 7.44 (ddd, 1H, J = 3.1 Hz, J = 7.1 Hz, J = 9.8 Hz), 7.01 (d, 2H, J = 8.9 
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Hz); 19F NMR (CDCl3, 376 MHz, 298 K) δ -116.33 (ddd, J = 5.2 Hz, J = 6.9 Hz, J = 
8.6 Hz); 13C NMR (CDCl3, 126 MHz, 298 K) δ 165.17 (s), 163.24 (s), 157.82 (s), 155.85 
(s), 136.34 (d, J = 7.8 Hz), 132.31 (s), 129.31 (s), 123.94 (d, J = 7.6 Hz), 123.74 (d, J = 
21.9 Hz), 114.30 (s), 112.34 (d, J = 27.2 Hz), 55.56 (s). 
 
N-(3,4-Dimethoxybenzoyl)-4-fluoro-2-nitroaniline (5c): 
 
This compound (487 mg, 51%) was obtained as a brilliant yellow solid after silica gel 
chromatography.  The eluant was dichloromethane/hexane (1:1): 1H NMR (CDCl3, 400 
MHz, 298 K) δ 11.22 (s, NH), 9.05 (dd, 1H, J = 5.3 Hz, J = 9.4 Hz), 8.00 (dd, 1H, J = 3.1 
Hz, J = 8.6 Hz), 7.56 (br s, 1H), 7.52 (s, 1H), 7.47 (ddd, 1H, J = 2.9 Hz, J = 6.9 Hz, J = 
9.7 Hz), 7.00 (s, 1H), 3.99 (s, OCH3), 3.98 (s, OCH3); 19F NMR (CDCl3, 376 MHz, 298 
K) δ -116.18 (ddd, J = 5.2 Hz, J = 7.4 Hz, J = 8.6 Hz); 13C NMR (CDCl3, 126 MHz, 298 
K) δ 165.20 (s), 157.84 (s), 155.87 (s), 149.33 (s), 136.35 (d, J = 8.4 Hz), 132.31 (s), 
126.25 (s), 123.89 (d, J = 10.0 Hz), 123.76 (d, J = 4.5 Hz), 120.30 (s), 112.39 (d, J = 27.7 
Hz), 110.57 (d, J = 15.7 Hz), 56.15 (s), 56.06 (s). 
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N-(3,4,5-Trimethoxybenzoyl)-4-fluoro-2-nitroaniline (5d): 
 
This compound (563 mg, 54%) was obtained as a brilliant yellow solid after silica gel 
chromatography.  The eluant was dichloromethane: 1H NMR (CDCl3, 400 MHz, 298 K) 
δ 11.23 (s, NH), 9.03 (dd, 1H, J = 5.3 Hz, J = 9.5 Hz), 8.00 (dd, 1H, J = 3.1 Hz, J = 8.4 
Hz), 7.47 (ddd, 1H, J = 3.2 Hz, J = 7.0 Hz, J = 9.8 Hz), 7.2 (s, 2H); 19F NMR (CDCl3, 
376 MHz, 298 K) δ -115.77 (ddd, J = 5.2 Hz, J = 6.9 Hz, J = 8.1 Hz); 13C NMR (CDCl3, 
126 MHz, 298 K) δ 165.44 (s), 158.15 (s), 153.67 (s), 142.15 (s), 136.56 (d, J = 8.7 Hz), 
132.30 (d, J = 2.6 Hz), 129.11 (s), 124.11 (d, J = 22.0 Hz), 123.90 (d, J = 7.3 Hz), 112.67 
(d, J = 27.0 Hz), 104.75 (s), 61.20 (s), 56.50 (s). 
 
N-(4-tert-Butylbenzoyl)-4-fluoro-2-nitroaniline (5e): 
 
This compound (495 mg, 52%) was obtained as a brilliant yellow solid after silica gel 
chromatography.  The eluant was hexane/ethyl acetate (93:7): 1H NMR (CDCl3, 400 
MHz, 298 K) δ 11.20 (s, NH), 9.15 (dd, 1H, J = 5.2 Hz, J = 8.4 Hz), 7.98 (dd, 1H, J = 3.0 
Hz, J = 8.5 Hz), 7.91 (d, 2H, J = 5.6), 7.56 (d, 2H, J = 5.6), 7.44 (ddd, 1H, J = 2.8 Hz, J = 
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5.4 Hz, J = 9.4 Hz), 1.38 (s, 9H); 19F NMR (CDCl3, 376 MHz, 298 K) δ -116.11 (ddd, 
J = 4.8 Hz, J = 6.2 Hz, J = 10.5 Hz); 13C NMR (CDCl3, 100 MHz, 298 K) δ 165.67 (s), 
157.92 (s), 156.58 (s), 136.49 (d, J = 8.1 Hz), 132.17 (s), 130.91 (s), 127.26 (s), 126.09 
(s), 124.02 (d, J = 7.3 Hz), 123.74 (d, J = 22.8 Hz), 112.42 (d, J = 29.2 Hz), 35.14 (s), 
31.13 (s). 
 
N-(4-Methylbenzoyl)-4-fluoro-2-nitroaniline (5f): 
 
This compound (435 mg, 52.9%) was obtained as a brilliant yellow solid after silica gel 
chromatography.  The eluant was hexane/ethyl acetate (93:7).  Because of the insolubility 
of the compound it was loaded onto the column using boiling solvent: 1H NMR (CDCl3, 
400 MHz, 298 K) δ 11.18 (s, NH), 9.05 (dd, 1H, J = 5.2 Hz, J = 9.4 Hz), 8.00 (dd, 1H, J 
= 3.1 Hz, J = 8.5 Hz), 7.88 (d, 2H, J = 8.2 Hz), 7.46 (ddd, 1H, J = 3.1 Hz, J = 7.1 Hz, J = 
9.8 Hz), 7.34 (d, 2H, J = 8.0 Hz); 19F NMR (CDCl3, 376 MHz, 298 K) δ -116.06 (ddd, J 
= 5.1 Hz, J = 6.8 Hz, J = 8.2 Hz); 13C NMR (CDCl3, 126 MHz, 298 K) δ 165.61 (s), 
157.90 (s), 155.93 (s), 143.56 (s), 132.15 (d, J = 2.8 Hz), 130.94 (s), 129.76 (s), 127.37 
(s), 123.98 (d, J = 7.5 Hz), 123.71 (d, J = 23.9 Hz), 112.39 (d, J = 26.4 Hz), 21.59 (s). 
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N-(4-Trifluoromethylbenzoyl)-4-fluoro-2-nitroaniline (5g): 
 
This compound (232 mg, 24%) was obtained as a brilliant yellow solid after silica gel 
chromatography.  The eluant was hexane/ethyl acetate (93:7): 1H NMR (CDCl3, 400 
MHz, 298 K) δ 11.24 (s, NH), 9.01 (dd, 1H, J = 5.1 Hz, J = 9.4 Hz), 8.09 (d, 2H, J = 8.2 
Hz), 7.99 (dd, 1H, J = 3.0 Hz, J = 8.2 Hz), 7.80 (d, 2H, J = 8.3 Hz), 7.47 (ddd, 1H, J = 
3.0 Hz, J = 7.0 Hz, J = 10.0 Hz); 19F NMR (CDCl3, 376 MHz, 298 K) δ -114.87 (ddd, J = 
5.2 Hz, J = 7.0 Hz, J = 10.0 Hz); 13C NMR (CDCl3, 126 MHz, 298 K) δ 164.32 (s), 
158.32 (s), 156.34 (s), 137.03 (s), 134.34 (d, J = 33.0 Hz), 131.45 (s), 127.82 (s), 126.19 
(s), 124.06 (s), 123.96 (d, J = 11.3 Hz), 123.74 (s), 112.64 (d, J = 27.7 Hz). 
 
N-(4-Cyanobenzoyl)-4-fluoro-2-nitroaniline (5h): 
 
This compound (276 mg, 32.6%) was recrystallized from hot toluene to yield yellow 
plates: 1H NMR (CDCl3, 400 MHz, 298 K) δ 11.17 (s, NH), 8.91 (dd, 1H, J = 5.2 Hz, J = 
9.6 Hz), 7.99 (d, 2H, J = 8.6 Hz), 7.92 (dd, 1H, J = 3.0 Hz, J = 8.4 Hz), 7.76 (d, 2H, J = 
8.7 Hz), 7.41 (ddd, 1H, J = 3.1 Hz, J = 7.0 Hz, J = 9.6 Hz); 19F NMR (CDCl3, 376 MHz, 
298 K) δ -114.42 (ddd, J = 5.2 Hz, J = 7.0 Hz, J = 8.4 Hz); 13C NMR (CDCl3, 100 MHz, 
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298 K) δ 164.04 (s), 137.83 (s), 137.02 (s), 133.17 (s), 131.43 (d, J = 2.9 Hz), 128.22 
(s), 124.27 (d, J = 7.4 Hz), 124.10 (d, J = 22.1 Hz), 117.88 (s), 116.57 (s) 113.04 (s), 
112.80 (s). 
 
N-(4-Dimethylaminobenzoyl)-4-fluoro-2-nitroaniline (5i): 
 
This compound (378 mg, 41.5%) was obtained as brilliant reddish orange needles from 
hot ethyl acetate: 1H NMR (CDCl3, 400 MHz, 298 K) δ 11.14 (s, NH), 9.08 (dd, 1H, J = 
5.1 Hz, J = 9.4 Hz), 7.98 (dd, 1H, J = 3.1 Hz, J = 8.6 Hz), 7.89 (d, 2H, J = 9.0 Hz), 7.44 
(ddd, 1H, J = 3.1 Hz, J = 7.2 Hz, J = 9.8 Hz), 6.77 (d, 2H, J = 8.9 Hz), 3.09 (s, 6H); 19F 
NMR (CDCl3, 376 MHz, 298 K) δ -117.34 (ddd, J = 5.3 Hz, J = 7.1 Hz, J = 8.6 Hz); 13C 
NMR (CDCl3, 126 MHz, 298 K) δ 165.83 (s), 157.70 (s), 155.73 (s), 153.40 (s), 136.23 
(d, J = 8.1 Hz), 133.17 (d, J = 2.8 Hz), 129.37 (s), 124.10 (d, J = 7.4 Hz), 123.95 (d, J = 
22.0 Hz), 120.18 (s), 112.36 (d, J = 27.5 Hz), 111.44 (s), 40.29 (s). 
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N-(4-Chlorobenzoyl)-4-fluoro-2-nitroaniline (5k): 
 
This compound (132 mg, 15%) was obtained as a brilliant yellow solid after silica gel 
chromatography.  The eluant was hexane/ethyl acetate (93:7).  Because of the insolubility 
of the compound it was loaded onto the column using boiling solvent: 1H NMR (CDCl3, 
400 MHz, 298 K) δ 11.18 (s, NH), 9.02 (dd, 1H, J = 5.1 Hz, J = 9.4 Hz), 8.01 (dd, 1H, J 
= 3.0 Hz, J = 8.4 Hz), 7.92 (d, 2H, J = 8.5 Hz), 7.52 (d, 2H, J = 8.5 Hz), 7.47 (ddd, 1H, J 
= 3.0 Hz, J = 7.0 Hz, J = 9.7 Hz); 19F NMR (CDCl3, 376 MHz, 298 K) δ -115.33 (ddd, J 
= 5.2 Hz, J = 7.0 Hz, J = 8.4 Hz); 13C NMR (CDCl3, 100 MHz, 298 K) δ 164.80 (s), 
158.59 (s), 156.12 (s), 139.46 (s), 132.35 (s), 131.92 (d, J = 2.9 Hz), 129.26 (d, J = 67.6 
Hz), 124.24 (s), 124.14 (d, J = 5.0 Hz), 123.90 (s), 112.73 (d, J = 27.8 Hz). 
 
N-(4-Fluorobenzoyl)-4-fluoro-2-nitroaniline (5l): 
 
This compound (503 mg, 60.3%) was obtained as a brilliant yellow solid after silica gel 
chromatography.  The eluant was hexane/ethyl acetate (93:7).  Because of the insolubility 
of the compound it was loaded onto the column using boiling solvent: 1H NMR (CDCl3, 
400 MHz, 298 K) δ 11.17 (s, NH), 9.01 (dd, 1H, J = 5.2 Hz, J = 9.4 Hz), 8.00 (dd, 2H, J 
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= 5.0 Hz, J = 9.0 Hz), 8.00 (dd, 1H, J = 4.3 Hz, J = 10.0 Hz), 7.48 (ddd, 1H, J = 3.2 
Hz, J = 7.1 Hz, J = 9.8 Hz), 7.23 (t, 2H, J = 8.6 Hz); 19F NMR (CDCl3, 376 MHz, 298 K) 
C6F6 internal standard: δ -108.86 (ddd, 1F, J = 5.0 Hz, J = 8.1 Hz, J = 13.2 Hz), -118.75 
(ddd, 1F, J = 5.2 Hz, J = 7.0 Hz, J = 8.6 Hz). 
 
General procedure for reduction of N-arylcarbonyl-4-fluoro-2-nitroanilines (6a–m): 
In a 20 mL vial with a stir bar, the appropriate N-arylcarbonyl-4-fluoro-2-nitroaniline 
(100–500 mg) was suspended in 2-propanol and 10 wt. % palladium on carbon (30–100 
mg) was added.  The vial was placed in a 375 mL stainless steel Parr pressure reactor and 
charged with 100–200 psi of H2.  The pressure reactor was placed on a magnetic stir plate 
and the solution was stirred under H2 for 12 h.  The reaction rate was generally observed 
to be governed by the solubility of the particular substrate.  The amines obtained from 
this procedure were generally sufficiently pure to carry on to the subsequent cyclization 
step. 
 
N-Benzoyl-4-fluoro-2-aminoaniline (6a): 
 
This compound (238 mg, 42%) was obtained as a colorless powder: 1H NMR (CDCl3, 
400 MHz, 298 K) δ 8.11 (s, NH), 7.77 (d, 2H, J = 7.3 Hz), 7.40 (t, 1H, J = 7.1 Hz), 7.32 
(t, 2H, J = 7.7 Hz), 6.99 (dd, 1H, J = 6.3 Hz, J = 8.4 Hz), 6.37 (dd, 1H, J = 2.7 Hz, J = 
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10.5 Hz), 6.27 (ddd, 1H, J = 2.8 Hz, J = 8.4 Hz, J = 11.2 Hz), 4.10 (s, NH2); 19F 
NMR (CDCl3, 376 MHz, 298 K) δ -117.66 (ddd, J = 5.2 Hz, J = 6.9 Hz, J = 8.1 Hz). 
 
N-(4-Methoxybenzoyl)-4-fluoro-2-aminoaniline (6b): 
 
This compound (163 mg, 47%) was obtained as a colorless powder: 1H NMR (CD3CN, 
400 MHz, 298 K) δ 8.22 (s, NH), 7.91 (d, 2H, J = 8.9 Hz), 7.10 (dd, 1H, J = 6.3 Hz, J = 
8.7 Hz), 7.02 (d, 2H, J = 8.9 Hz), 6.53 (dd, 1H, J = 2.9 Hz, J = 10.9 Hz), 6.41 (ddd, 1H, J 
= 3.0 Hz, J = 8.6 Hz, J = 11.5 Hz), 4.44 (s, NH2), 3.86 (s, OCH3); 19F NMR (CD3CN, 
376 MHz, 298 K) δ -117.34 (ddd, J = 6.5 Hz, J = 8.6 Hz, J = 10.7 Hz). 
 
N-(3,4-Dimethoxybenzoyl)-4-fluoro-2-aminoaniline (6c): 
 
This compound (80 mg, 18%) was obtained as a colorless powder: 1H NMR (CDCl3, 400 
MHz, 298 K) δ 7.61 (s, NH), 7.50 (s, 1H), 7.43 (dd, 1H, J = 1.8 Hz, J = 8.3 Hz), 7.16 (dd, 
1H, J = 6.0 Hz, J = 8.4 Hz), 6.9 (d, 1H, J = 8.3 Hz), 6.54 (dd, 1H, J = 2.7 Hz, J = 9.7 Hz), 
6.52 (ddd, 1H, J = 2.5 Hz, J = 8.2 Hz, J = 11.0 Hz), 4.02 (s, NH2), 3.95 (s, 6H); 19F NMR 
(CDCl3, 376 MHz, 298 K) δ -114.92 (ddd, J = 7.6 Hz, J = 9.0 Hz, J = 10.5 Hz). 
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N-(3,4,5-Trimethoxybenzoyl)-4-fluoro-2-aminoaniline (6d): 
 
This compound (108 mg, 21%) was obtained as a colorless powder: 1H NMR (CD3CN, 
400 MHz, 298 K) δ 8.32 (s, NH), 7.22 (s, 2H), 7.11 (dd, 1H, J = 6.3 Hz, J = 8.6 Hz), 6.54 
(dd, 1H, J = 2.8 Hz, J = 10.9 Hz), 6.43 (ddd, 1H, J = 2.9 Hz, J = 8.4 Hz, J = 11.5 Hz), 
3.89 (s, 6H), 3.79 (s, 3H); 19F NMR (CD3CN, 376 MHz, 298 K) δ -117.13 (ddd, J = 6.5 
Hz, J = 8.6 Hz, J = 10.6 Hz). 
 
N-(4-tert-Butylbenzoyl)-4-fluoro-2-aminoaniline (6e): 
 
This compound (226 mg, 50%) was obtained as a colorless powder: 1H NMR (30% 
CD3OD in CD3CN, 400 MHz, 298 K) δ 8.83 (s, NH), 7.86 (d, 2H, J = 8.5 Hz), 7.54 (d, 
2H, J = 8.3 Hz), 7.10 (dd, 1H, J = 6.2 Hz, J = 8.5 Hz), 6.54 (dd, 1H, J = 2.8 Hz, J = 11.0 
Hz), 6.41 (ddd, 1H, J = 2.5 Hz, J = 8.5 Hz, J = 11.3 Hz), 4.56 (s, NH2), 1.33 (s, 9H); 19F 
NMR (30% CD3OD in CD3CN, 376 MHz, 298 K) δ -117.20 (ddd, J = 6.3 Hz, J = 8.6 Hz, 
J = 10.8 Hz). 
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N-(4-Methylbenzoyl)-4-fluoro-2-aminoaniline (6f): 
 
This compound (240 mg, 62%) was obtained as a colorless powder: 1H NMR (CD3CN, 
400 MHz, 298 K) δ 8.26 (s, NH), 7.83 (d, 2H, J = 8.0 Hz), 7.33 (d, 2H, J = 8.1 Hz), 7.11 
(dd, 1H, J = 6.3 Hz, J = 8.4 Hz), 6.54 (dd, 1H, J = 2.9 Hz, J = 11.0 Hz), 6.42 (ddd, 1H, J 
= 3.1 Hz, J = 8.6 Hz, J = 11.5 Hz), 4.45 (s, NH2), 2.41 (s, 3H); 19F NMR (CD3CN, 376 
MHz, 298 K) δ -117.22 (ddd, J = 6.5 Hz, J = 8.5 Hz, J = 10.9 Hz). 
 
N-(4-Trifluoromethylbenzoyl)-4-fluoro-2-aminoaniline (6g): 
 
This compound (193 mg, 91%) was obtained as a colorless powder: 1H NMR (30% 
CD3OD in CD3CN, 400 MHz, 298 K) δ 8.68 (s, NH), 8.09 (d, 2H, J = 8.2 Hz), 7.82 (d, 
2H, J = 8.2 Hz), 7.13 (dd, 1H, J = 6.4 Hz, J = 8.8 Hz), 6.55 (dd, 1H, J = 3.0 Hz, J = 10.9 
Hz), 6.42 (ddd, 1H, J = 2.8 Hz, J = 8.6 Hz, J = 11.3 Hz), 4.50 (s, NH2); 19F NMR (30% 
CD3OD in CD3CN, 376 MHz, 298 K) δ -63.47 (s, CF3), -116.75 (ddd, 1F, J = 6.1 Hz, J = 
8.3 Hz, J = 10.8 Hz). 
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N-(4-Cyanobenzoyl)-4-fluoro-2-aminoaniline (6h): 
 
This compound (110 mg, 45%) was obtained as a colorless powder: 1H NMR (CD3OD, 
400 MHz, 298 K) δ 9.98 (s, NH), 8.37 (d, 2H, J = 8.0 Hz), 7.84 (d, 2H, J = 8.0 Hz), 7.63 
(dd, 1H, J = 6.0 Hz, J = 8.5 Hz), 7.09 (dd, 1H, J = 2.7 Hz, J = 10.8 Hz), 6.95 (ddd, 1H, J 
= 2.6 Hz, J = 8.4 Hz, J = 11.0 Hz), 4.86 (s, NH2); 19F NMR (CD3OD, 376 MHz, 298 K) 
δ -117.31 (m). 
 
N-(4-Dimethylaminobenzoyl)-4-fluoro-2-aminoaniline (6i): 
 
This compound (74 mg, 22%) was obtained as a colorless powder: 1H NMR (30% 
CD3OD in CD3CN, 300 MHz, 298 K) δ 8.54 (s, NH), 7.80 (d, 2H, J = 9.0 Hz), 7.07 (dd, 
1H, J = 6.2 Hz, J = 8.7 Hz), 6.75 (d, 2H, J = 9.1 Hz), 6.53 (dd, 1H, J = 2.9 Hz, J = 11.0 
Hz), 6.40 (ddd, 1H, J = 2.9 Hz, J = 8.5 Hz, J = 11.4 Hz), 4.52 (s, NH2), 3.00 (s, 6H); 19F 
NMR (30% CD3OD in CD3CN, 282 MHz, 298 K) δ -117.64 (ddd, J = 6.2 Hz, J = 8.5 Hz, 
J = 10.9 Hz). 
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N-(4-Chlorobenzoyl)-4-fluoro-2-aminoaniline (6k): 
 
This compound (106 mg, 89%) was obtained as a colorless powder: 1H NMR (30% 
CD3OD in CD3CN, 400 MHz, 298 K) δ 10.12 (s, NH), 8.04 (d, 2H, J = 7.2 Hz), 7.62 (t, 
1H, J = 7.4 Hz), 7.59 (d, 2H, J = 7.1 Hz), 7.31 (dd, 1H, J = 3.1 Hz, J = 8.8 Hz), 7.23 
(ddd, 1H, J = 2.8 Hz, J = 7.9 Hz, J = 10.9 Hz), 4.73 (s, NH2); 19F NMR (30% CD3OD in 
CD3CN, 376 MHz, 298 K) δ -114.77 (ddd, J = 5.5 Hz, J = 8.0 Hz, J = 8.9 Hz). 
 
N-(4-Fluorobenzoyl)-4-fluoro-2-aminoaniline (6l): 
 
This compound (256 mg, 57%) was obtained as a colorless powder: 1H NMR (30% 
CD3OD in CD3CN, 400 MHz, 298 K) δ 8.88 (s, NH), 7.97 (dd, 2H, J = 5.5 Hz, J = 8.9 
Hz), 7.23 (t, 2H, J = 8.9 Hz), 7.09 (dd, 1H, J = 6.1 Hz, J = 8.8 Hz), 6.53 (dd, 1H, J = 2.8 
Hz, J = 10.9 Hz), 6.41 (ddd, 1H, J = 2.9 Hz, J = 8.6 Hz, J = 11.5 Hz), 4.57 (s, NH2); 19F 
NMR (30% CD3OD in CD3CN, 376 MHz, 298 K) δ -110.15 (ddd, 1F, J = 5.5 Hz, J = 8.9 
Hz, J = 14.4 Hz), -117.00 (ddd, 1F, J = 6.1 Hz, J = 8.4 Hz, J = 10.9 Hz). 
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N-Cyclohexyl-4-fluoro-2-aminoaniline (6m): 
 
In a 20 mL vial equipped with a magnetic stir bar, N-benzoyl-4-fluoro-2-nitroaniline (70 
mg) was suspended in 2-propanol and platinum oxide (48.7 mg) was added.  The vial was 
placed in a 375 mL stainless steel Parr pressure reactor and charged with 400 psi of H2.  
The pressure reactor was placed on a magnetic stir plate and the solution was stirred 
under H2 for 48 h.  The crude solid was recrystallized from hot methylene 
chloride/hexanes to yield colorless crystals (48 mg, 75%) 1H NMR (CDCl3, 400 MHz, 
298 K) δ 7.35 (s, NH), 6.99 (dd, 1H, J = 5.9 Hz, J = 8.6 Hz), 6.37 (dd, 1H, J = 2.8 Hz, J = 
10.4 Hz), 6.30 (ddd, 1H, J = 2.8 Hz, J = 8.4 Hz, J = 11.1 Hz), 3.98 (s, NH2), 2.21 (tt, 1H, 
J = 3.5 Hz, J = 11.6 Hz), 1.94–1.79 (m, 2H), 1.78–1.67 (m, 2 H), 1.64–1.53 (m, 1H), 1.45 
(ddd, 2H, J = 2.9 Hz, J = 12.2 Hz, J = 15.1 Hz), 1.31–1.08 (m, 3 H); 19F NMR (CDCl3, 
376 MHz, 298 K) δ -116.38 (ddd, J = 6.2 Hz, J = 8.5 Hz, J = 10.2 Hz). 
 
General procedure for the preparation of 2-aryl-5-fluorobenzimidazoles (7a–m): In 
a Schlenk storage tube with a stir bar was placed the appropriate N-benzoyl-4-fluoro-2-
aminoaniline, 3 Å molecular sieves, and a 13:1 mixture of toluene and acetic acid.  The 
vessel was closed and heated at 110 °C for 12 h.  The mixture was allowed to cool and 
neutralized with aqueous sodium bicarbonate.  The mixture was extracted several times 
with ethyl acetate.  The organic layer was dried over sodium sulfate, evaporated, and 
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purified as described.  NMR spectra generally showed that the two tautomers 
interconverted on the NMR timescale.  More resolved spectra were obtained in CDCl3 
than in CD3CN, indicating that the rate of tautomer interconversion was slower in the less 
polar solvent. 
 
2-Phenyl-5-fluorobenzimidazole (7a): 
 
This compound was recrystallized from hot toluene.  This compound was obtained as 
colorless crystals (64.5 mg, 25%): The NMR spectra in CD3CN showed a nearly equal 
mixture of the two tautomeric forms: 1H NMR (CD3CN, 400 MHz, 298 K) δ 10.96 (s, 
NH, 2H), 8.08 (d, 4H, J = 7.0 Hz), 7.64 (br m, 1H), 7.59–7.46 (m, 7H), 7.39 (br m, 1H), 
7.28 (br m, 1H), 7.04 (br m, 1H); 19F NMR (CD3CN, 376 MHz, 298 K) δ -121.10 (br s, 
1F), 123.06 (br s, 1F). 
 
2-(4-Methoxyphenyl)-5-fluorobenzimidazole (7b): 
 
This compound was chromatographed on silica using hexane/ethyl acetate (1:1 v/v).  
Obtained as a colorless powder (104 mg, 59%): 1H NMR (CDCl3, 400 MHz, 298 K) δ 
7.87 (d, 2H, J = 8.8 Hz), 7.46–7.36 (br m, 1H), 7.20–7.13 (br m, 1H), 6.90–6.85 (m), 
3.76 (s, OCH3); 19F NMR (CDCl3, 376 MHz, 298 K) δ -119.84 (br s). 
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2-(3,4-Dimethoxyphenyl)-5-fluorobenzimidazole (7c): 
 
This compound was recrystallized by layering hexane onto a saturated ethyl acetate 
solution.  This compound was obtained as colorless needles (50 mg, 59%): The NMR 
spectra in CDCl3 showed a nearly equal mixture of the two tautomeric forms: 1H NMR 
(CDCl3, 500 MHz, 298 K) δ 9.99 (s, NH), 9.92 (s, NH), 7.71 (dd, 1H, J = 4.8 Hz, J = 8.9 
Hz), 7.67 (dd, 2H, J = 2.2 Hz, J = 3.0 Hz), 7.50–7.44 (m, 3H), 7.35 (dd, 1H, J = 4.7 Hz, J 
= 8.9 Hz), 7.12 (dd, 1H, J = 2.2 Hz, J = 8.4 Hz), 7.00 (m, 2H), 6.94 (d, 2H, J = 8.3 Hz), 
3.94 (s, 6H), 3.91 (s, 3H), 3.90 (s, 3H); 19F NMR (CD3CN, 376 MHz, 298 K) δ -121.69 
(br s, 1F), -123.29 (br s, 1F). 
 
2-(3,4,5-Trimethoxyphenyl)-5-fluorobenzimidazole (7d): 
 
This compound was crystallized from the reaction solution by cooling to 0 ˚C.  The crude 
solid was dissolved in ethyl acetate and washed with aqueous sodium bicarbonate 
solution.  The organic layer was dried over sodium sulfate and evaporated.  This 
compound was obtained as a colorless solid (49 mg, 43%): 1H NMR (CD3CN, 400 MHz, 
298 K) δ 9.77 (s, NH), 7.56 (dd, 1H, J = 4.9 Hz, J = 8.2 Hz), 7.35 (s, 2 H), 7.34 (dd, 1H, 
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J = 2.5 Hz, J = 9.5 Hz), 7.03 (ddd, 1H, J = 2.5 Hz, J = 8.8 Hz, J = 10.1 Hz), 3.92 (s, 
6H), 3.79 (s, 3H); 19F NMR (CD3CN, 376 MHz, 298 K) δ -122.06 (br s). 
 
2-(4-tert-Butylphenyl)-5-fluorobenzimidazole (7e): 
 
The crude product was treated with 3 mL of ethyl acetate, filtered, and washed with an 
additional 2 mL of ethyl acetate.  The material was transferred to a tared vial and residual 
solvent was removed under reduced pressure to yield the compound as a colorless 
powder (104 mg, 43%): The NMR spectra in CDCl3 showed an equal mixture of the two 
tautomeric forms: 1H NMR (CDCl3, 400 MHz, 298 K) δ 9.38 (s, NH, 1H), 9.36 (s, NH, 
1H), 7.85 (d, 2H, J = 8.4 Hz), 7.84 (d, 2H, J = 8.4 Hz), 7.62 (dd, 1H, J = 4.8 Hz, J = 8.8 
Hz), 7.40 (d, 2H, J = 8.4 Hz), 7.40 (d, 2H, J = 8.4 Hz), 7.38 (dd, 1H, J = 2.3 Hz, J = 8.7 
Hz), 7.28 (dd, 1H, J = 4.6 Hz, J = 8.7 Hz), 7.05 (dd, 1H, J = 2.4 Hz, J = 8.5 Hz), 6.92 
(ddd, 2H, J = 2.1 Hz, J = 9.0 Hz, J = 11.3 Hz), 1.27 (s, 18H); 19F NMR (CDCl3, 376 
MHz, 298 K) δ -118.66 (ddd, 1F, J = 4.8 Hz, J = 8.6 Hz, J = 9.0 Hz); -120.53 (td, 1F, J = 
4.6 Hz, J = 8.6 Hz). 
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2-(4-Methylphenyl)-5-fluorobenzimidazole (7f): 
 
This compound was chromatographed on silica using hexane/ethyl acetate (7:3 v/v).  
Obtained as a colorless powder (83 mg, 32%). 
 
Alternate method: After thermolysis of the corresponding diaryliodonium salt (16f), N-
tert-butyloxycarbonyl-2-(4-methylphenyl)-5-fluorobenzimidazole and N-tert-
butyloxycarbonyl-2-(4-methylphenyl)-6-fluorobenzimidazole were isolated by column 
chromatography on silica.  After dissolving in acetonitrile, trifluoroacetic acid (15% by 
volume) was added dropwise.  The solution was stirred until conversion was complete by 
TLC (~30 minutes).  Solvents were removed in vacuo.  The resulting oil was dissolved in 
dichloromethane and washed with saturated aqueous sodium bicarbonate.  The aqueous 
layer was extracted twice with dichloromethane.  The combined organic layers were 
dried over sodium sulfate and solvent was removed in vacuo. 
 
The NMR spectra in CD3CN showed a nearly equal mixture of the two tautomeric forms: 
1H NMR (CD3CN, 400 MHz, 298 K) δ 10.93 (s, NH, 2H), 7.96 (d, 4H, J = 8.4 Hz), 7.60 
(br m, 1H), 7.50 (br m, 1H), 7.35 (d, 4H, J = 8.4 Hz), 7.27 (br m, 1H), 7.02 (ddd, 2H, J = 
2.6 Hz, J = 10.1 Hz, J = 11.3 Hz); 19F NMR (CD3CN, 376 MHz, 298 K) δ -121.38 (br s, 
1F), 123.20 (br s, 1F). 
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2-(4-Trifluoromethylphenyl)-5-fluorobenzimidazole (7g): 
 
This compound was chromatographed on silica using hexane/ethyl acetate (7:3 v/v).  
Obtained as a colorless powder (104 mg, 51%): The NMR spectra in CDCl3 showed a 
nearly equal mixture of the two tautomeric forms: 1H NMR (CDCl3, 400 MHz, 298 K) δ 
9.62 (s, NH, 2H), 8.14 (dd, 4H, J = 4.9 Hz, J = 8.1 Hz), 7.77 (d, 4H, J = 6.9 Hz), 7.52 
(dd, 1H, J = 2.3 Hz, J = 9.3 Hz), 7.43 (dd, 1H, J = 4.5 Hz, J = 8.8 Hz), 7.20 (dd, 1H, J = 
2.4 Hz, J = 8.3 Hz), 7.08 (m, 2H; 19F NMR (CD3CN, 376 MHz, 298 K) δ -62.83 (s, 6F), -
117.04 (ddd, 1H, J = 5.7 Hz, J = 9.2 Hz, J = 13.8 Hz), -119.48 (ddd, 1H, J = 4.7 Hz, J = 
9.2 Hz, J = 13.9 Hz). 
 
2-(4-Dimethylaminophenyl)-5-fluorobenzimidazole (7i): 
 
This compound was purified by column chromatography using hexane/ethyl acetate (1:1 
v/v).  Following evaporation of the solvents the compound was rinsed with CDCl3 and 
obtained as a colorless powder (15 mg, 22%): 1H NMR (CDCl3, 400 MHz, 298 K) δ 9.90 
(br s, NH), 7.93 (d, 2H, J = 9.0), 7.46 (br m, 1H), 7.23 (br m, 1H), 6.94 (td, 1H, J = 2.4 
Hz, J = 9.6 Hz), 6.73 (d, 2H, J = 9.0 Hz) 3.02 (s, 6H); 19F NMR (CDCl3, 376 MHz, 298 
K) δ -120.63 (br s). 
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2-(4-Chlorophenyl)-5-fluorobenzimidazole (7k): 
 
This compound was chromatographed on silica using hexane/ethyl acetate (7:3 v/v).  
Obtained as a colorless powder (42 mg, 37%): The NMR spectra in CD3CN showed a 
nearly equal mixture of the two tautomeric forms: 1H NMR (CD3CN, 300 MHz, 298 K) δ 
10.35 (s, NH), 8.04 (dd, 2H, J = 3.7 Hz, J = 7.4 Hz), 7.70–7.38 (br m, 1H), 7.47 (dd, 2H, 
J = 2.5 Hz, J = 4.0 Hz), 7.38–7.11 (br m, 1H), 7.01 (dd, 1H, J = 2.4 Hz, J = 9.5 Hz); 19F 
NMR (CD3CN, 282 MHz, 298 K) δ -118.35 (br s, 1F), 120.21 (br s, 1F). 
 
2-(4-Fluorophenyl)-5-fluorobenzimidazole (7l): 
 
This compound was chromatographed on silica using hexane/ethyl acetate (7:3 v/v).  
Obtained as a colorless powder which turned yellow upon rotary evaporation (153 mg, 
55%): The NMR spectra in CD3CN showed a nearly equal mixture of the two tautomeric 
forms: 1H NMR (CD3CN, 400 MHz, 298 K) δ 10.99 (s, NH), 8.09 (dd, 2H, J = 5.3 Hz, J 
= 8.8 Hz), 7.55 (br m, 1H), 7.32 (br m, 1H), 7.26 (t, 2H, J = 9.0 Hz), 7.03 (dd, 1H, J = 2.6 
Hz, J = 9.9 Hz); 19F NMR (CD3CN, 376 MHz, 298 K) δ -112.19 (br s, 2F), -121.03 (br s, 
1F), 122.92 (br s, 1F). 
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2-Cyclohexyl-5-fluorobenzimidazole (7m): 
 
This compound was recrystallized from hot hexanes.  This compound was obtained as 
colorless crystals (19 mg, 37%): 1H NMR ((CD3)2SO, 400 MHz, 298 K) δ 12.21 (s, NH), 
7.43 (dd, 1H, J = 5.0 Hz, J = 8.5 Hz), 7.25 (dd, 1H, J = 1.9 Hz, J = 9.6 Hz), 6.94 (ddd, 
1H, J = 2.5 Hz, J = 8.8 Hz, J = 10.0 Hz), 2.82 (tt, J = 3.9 Hz, J = 11.2 Hz), 2.00 (dd, 2H, 
J = 3.0 Hz, J = 13.2 Hz), 1.69 (dt, 1H, J = 3.3 Hz, J = 11.8 Hz), 1.58 (ddd, 2H, J = 3.3 
Hz, J = 12.4 Hz, J = 15.7 Hz), 1.37 (qt, 2H, J = 3.5 Hz, J = 12.4 Hz), 1.27 (tt, 1H, J = 3.0 
Hz, J = 11.8 Hz); 19F NMR ((CD3)2SO, 376 MHz, 298 K) C6F6 internal reference 
standard δ -124.58 (br s). 
 
4-Bromoacetanilide (8): 
 
In an oven-dried 2 L round-bottom flask, 4-bromoaniline (50 g, 0.30 mol) was suspended 
in acetic anhydride (300 mL), and chilled to 0 ˚C.  Concentrated sulfuric acid (15 mL) 
was slowly added.  Once the solution became homogenous, the ice bath was removed and 
the solution was as allowed to warm to room temperature.  After 2 hours, the solution 
was poured over 400 mL ice-water (~1:1).  Once the ice had melted, the mixture was 
filtered.  The solid was dried at 110 ˚C for several hours to yield the colorless product 
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(60.82 g, 97.7%): 1H NMR (CDCl3, 500 MHz, 298 K): δ 7.43 (d, J = 9.1 Hz, 2H), 
7.40 (d, J = 9.1 Hz, 2H), 7.28 (br s, NH), 2.18 (s, 3H); 13C NMR (CDCl3, 126 MHz, 298 
K): δ 168.31, 136.93, 131.97, 121.37, 116.88, 24.64; HRMS: (EI+) calcd. for C8H8BrNO 
[M]+ 212.9789, 214.9769 found 212.9799, 214.9779. 
 Mohan,	 J.	 “Confirmatory	Tests	and	Derivatization	of	Common	Organic	Compounds,	Their	Derivatization	and	Classified	Tables	 including	Melting	and	Boiling	Points”	 in	“Organic	 Analytical	 Chemistry:	 Theory	 and	 Practice”;	 Alpha	 Science	 Int’l	 Ltd.:	Oxford,	United	Kingdom,	2003.	
 
4-Bromo-2-nitroacetanilide (9): 
 
In a 125 mL erlenmeyer flask, fuming nitric acid (75 mL) was cooled to -40 ˚C in an 
acetonitrile/dry ice bath.  4-bromoacetanilide (6.00 g, 28.0 mmol) was added, in portions, 
while swirling the flask.  After addition the flask was allowed to stand for 15 minutes.  
The solution was poured over 200 g of ice.  After the ice had melted, the mixture was 
filtered and the solid was washed with cold water.  The solid was recrystallized from 
ethanol (200 proof) and dried in vacuo to yield a pale yellow solid (6.69 g, 92.3%): 1H 
NMR (CDCl3, 500 MHz, 298 K): δ 10.27 (br s, NH), 8.73 (d, J = 9.1 Hz, 1H), 8.36 (d, J 
= 2.3 Hz, 1H), 7.74 (dd, J = 9.1 Hz, J = 2.3 Hz, 1H), 2.30 (s, 3H); 13C NMR (CDCl3, 126 
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MHz, 298 K): δ 169.19, 138.97, 136.71, 134.16, 128.42, 123.78, 115.46, 25.84; 
HRMS: (EI+) calcd. for C8H7BrN2O3 [M]+ 257.9640, 259.9620 found 257.9648, 
259.9627. 
 
Hay, M. P.; Hicks, K. O.; Pchalek, K.; Lee, H. H.; Blaser, A.; Pruijn, F. B.; Anderson, R. 
F.; Shinde, S. S.; Wilson, W. R.; Denny, W. A. J. Med. Chem., 2008, 51, 6853–6865. 
 
4-Bromo-2-nitroaniline (10): 
 
In a 250 mL round-bottom flask, 4-bromo-2-nitroacetanilide (1.295 g, 5.00 mmol) was 
dissolved in 50 mL THF.  Aqueous HCl (2 M, 200 mL) was added with vigorous stirring.  
The mixture was heated to reflux overnight.  The solution was neutralized with saturated 
aqueous sodium bicarbonate and extracted three times with ethyl acetate.  The organic 
layers were washed once with brine, dried over sodium sulfate, and the solvent was 
removed in vacuo.  The crude product was sublimed under high dynamic vacuum at 65 
˚C for 24 hours to yield an orange solid (0.961 g, 88.6%): 1H NMR (CDCl3, 500 MHz, 
298 K): δ 8.26 (d, J = 2.2 Hz, 1H), 7.43 (dd, J = 8.9 Hz, J = 2.2 Hz, 1H), 6.74 (d, J = 8.9 
Hz, 1H), 6.14 (br s, NH2); 13C NMR (CDCl3, 126 MHz, 298 K): δ 143.77, 138.65, 
132.60, 128.49, 128.46, 128.42, 120.52, 107.99; HRMS: (EI+) calcd. for C6H5BrN2O2 
[M]+ 215.9534, 217.9514 found 215.9532, 217.9521. 
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General procedure for the preparation of N-arylcarbonyl-5-bromo-2-
nitroanilines (11a–l) by method 1, with liquid benzoyl chlorides: 4-Bromo-2-
nitroaniline (3.00 g, 13.8 mmol), and triethylamine (4 mL) were dissolved in 60 mL of 
dry acetonitrile.  The appropriate acid chloride (20.7 mmol) was added dropwise by 
syringe and the reaction was heated at 80 °C for 20 hours.  The reaction mixture was 
diluted with dichloromethane and transferred to a separatory funnel containing saturated 
aqueous sodium bicarbonate in deionized water (1:1).  The organic layer was separated, 
the aqueous layer was extracted with dichloromethane.  The combined organic layers 
were dried over sodium sulfate, evaporated, and purified by column chromatography or 
recrystallization using the indicated solvent(s). 
 
General procedure for the preparation of N-arylcarbonyl-5-bromo-2-nitroanilines 
(11a–l) by method 1, with solid benzoyl chlorides: 4-Bromo-2-nitroaniline (3.00 g, 
13.8 mmol), triethylamine (4 mL), and the appropriate acid chloride (20.7 mmol) were 
dissolved in 60 mL of dry acetonitrile.  The reaction was heated at 80 °C for 20 hours.  
The reaction mixture was diluted with dichloromethane and transferred to a separatory 
funnel containing saturated aqueous sodium bicarbonate in deionized water (1:1).  The 
organic layer was separated, the aqueous layer was extracted with dichloromethane.  The 
combined organic layers were dried over sodium sulfate, evaporated, and purified by 
column chromatography or recrystallization using the indicated solvent(s). 
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General procedure for the preparation of N-arylcarbonyl-5-bromo-2-
nitroanilines (11a–l) by method 2, with liquid benzoyl chlorides: 4-Bromo-2-
nitroaniline (4.00 g, 18.4 mmol) and pyridine (3 mL) were dissolved in 25 mL of dry 
acetonitrile.  The appropriate acid chloride (18.4 mmol) was added dropwise by syringe 
and the reaction was heated at 80 °C for 20 hours.  The reaction mixture was diluted with 
dichloromethane and transferred to a separatory funnel containing saturated aqueous 
sodium bicarbonate in deionized water (1:1).  The organic layer was separated, the 
aqueous layer was extracted with dichloromethane.  The combined organic layers were 
dried over sodium sulfate, evaporated, and purified by column chromatography or 
recrystallization using the indicated solvent(s). 
 
General procedure for the preparation of N-arylcarbonyl-5-bromo-2-nitroanilines 
(11a–l) by method 2, with solid benzoyl chlorides: 4-Bromo-2-nitroaniline (4.00 g, 
18.4 mmol), pyridine (3 mL), and appropriate acid chloride (18.4 mmol) were dissolved 
in 25 mL of dry acetonitrile.  The reaction was heated at 80 °C for 20 hours.  The reaction 
mixture was diluted with dichloromethane and transferred to a separatory funnel 
containing saturated aqueous sodium bicarbonate in deionized water (1:1).  The organic 
layer was separated, the aqueous layer was extracted with dichloromethane.  The 
combined organic layers were dried over sodium sulfate, evaporated, and purified by 
column chromatography or recrystallization using the indicated solvent(s). 
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General procedure for the preparation of N-arylcarbonyl-5-bromo-2-
nitroanilines (11a–l) by hydrolysis of the corresponding imide: In a 100 mL round-
bottom flask, the corresponding imide (6.32 mmol) was dissolved in a solution of 
methanol (13 mL) in dioxane (22 mL).  Sodium hydroxide (34.7 mg, 20 mol%) was 
crushed and dissolved in methanol (9 mL).  This base solution was added, dropwise, with 
stirring to the flask.  The solution darkened in color throughout addition.  The solution 
was stirred for 30 min, diluted with dichloromethane (200 mL), and washed with water 
(10 mL) in saturated aqueous ammonium chloride (40 mL).  The organic layer was 
washed with saturated aqueous sodium bicarbonate (20 mL), dried over sodium sulfate, 
and solvents were removed in vacuo.  The crude product was purified by column 
chromatography or recrystallization using the indicated solvent(s). 
 
N-Benzoyl-4-bromo-2-nitroaniline (11a): 
 
This compound (method 1: 1.34 g, 30.4%; method 2: 5.16 g, 87.1%) was obtained as dull 
yellow needles from method 1 after recrystallization from boiling ethanol (200 proof), 
followed by chromatography on silica with ethyl acetate in hexanes (15%, v/v), or from 
method 2 after recrystallization from boiling ethanol (200 proof): 1H NMR (CDCl3, 500 
MHz, 298 K): δ 11.28 (br s, NH), 8.97 (d, J = 9.1 Hz, 1H), 8.43 (d, J = 2.1 Hz, 1H), 7.99 
(d, J = 7.5 Hz, 2H), 7.81 (dd, J = 9.1 Hz, J = 2.1 Hz, 1H), 7.63 (t, J = 7.5 Hz, 1H), 7.56 (t, 
J = 7.5 Hz, 2H); 13C NMR (CDCl3, 126 MHz, 298 K): δ 165.88, 139.21, 136.89, 134.69, 
N
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133.87, 133.10, 129.34, 128.63, 127.58, 123.76, 115.59; HRMS: (EI+) calcd. for 
C13H9BrN2O3 [M]+ 319.9797, 321.9776 found 319.9803, 321.9783. 
 
N-(4-Methoxybenzoyl)-4-bromo-2-nitroaniline (11b): 
 
This compound was obtained by method 1 (1.64 g, 37.2%) as a dull yellow solid after 
recrystallization from boiling ethanol in ethyl acetate (2:1 v/v), and by method 2 (2.25 g, 
36.6%) after recrystallization from boiling ethyl acetate in hexanes (2:1 v/v): 1H NMR 
(CDCl3, 500 MHz, 298 K): δ 11.22 (br s, NH), 8.95 (d, J = 9.1 Hz, 1H), 8.41 (d, J = 2.4 
Hz, 1H), 7.94 (d, J = 8.9 Hz, 2H), 7.78 (dd, J = 9.1 Hz, J = 2.4 Hz, 1H), 7.02 (d, J = 8.9 
Hz, 2H), 3.90 (s, 3H); 13C NMR (CDCl3, 126 MHz, 298 K): δ 165.36, 163.52, 139.17, 
136.71, 135.03, 129.62, 128.57, 126.03, 123.70, 115.20, 114.53, 55.77; HRMS: (EI+) 
calcd. for C14H11BrN2O4 [M]+ 349.9902, 351.9882 found 349.9916, 351.9895. 
 
N-(3,4-Dimethoxybenzoyl)-4-bromo-2-nitroaniline (11c): 
 
This compound (1.95 g, 37.0%) was obtained by method 1 as a fluffy yellow solid after 
recrystallization from a dilute solution of boiling ethanol: 1H NMR (CDCl3, 500 MHz, 
298 K): δ 11.22 (br s, NH), 8.89 (d, J = 9.1 Hz, 1H), 8.36 (d, J = 2.4 Hz, 1H), 7.73 (dd, J 
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= 9.1 Hz, J = 2.4 Hz, 1H), 7.50 (dd, J = 8.1 Hz, J = 2.1 Hz, 1H), 7.48 (d, J = 2.1 Hz, 
1H), 6.91 (d, J = 8.1 Hz, 1H), 3.92 (s, 3H), 3.91 (s, 3H); 13C NMR (CDCl3, 126 MHz, 
298 K): δ 165.44, 153.19, 149.57, 139.27, 136.71, 135.02, 128.63, 126.38, 123.61, 
120.60, 115.28, 110.86, 110.75, 56.38, 56.28; HRMS: (EI+) calcd. for C15H13BrN2O5 
[M]+ 380.0008, 381.9987 found 380.0023, 382.0006. 
 
N-(3,4,5-Trimethoxybenzoyl)-4-bromo-2-nitroaniline (11d): 
 
This compound (0.294 g, 19.6%) was obtained by method 1 as a fluffy yellow solid after 
recrystallization from boiling ethanol in ethyl acetate (3:7, v/v): 1H NMR (CDCl3, 500 
MHz, 298 K): δ 11.31 (br s, NH), 8.96 (d, J = 9.1 Hz, 1H), 8.44 (d, J = 2.3 Hz, 1H), 7.82 
(dd, J = 9.1 Hz, J = 2.3 Hz, 1H), 7.22 (s, 2H), 3.97 (s, 6H), 3.94 (s, 3H); 13C NMR 
(CDCl3, 126 MHz, 298 K): δ 165.47, 153.71, 142.29, 139.38, 136.73, 134.84, 129.05, 
128.69, 123.50, 115.53, 104.83, 61.24, 56.53; HRMS: (EI+) calcd. for C16H15BrN2O6 
[M]+ 410.0113, 412.0093 found 410.0103, 412.0072. 
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N-(tert-Butylbenzoyl)-4-bromo-2-nitroaniline (11e): 
 
This compound (1.26 g, 24.2%) was obtained by method 1 as dull yellow needles after 
chromatographing on silica with ethyl acetate in hexanes (7%, v/v).  Due to the 
insolubility of this compound in the elution solvent, it was deposited on silica and dry-
loaded onto the column. More material was recovered by hydrolysis of N,N-(di-4-tert-
butylbenzoyl)-4-bromo-2-nitroaniline (0.461 g, 84.5%): 1H NMR (CDCl3, 500 MHz, 298 
K): δ 11.27 (br s, NH), 8.98 (d, J = 9.1 Hz, 1H), 8.43 (d, J = 2.3 Hz, 1H), 7.92 (d, J = 8.5 
Hz, 2H), 7.80 (dd, J = 9.1 Hz, J = 2.3 Hz, 1H), 7.57 (d, J = 8.5 Hz, 2H), 1.38 (s, 9H); 13C 
NMR (CDCl3, 126 MHz, 298 K): δ 165.85, 156.90, 139.16, 136.80, 134.87, 130.99, 
128.59, 127.48, 126.30, 123.73, 115.36, 35.34, 31.30; HRMS: (EI+) calcd. for 
C17H17BrN2O3 [M]+ 376.0423, 378.0402 found 376.0416, 378.0421. 
 
N-(4-Methylbenzoyl)-4-bromo-2-nitroaniline (11f): 
 
This compound (1.70 g, 36.7%) was obtained by method 1 as dull yellow needles after 
chromatographing on silica with ethyl acetate in hexanes (7%, v/v).  Due to the 
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insolubility of this compound in the elution solvent, it was deposited on silica and 
dry-loaded onto the column: 1H NMR (CDCl3, 600 MHz, 298 K): δ 11.25 (s, NH), 8.97 
(d, J = 9.1 Hz, 1H), 8.42 (d, J = 2.3 Hz, 1H), 7.88 (d, J = 8.2 Hz, 2H), 7.80 (dd, J = 9.1 
Hz, J = 2.3 Hz, 1H), 7.35 (d, J = 8.2 Hz, 2H), 2.46 (s, 3H); 13C NMR (CDCl3, 126 MHz, 
298 K): δ 165.87, 143.91, 139.18, 136.87, 134.91, 131.13, 130.02, 128.61, 127.65, 
123.79, 115.39, 21.80; HRMS: (EI+) calcd. for C14H11BrN2O3 [M]+ 333.9953, 335.9933 
found 333.9948, 335.9931. 
 
N-(4-Cyanobenzoyl)-4-bromo-2-nitroaniline (11h): 
 
This compound (method 1: 2.74 g, 57.4%; method 2: 1.73 g, 30.2%) was obtained as dull 
yellow plates after recrystallization from boiling toluene: 1H NMR (CDCl3, 500 MHz, 
298 K): δ 11.36 (br s, NH), 8.92 (d, J = 9.1 Hz, 1H), 8.46 (d, J = 1.9 Hz, 1H), 8.09 (d, J = 
8.2 Hz, 2H), 7.87 (d, J = 8.2 Hz, 2H), 7.85 (dd, J = 9.1 Hz, J = 1.9 Hz, 1H); 13C NMR 
(CDCl3, 126 MHz, 298 K): δ 164.03, 139.43, 137.69, 137.08, 133.96, 133.17, 128.82, 
128.23, 123.77, 117.88, 116.64, 116.50; HRMS: (EI+) calcd. for C14H8BrN3O3 [M]+ 
344.9749, 346.9729 found 344.9762, 346.9743. 
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N-(4-Dimethylaminobenzoyl)-4-bromo-2-nitroaniline (11i): 
 
This compound (1.29 g, 25.6%) was obtained by method 1 as a dull red solid after 
recrystallization from boiling ethyl acetate: 1H NMR (CDCl3, 500 MHz, 298 K): δ 11.20 
(br s, NH), 8.99 (d, J = 9.2 Hz, 1H), 8.40 (d, J = 2.4 Hz, 1H), 7.88 (d, J = 8.9 Hz, 2H), 
7.76 (dd, J = 9.2 Hz, J = 2.4 Hz, 1H), 6.67 (d, J = 8.9 Hz, 2H), 3.01 (s, 6H). 
 
N-(4-Nitrobenzoyl)-4-bromo-2-nitroaniline (11j): 
 
This compound was obtained by method 1 (8.0 mmol scale) after trituration with hexanes 
and recrystallization from boiling ethyl acetate in ethanol (2:1 v/v) to yield a yellow solid 
(2.40 g, 81.9%): 1H NMR (CDCl3, 500 MHz, 298 K): δ 11.39 (br s, NH), 8.93 (d, J = 9.1 
Hz, 1H), 8.47 (d, J = 2.3 Hz, 1H), 8.42 (d, J = 8.9 Hz, 2H), 8.16 (d, J = 8.9 Hz, 2H), 7.87 
(dd, J = 9.1 Hz, J = 2.3 Hz, 1H); 13C NMR (CDCl3, 126 MHz, 298 K): δ 163.79, 150.54, 
139.47, 139.29, 137.09, 133.90, 128.85, 128.81, 124.56, 123.76, 116.61; HRMS: (EI+) 
calcd. for C13H8BrN3O5 [M]+ 364.9647, 366.9627 found 364.9663, 366.9627. 
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N-(4-Chlorobenzoyl)-4-bromo-2-nitroaniline (11k): 
 
This compound (method 1: 1.35 g, 22.9%; method 2: 4.09 g, 69.4%) was obtained as dull 
yellow fine needles after recrystallization from ethanol in ethyl acetate (2:1 v/v): 1H 
NMR (CDCl3, 500 MHz, 298 K): δ 11.26 (br s, NH), 8.93 (d, J = 9.1 Hz, 1H), 8.43 (d, J 
= 2.3 Hz, 1H), 7.93 (d, J = 8.7 Hz, 2H), 7.82 (dd, J = 9.1 Hz, J = 2.3 Hz, 1H), 7.53 (d, J = 
8.7 Hz, 2H); 13C NMR (CDCl3, 126 MHz, 298 K): δ 164.81, 139.60, 139.29, 136.93, 
134.47, 132.27, 129.66, 128.99, 128.69, 123.74, 115.88. 
 
N-(4-Fluorobenzoyl)-4-bromo-2-nitroaniline (11l): 
 
This compound (1.89 g, 88.1%) was obtained as pale yellow needles after hydrolysis of 
N,N-(di-4-fluorobenzoyl)-4-bromo-2-nitroaniline: 1H NMR (CDCl3, 500 MHz, 298 K): δ 
11.24 (s, NH), 8.92 (d, J = 9.1 Hz, 1H), 8.41 (d, J = 2.3 Hz, 1H), 7.99 (dd, J = 8.7 Hz, J = 
5.2 Hz, 2H), 7.80 (dd, J = 9.1 Hz, J = 2.3 Hz, 1H), 7.22 (t, J = 8.7 Hz, 2H); 13C NMR 
(CDCl3, 126 MHz, 298 K): δ 166.75, 164.71, 139.25, 136.87, 134.55, 130.09 (d, J = 9.4 
Hz), 128.65, 123.69, 116.51 (d, J = 22.1 Hz), 115.72; 19F NMR (CDCl3, 376 MHz, 298 
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K): δ -103.87 (m, 1F) ; HRMS: (EI+) calcd. for C13H8BrFN2O3 [M]+ 337.9702, 
339.9682 found 337.9717, 339.9680. 
 
N,N-Dibenzoyl-4-bromo-2-nitroaniline (12a): 
 
This compound (5.01 g, 56.9%) was obtained by method 1 as a faintly yellow solid after 
recrystallization from boiling ethanol (200 proof), followed by chromatography on silica 
with ethyl acetate in hexanes as a gradient from 15% (v/v) to 25% (v/v): 1H NMR 
(CDCl3, 500 MHz, 298 K): δ 8.32 (d, J = 2.3 Hz, 1H), 7.78 (dd, J = 8.3 Hz, J = 1.2 Hz, 
4H), 7.69 (dd, J = 8.4 Hz, J = 2.3 Hz, 1H), 7.47 (dt, J = 8.3 Hz, J = 1.2 Hz, 2H), 7.36 (t, J 
= 8.3 Hz, 4H), 7.10 (d, J = 8.4 Hz, 1H); 13C NMR (CDCl3, 126 MHz, 298 K): δ 172.19, 
144.97, 137.23, 134.19, 132.91, 132.78, 132.27, 129.30, 129.19, 128.76, 128.73, 128.70, 
128.68, 128.67, 128.65, 121.98; HRMS (EI+): calcd. for C20H13BrN2O4 [M]+ 424.0059, 
426.0038 found 424.0047, 426.0035. 
N
O2N
Br
O
O
 304 
 
N,N-(Di-4-fluorobenzoyl)-4-bromo-2-nitroaniline (12l): 
 
This compound (2.92 g, 67.6%) was obtained by method 1 as a pale yellow solid after 
recrystallization from hexanes in ethyl acetate (4:1 v/v): 1H NMR (CDCl3, 400 MHz, 298 
K): δ 8.31 (d, J = 2.3 Hz, 1H), 7.78 (dd, J = 8.8 Hz, J = 5.2 Hz, 4H), 7.70 (dd, J = 8.5 Hz, 
J = 2.3 Hz, 1H), 7.06 (d, J = 8.5 Hz, 1H), 7.04 (dd, J = 8.8 Hz, J = 2.4 Hz, 4H); 19F NMR 
(CDCl3, 376 MHz, 298 K): δ -103.88 (m, 2F); HRMS (EI+): calcd. for C20H11BrF2N2O4 
[M]+ 459.9870, 461.9850 found 459.9886, 461.9853. 
 
General procedure for reduction/cyclization of N-arylcarbonyl-4-bromo-2-
nitroanilines (13a–m): In a 50 mL Schlenk storage tube with a stirbar, N-aryl-4-bromo-
2-nitroaniline was combined with iron powder or iron filings (400 mol%).  Hot acetic 
acid (15–30 mL) was added until the mixture could be stirred smoothly.  The tube was 
sealed and heated to 110 ˚C for 24 hours to a week, monitoring reaction progress by TLC.  
The reaction mixture was transferred to a 250 mL round-bottom flask and benzene (20 
mL) was added to facilitate azeotropic removal of acetic acid.  Volume was reduced to an 
oil in vacuo with heating.  The oil was dissolved in ethyl acetate and carefully washed 
three times with a mixutre of saturated aqueous sodium bicarbonate and brine (1:1 v/v).  
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The organic layer was dried over sodium sulfate and solvent was removed  in vacuo.  
The crude product was purified by column chromatography or recrystallization using the 
indicated solvent(s).  
 
Morningstar, M. L.; Roth, T.; Farnsworth, D. W.; Smith, M. K.; Watson, K.; Buckheit, R. 
W.; Jr., ; Das, K.; Zhang, W.; Arnold, E.; Julias, J. G.; Hughes, S. H.; Michejda, C. J. J. 
Med. Chem. 2007, 50, 4003–4015. 
 
2-Phenyl-5-bromobenzimidazole (13a): 
 
This compound (16.1 mmol scale, 3.90 g, 89.0%) was obtained as a sufficiently pure 
colorless powder after liquid-liquid extraction: 1H NMR (CDCl3, 400 MHz, 298 K) δ 
9.65 (br s, NH), 8.04 (d, J = 7.9 Hz, 2H), 7.80 (br s, 2H), 7.52 (m, 3H), 7.39 (dd, J = 8.5 
Hz, J = 1.8 Hz, 1H). 
 
2-(4-Methoxyphenyl)-5-bromobenzimidazole (13b): 
 
This compound (6.4 mmol scale, 1.59 g, 82.0%) was obtained as a sufficiently pure 
colorless powder after liquid-liquid extraction: 1H NMR (CDCl3, 400 MHz, 298 K) δ 
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9.32 (br s, NH), 7.97 (d, J = 8.9 Hz, 2H), 7.76 (br s, 1H), 7.51 (br s, 1H), 7.37 (dd, J = 
8.5 Hz, J = 1.7 Hz, 1H), 7.04 (d, J = 8.9 Hz, 2H), 3.90 (s, 3H). 
 
2-(3,4-Dimethoxyphenyl)-5-bromobenzimidazole (13c): 
 
This compound (2.4 mmol scale, 0.672 g, 85.7%) was obtained as a colorless powder 
after chromatographing with methanol in dichloromethane (7% v/v): 1H NMR (CDCl3, 
400 MHz, 298 K) δ 10.03 (br s, NH), 7.75 (br s, 1H), 7.68 (br s, 1H), 7.51 (d, J = 8.4 Hz, 
1H), 7.48 (br s, 1H), 7.36 (d, J = 8.4 Hz, 1H), 6.94 (d, J = 8.3 Hz, 1H), 3.94 (s, 3H), 3.88 
(s, 3H). 
 
2-(3,4,5-Trimethoxyphenyl)-5-bromobenzimidazole (13d): 
 
This compound (3.6 mmol scale,  1.23 g, 94.4%) was obtained as a colorless powder after 
chromatographing on silica using methanol in dichloromethane (3% v/v).  The NMR 
spectra in CD2Cl2 showed a nearly equal mixture of the two tautomeric forms: 1H NMR 
(CD2Cl2, 400 MHz, 298 K) δ 10.65 (br s, 0.5H), 10.56 (br s, 0.5H), 7.92 (br s, 0.5H), 7.69 
(br s, 1H), 7.42 (br s, 0.5H), 7.41 (dd, J = 8.4 Hz, J = 1.7 Hz, 1H), 7.32 (s, 2H), 3.86 (s, 
3H), 3.84 (s, 6H); HRMS (ESI): calcd. for C16H15BrN2NaO3 [M+Na]+ 385.0164, 
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387.0143 found 385.0153, 387.0143; HRMS: (EI+) calcd. for C16H15BrN2O3 [M]+ 
362.0266, 364.0246 found 362.0262, 364.0243. 
 
2-(4-tert-Butylphenyl)-5-bromobenzimidazole (13e): 
 
This compound (3.2 mmol scale, 0.763 g, 69.2%) was obtained as a colorless powder 
after chromatographing on silica using methanol in dichloromethane (3% v/v): 1H NMR 
(CDCl3, 400 MHz, 298 K) δ 7.98 (d, J = 8.4 Hz, 2H), 7.73 (br s, 1H), 7.49 (d, J = 8.4 Hz, 
2H), 7.46 (br s, 1H), 7.34 (dd, J = 8.7 Hz, J = 1.2 Hz, 1H), 1.35 (s, 9H); HRMS: (EI+) 
calcd. for C17H17BrN2 [M]+ 328.0575, 330.0555 found 328.0579, 330.0554. 
 
2-(4-Methylphenyl)-5-bromobenzimidazole (13f): 
 
This compound (7.8 mmol scale, 1.43 g, 64.1%) was obtained as a colorless powder after 
chromatographing with methanol in dichloromethane (3% v/v).  The NMR spectra in 
CDCl3 showed a nearly equal mixture of the two tautomeric forms: 1H NMR (CDCl3, 400 
MHz, 298 K) δ 9.49 (br s, NH), 7.95 (br s, 0.5H), 7.92 (d, J = 7.9 Hz, 2H), 7.67 (d, J = 
8.6 Hz, 0.5H), 7.61 (br s, 0.5H), 7.38 (dd, J = 10.4 Hz, J = 1.8 Hz, 1H), 7.36 (br s, 0.5H), 
7.33 (d, J = 7.9 Hz, 2H); HRMS (ESI): calcd. for C14H12BrN2 [M+Na]+ 287.0184, 
289.0163 found 287.0180, 289.0176. 
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2-(4-Cyanophenyl)-5-bromobenzimidazole (13h): 
 
This compound (4.4 mmol scale, 0.841 g, 61.4%) was obtained as a colorless powder 
after dry column vacuum chromatography on silica using three respective fractions of 
dichloromethane, ethyl acetate, and acetone: 1H NMR (CD2Cl2, 400 MHz, 298 K) δ 
10.48 (br s, NH), 8.02 (d, J = 7.9 Hz, 2H), 7.64 (m, 3H), 7.41 (d, J = 8.5 Hz, 1H), 7.32 (d, 
J = 8.5 Hz, 1H); HRMS: (EI+) calcd. for C14H8BrN3 [M]+ 296.9902, 298.9881 found 
296.9904, 298.9893. 
 
2-(4-Nitrophenyl)-5-bromobenzimidazole (13m): 
 
This compound (4.1 mmol scale, 0.760 g, 58.4%) was obtained as a colorless powder 
after chromatographing with methanol in dichloromethane (5% v/v): 1H NMR (CDCl3, 
400 MHz, 298 K) δ 9.64 (br s, NH), 8.40 (d, J = 8.9 Hz, 2H), 8.23 (d, J = 8.9 Hz, 2H), 
7.84 (br s, 1H), 7.60 (br s, 1H), 7.46 (dd, J = 8.5 Hz, J = 1.6 Hz, 1H). 
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2-(4-Chlorophenyl)-5-bromobenzimidazole (13k): 
 
This compound (11.5 mmol scale, 1.74 g, 49.2%) was obtained as a sufficiently pure 
colorless powder after liquid-liquid extraction: 1H NMR (CDCl3, 400 MHz, 298 K) δ 
10.35 (br s, NH), 7.97 (d, J = 8.4 Hz, 2H), 7.75 (br s, 1H), 7.49 (br s, 1H), 7.45 (d, J = 8.4 
Hz, 2H), 7.38 (d, J = 7.9 Hz, 1H). 
 
2-(4-Fluorophenyl)-5-bromobenzimidazole (13l): 
 
This compound (4.2 mmol scale, 0.873 g, 71.4%) was obtained as a colorless powder 
after chromatographing with methanol in dichloromethane (3% v/v): 1H NMR (CDCl3, 
400 MHz, 298 K) δ 9.47 (br s, NH), 8.02 (dd, J = 8.8 Hz, J = 5.2 Hz, 2H), 7.79 (br s, 
1H), 7.51 (br s, 1H), 7.40 (dd, J = 8.5 Hz, J = 1.8 Hz, 1H), 7.22 (t, J = 8.8 Hz, 2H); 19F 
NMR (CDCl3, 376 MHz, 298 K): δ -109.06 (br m, 1F); HRMS: (EI+) calcd. for 
C13H8BrFN2 [M]+ 289.9855, 291.9834 found 289.9856, 291.9831. 
 
General procedure for Boc-protection of 2-aryl-5-bromobenzimidazoles (14a–k): In 
a 100 mL round-bottom flask with a stirbar, 2-aryl-5-bromobenzimidazole was 
suspended in acetonitrile (10–30 mL; dried over 3Å molecular sieves) with triethylamine 
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(400 mol%; dried over potassium hydroxide).  N,N-dimethylaminopyridine (30 
mol%) was added in portions.  Di-tert-butyl dicarbonate (200 mol%) was added slowly, 
in portions.  The mixture was stirred, under N2, for 12–24 hours.  Solvent was removed in 
vacuo and the resulting oil was diluted with dichloromethane.  The mixture was washed 
twice with a mixture of saturated aqueous ammonium chloride and brine (1:1 v/v).  The 
organic layer was dried over sodium sulfate and solvent was removed in vacuo.  The 
crude product was purified by column chromatography on silica, deactivated with 
triethylamine in hexanes (5% v/v), using the indicated solvent(s). 
 
Sue, M. D.; Delgado, M. M. M.; Joseph, S. J.; J, A. R.; G, L. B.; Iii, H. R. L.; Isabel, S. 
G.; Dehua, H.; Lyn, S. K.; K, P. G.; Simon, P. J.; William, P. P.; Radnia, T. L.; Sophie, P. 
PCT	Int.	Appl.	2008,	WO2008051493	A3. 
 
N-tert-Butyloxycarbonyl-2-phenyl-5-bromobenzimidazole (14a): 
 
A nearly equal mixture of two regioisomers (14.3 mmol scale, 4.54 g, 85.1%) was 
obtained as a colorless waxy solid after chromatography, on deactivated silica, with ethyl 
acetate in hexanes (15% v/v): 1H NMR (CD3CN, 400 MHz, 298 K): δ 8.19 (d, J = 2.0 Hz, 
1H), 7.94 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 2.0 Hz, 1H), 7.62 (m, 5H), 7.50 (m, 8H), 1.38 
(s, 9H), 1.37 (s, 9H); 13C NMR (CD3CN, 126 MHz, 298 K): δ 155.82, 155.27, 149.08, 
N
N
Br
Boc
 311 
149.02, 144.94, 142.70, 135.89, 134.03, 133.28, 130.52, 130.28, 128.82, 128.43, 
128.19, 123.39, 122.11, 118.65, 117.51, 117.24, 86.68, 86.61, 27.76. 
  
N-tert-Butyloxycarbonyl-2-(4-methoxyphenyl)-5-bromobenzimidazole (14b): 
 
A nearly equal mixture of two regioisomers (5.3 mmol scale, 1.53 g, 89.5%) was 
obtained as a pale yellow foam after chromatography, on deactivated silica, with ethyl 
acetate in hexanes (15% v/v): 1H NMR (CD3CN, 400 MHz, 298 K): δ 8.16 (d, J = 1.8 Hz, 
1H), 7.91 (d, J = 8.7 Hz, 1H), 7.86 (d, J = 1.8 Hz, 1H), 7.59 (m, 5H), 7.47 (m, 2H), 7.03 
(d, J = 8.7 Hz, 4H), 3.87 (s, 6H), 1.45 (s, 9H), 1.44 (s, 9H); 13C NMR (CD3CN, 126 
MHz, 298 K): δ 161.96, 161.92, 156.02, 155.48, 149.36, 149.30, 145.09, 142.84, 136.08, 
134.22, 131.99, 131.96, 128.21, 128.18, 125.31, 125.25, 123.23, 121.99, 118.70, 118.11, 
117.47, 117.31, 114.25, 86.74, 86.67, 56.17, 27.87, 27.84. 
  
N-tert-Butyloxycarbonyl-2-(3,4-dimethoxyphenyl)-5-bromobenzimidazole (14c): 
 
A nearly equal mixture of two regioisomers (2.0 mmol scale, 0.746 g, 88.0%) was 
obtained as a colorless waxy solid after chromatography, on deactivated silica, with ethyl 
acetate in hexanes (30% v/v): 1H NMR (CD3CN, 400 MHz, 298 K): δ 8.16 (d, J = 1.7 Hz, 
1H), 7.91 (d, J = 8.6 Hz, 1H), 7.87 (d, J = 1.7 Hz, 1H), 7.60 (d, J = 8.5 Hz, 1H), 7.49 (m, 
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2H), 7.22 (d, J = 1.7 Hz, 2H), 7.19 (m, 2H), 7.02 (d, 2H), 3.87 (s, 3H), 3.83 (s, 3H), 
1.43 (s, 9H), 1.42 (s, 9H); 13C NMR (CD3CN, 150 MHz, 298 K): δ 156.10, 155.56, 
151.70, 151.66, 149.54, 149.36, 149.29, 145.02, 142.79, 136.06, 134.19, 128.31, 128.24, 
125.50, 125.44, 123.42, 123.39, 123.26, 122.03, 118.68, 117.49, 117.29, 114.00, 111.94, 
86.66, 86.59, 56.60, 56.53, 27.86, 27.83; HRMS (ESI): calcd. for C20H21BrN2NaO4 
[M+Na]+ 455.0582, 457.0562 found 455.0598, 457.0614. 
  
N-tert-Butyloxycarbonyl-2-(3,4,5-trimethoxyphenyl)-5-bromobenzimidazole (14d): 
 
A nearly equal mixture of two regioisomers (0.95 mmol scale, 0.399 g, 90.3%) was 
obtained as a colorless waxy solid after chromatography, on deactivated silica, with ethyl 
acetate in hexanes (30% v/v): 1H NMR (CD3CN, 400 MHz, 298 K): δ 8.21 (d, J = 1.7 Hz, 
1H), 7.96 (d, J = 8.5 Hz, 1H), 7.90 (d, J = 1.7 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.53 (dd, 
J = 8.5 Hz, J = 1.9 Hz, 1H), 7.53 (dd, J = 8.5 Hz, J = 1.9 Hz, 1H), 6.90 (s, 4H), 3.83 (s, 
12H), 3.78 (s, 6H), 1.41 (s, 9H), 1.40 (s, 9H); 13C NMR (CD3CN, 150 MHz, 298 K): δ 
155.91, 155.40, 154.05, 154.03, 149.23, 149.21, 144.93, 142.74, 140.45, 136.03, 134.13, 
128.88, 128.79, 128.63, 128.44, 123.46, 122.28, 118.79, 117.62, 117.39, 108.08, 108.07, 
86.65, 86.56, 61.12, 61.10, 57.06, 57.04, 27.87, 27.87; HRMS (ESI): calcd. for 
C21H23BrN2NaO5 [M+Na]+ 485.0688, 487.0668 found 485.0690, 487.0647. 
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N-tert-Butyloxycarbonyl-2-(4-tert-butylphenyl)-5-bromobenzimidazole (14e): 
 
A nearly equal mixture of two regioisomers (1.7 mmol scale, 0.472 g, 81.1%) was 
obtained as a colorless waxy solid after chromatography, on deactivated silica, with ethyl 
acetate in hexanes (2% v/v): 1H NMR (CDCl3, 400 MHz, 298 K): δ 8.25 (d, J = 1.9 Hz, 
1H), 7.93 (d, J = 8.9 Hz, 1H), 7.91 (d, J = 1.9 Hz, 1H), 7.63 (d, J = 8.9 Hz, 1H), 7.55 (d, 
J = 8.3 Hz, 4H), 7.49 (d, J = 8.3 Hz, 4H), 7.49 (m, 2H), 1.39 (s, 9H), 1.37 (s, 9H). 
  
N-tert-Butyloxycarbonyl-2-(4-methylphenyl)-5-bromobenzimidazole (14f): 
 
A nearly equal mixture of two regioisomers (4.8 mmol scale, 1.71 g, 92.0%) was 
obtained as a colorless foam after chromatography, on deactivated silica, with ethyl 
acetate in hexanes (10% v/v): 1H NMR (CD3CN, 400 MHz, 298 K): δ 8.16 (d, J = 1.7 Hz, 
1H), 7.91 (d, J = 8.7 Hz, 1H), 7.87 (d, J = 1.7 Hz, 1H), 7.60 (d, J = 8.7 Hz, 6H), 7.50 (m, 
4H), 7.30 (d, J = 8.0 Hz, 1H), 2.41 (s, 6H), 1.40 (s, 9H), 1.40 (s, 9H); 13C NMR (CD3CN, 
75 MHz, 298 K): δ 156.30, 155.76, 149.35, 149.29, 145.13, 142.90, 141.10, 141.05, 
136.10, 134.23, 130.39, 130.33, 130.31, 129.51, 128.45, 128.31, 123.41, 122.18, 118.78, 
117.55, 117.39, 86.87, 86.79, 27.84, 27.81, 21.54; HRMS (EI+): calcd. for C19H20N2NaO2 
[M-Br +Na]+ 331.1422 found 331.1421. 
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N-tert-Butyloxycarbonyl-2-(4-cyanophenyl)-5-bromobenzimidazole (14h): 
 
A nearly equal mixture of two regioisomers (1.6 mmol scale, 0.435 g, 86.2%) was 
obtained as a colorless waxy solid after chromatography, on deactivated silica, with ethyl 
acetate in hexanes (2% v/v): 1H NMR (CDCl3, 400 MHz, 298 K): δ 8.25 (d, J = 1.9 Hz, 
1H), 7.95 (d, J = 1.9 Hz, 1H), 7.93 (d, J = 8.7 Hz, 1H), 7.79 (d, J = 8.7 Hz, 4H), 7.77 (d, 
J = 8.7 Hz, 4H), 7.55 (dd, J = 8.7 Hz, J = 1.9 Hz, 1H), 7.67 (d, J = 8.5 Hz, 1H), 7.54 (dd, 
J = 8.5 Hz, J = 1.9 Hz, 1H), 1.47 (s, 9H), 1.47 (s, 9H). 
  
N-tert-Butyloxycarbonyl-2-(4-chlorophenyl)-5-bromobenzimidazole (14k): 
 
A nearly equal mixture of two regioisomers (5.7 mmol scale, 2.13 g, 92.3%) was 
obtained as a colorless oily solid after chromatography, on deactivated silica, with 
dichloromethane: 1H NMR (CD3CN, 400 MHz, 298 K): δ 8.20 (d, J = 2.0 Hz, 1H), 7.95 
(d, J = 8.8 Hz, 1H), 7.90 (d, J = 2.0 Hz, 1H), 7.62 (m, 5H), 7.52 (m, 6H), 1.41 (s, 9H), 
1.41 (s, 9H); 13C NMR (CD3CN, 126 MHz, 298 K): δ 154.87, 154.33, 149.07, 149.01, 
144.97, 142.76, 136.25, 136.20, 136.01, 134.14, 132.15, 132.12, 132.08, 132.07, 129.03, 
128.77, 128.44, 123.55, 122.31, 118.92, 118.67, 117.67, 117.56, 87.12, 87.04, 27.81, 
27.78. 
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General procedure for stannylation of N-tert-butyloxycarbonyl-2-aryl-5-
bromobenzimidazoles  (15a–f): N-tert-Butyloxycarbonyl-2-aryl-5-bromobenzimidazole 
was transferred to a 50 mL Schlenk storage tube.  In a glovebox, charged with N2, 
bis(dibenzylideneacetone)palladium(0) (5 mol%) and tris(tert-butyl)phosphine (40 
mol%) were suspended in a small portion of dry benzene (~1–5 mL).  This mixture was 
added to the storage tube by pipet.  By syringe, bis(tributyltin) (300 mol%), distilled 
under vacuum, was added to the storage tube.  The mixture was diluted with more 
benzene to approximately 0.1 M.  The tube was sealed, and heated to 110 ˚C for 24–48 
hours (to monitor reaction progress, a 16 µmol reaction, using 0.6 mL benzene-d6, was 
set up in an NMR	 tube	 fitted	with	 a	 Teflon	 screw	 cap	 closure).  Benzene was removed 
in vacuo and the crude oil was purified by column chromatography on silica, deactivated 
with triethylamine in hexanes (5% v/v), using the indicated solvents. 
 
N-tert-Butyloxycarbonyl-2-(3,4-dimethoxyphenyl)-5-(tributylstannyl)-benzimidazole 
(15c): 
 
A mixture of two regioisomers (1.4 mmol scale, 0.400 g, 43.4%) was obtained as a pale 
yellow viscous oil after chromatography, on deactivated silica, with a gradient from 
hexanes (100%) to ethyl acetate in hexanes (20% v/v), run twice successively: 1H NMR 
(CD3CN, 400 MHz, 298 K): δ 8.11 (s, 1H), 7.98 (d, J = 7.4 Hz, 1H), 7.80 (s, 1H), 7.67 
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(d, J = 7.4 Hz, 1H), 7.46 (m, 2H), 7.23 (m, 3H), 7.19 (dd, J = 4.5 Hz, J = 2.0 Hz, 1H), 
7.02 (d, J = 8.1 Hz, 2H), 3.87 (s, 6H), 3.83 (s, 6H), 1.59 (m, 12H), 1.49 (s, 9H), 1.44 (s, 
9H), 1.34 (m, 12H), 1.13 (m, 12H), 0.88 (m, 18H); 13C NMR (CD3CN, 100 MHz, 298 
K): δ 154.43, 151.47, 151.43, 149.86, 149.77, 149.48, 143.94, 143.86, 138.80, 137.64, 
135.09, 133.29, 132.77, 128.46, 126.14, 125.97, 123.37, 123.33, 122.96, 120.25, 115.44, 
114.06, 111.87, 86.03, 85.97, 56.58, 56.52, 29.94, 28.11, 28.09, 28.06, 27.94, 14.03, 
10.48, 10.35. 
 
N-tert-Butyloxycarbonyl-2-(3,4,5-trimethoxyphenyl)-5-(tributylstannyl)-
benzimidazole (15d): 
 
A mixture of two regioisomers (1.5 mmol scale, 0.501 g, 50.0%) was obtained as a pale 
yellow sticky solid after chromatography, on deactivated silica, with a gradient from 
hexanes (100%) to ethyl acetate in hexanes (10% v/v), run twice successively: 1H NMR 
(CD3CN, 400 MHz, 298 K): δ 8.14 (s, 1H), 8.00 (d, J = 7.9 Hz, 1H), 7.82 (s, 1H), 7.68 
(d, J = 7.9 Hz, 1H), 7.49 (d, J = 7.9 Hz, 1H), 7.47 (d, J = 7.9 Hz, 1H), 6.92 (s, 2H), 6.91 
(s, 2H), 3.83 (s, 12H), 3.79 (s, 6H), 1.58 (m, 12H), 1.47 (s, 9H), 1.42 (s, 9H), 1.35 (m, 
12H), 1.14 (m, 12H), 0.88 (m, 18H); 13C NMR (CD3CN, 150 MHz, 298 K): δ 154.13, 
153.90, 149.64, 143.76, 140.19, 139.12, 137.79, 134.95, 133.45, 132.79, 129.38, 129.19, 
128.52, 122.90, 120.30, 115.39, 108.07, 85.96, 61.02, 56.95, 29.88, 28.05, 28.02, 27.97, 
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27.87, 13.96, 10.46, 10.32; HRMS (ESI): calcd. for C33H50N2NaO5Sn [M+Na]+ 
697.2639 found 697.2625. 
 
N-tert-Butyloxycarbonyl-2-(4-tert-butylphenyl)-5-(tributylstannyl)-benzimidazole 
(15e): 
 
A mixture of two regioisomers (0.27 mmol scale, 0.0914 g, 52.3%) was obtained as a 
pale yellow viscous oil after chromatography, on deactivated silica, with a gradient from 
hexanes (100%) to ethyl acetate in hexanes (15% v/v): 1H NMR (CD3CN, 400 MHz, 298 
K): δ 8.13 (s, 1H), 7.99 (d, J = 8.0 Hz, 1H), 7.81 (s, 1H), 7.67 (d, J = 7.7 Hz, 1H), 7.56 
(d, J = 8.4 Hz, 4H), 7.51 (d, J = 8.4 Hz, 4H), 7.46 (m, 2H), 1.58 (m, 12H), 1.44 (s, 9H), 
1.35 (s, 18H), 1.33 (m, 12H), 1.13 (m, 12H), 0.88 (m, 18H). 
 
N-tert-Butyloxycarbonyl-2-(4-methylphenyl)-5-(tributylstannyl)-benzimidazole 
(15f): 
 
A mixture of two regioisomers (4.4 mmol scale, 1.37 g, 51.7%) was obtained as a pale 
yellow viscous oil after chromatography, on deactivated silica, with a gradient from 
hexanes (100%) to ethyl acetate in hexanes (10% v/v): 1H NMR (CD3CN, 400 MHz, 298 
K): δ 8.12 (s, 1H), 7.98 (d, J = 8.0 Hz, 1H), 7.81 (s, 1H), 7.67 (d, J = 7.1 Hz, 1H), 7.52 
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(m, 4H), 7.46 (dd, J = 11.0 Hz, J = 8.0 Hz, 2H), 7.29 (d, J = 8.0 Hz, 4H), 2.41 (s, 6H), 
1.57 (m, 12H), 1.47 (s, 9H), 1.42 (s, 9H), 1.34 (m, 12H), 1.13 (m, 12H), 0.88 (m, 18H); 
13C NMR (CD3CN, 100 MHz, 298 K): δ 154.59, 154.56, 149.80, 149.72, 144.02, 143.94, 
140.72, 140.67, 138.92, 137.66, 135.06, 133.37, 132.77, 130.96, 130.84, 130.35, 130.33, 
129.42, 128.55, 123.04, 120.33, 115.49, 86.15, 86.11, 29.95, 28.13, 28.10, 28.00, 27.88, 
21.51, 14.05, 10.49, 10.36. 
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General procedure for diaryl iodonium salt formation from N-tert-
butyloxycarbonyl-2-aryl-5-tributylstannylbenzimidazoles  (16d–f): In a nitrogen-
charged glove box, the appropriate aryl tin compound (1.05 eq.) and bis(acetoxy)-4-
methoxybenzene (1 eq.) were dissolved in minimal dry acetonitrile in a glass vial.  In 
another glass vial, trimethylsilyl trifluoromethanesulfonate (1 eq.) was dissolved in 
approximately 0.4x the previous volume of acetonitrile.  The trimethylsilyl 
trifluoromethanesulfonate solution was added, dropwise, over the course of 5 minutes to 
the first vial, with stirring.  The solution was removed from the glove box, and solvent 
was removed in vacuo.  The crude oil was dissolved in minimal dichloromethane and 
added to 30x the volume of a solution of ether in pentane (10% v/v).  A sticky yellow 
solid immediately precipitated.  The mixture was allowed to stand for 15 minutes before 
being vacuum filtered through a 0.2 µm PTFE membrane filter.  The product was further 
purified, using the indicated method. 
 
(N-tert-Butyloxycarbonyl-2-(3,4,5-trimethoxyphenyl)-5-benzimidazolyl)(4-
methoxyphenyl)iodonium triflate (16d): 
 
A mixture of two regioisomers (0.445 mmol scale, 0.282 g, 81.0%) was obtained as 
yellow powder after dissolving in minimal dichloromethane, diluting with pentane to the 
cloud point, adding more dichloromethane to bring back into solution, and pouring into a 
stirring solution of ether in pentane (10% v/v): 1H NMR (CD3CN, 400 MHz, 298 K): δ 
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8.76 (d, J = 1.8 Hz, 1H), 8.48 (d, J = 1.8 Hz, 1H), 8.17 (d, J = 8.7 Hz, 1H), 8.06 (d, J 
= 9.2 Hz, 4H), 8.02 (dd, J = 8.7 Hz, J = 1.8 Hz, 2H), 7.85 (d, J = 8.7 Hz, 1H), 7.43 (s, 
2H), 7.07 (d, J = 9.2 Hz, 4H), 6.90 (s, 2H), 3.84 (s, 6H), 3.82 (s, 12H), 3.78 (s, 6H), 1.40 
(s, 9H), 1.38 (s, 9H); 19F NMR (CD3CN, 400 MHz, 298 K): δ -79.30 (s, OTf); HRMS 
(ESI): calcd. for C28H30IN2O6 [M-OTf]+ 617.1149 found 617.1178. 
 
(N-tert-Butyloxycarbonyl-2-(4-tert-butylphenyl)-5-benzimidazolyl)(4-
methoxyphenyl)iodonium triflate (16e): 
 
A mixture of two regioisomers (0.252 mmol scale, 0.060 g, 32.3%) was obtained as an 
off-white solid after dissolving in minimal dichloromethane, diluting with pentane to the 
cloud point, adding more dichloromethane to bring back into solution, and pouring into a 
stirring solution of ether in pentane (10% v/v): 1H NMR (CD3CN, 400 MHz, 298 K): δ 
8.75 (s, 1H), 8.47 (s, 1H), 8.16 (d, J = 8.6 Hz, 2H), 8.12–7.93 (m, 6H), 7.82 (d, J = 8.6 
Hz, 2H), 7.54 (d, J = 9.1 Hz, 4H), 7.50 (d, J = 9.1 Hz, 4H), 6.95 (d, J = 9.0 Hz, 2H), 3.84 
(s, 3H), 3.83 (s, 3H), 1.39 (s, 36H); 19F NMR (CD3CN, 400 MHz, 298 K): δ -79.30 (s, 
OTf). 
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(N-tert-Butyloxycarbonyl-2-(4-methylphenyl)-5-benzimidazolyl)(4-
methoxyphenyl)iodonium triflate (16f): 
 
A mixture of two regioisomers (0.427 mmol scale, 0.149 g, 46.1%) was obtained as an 
off-white solid after recrystallization by layering pentane onto a solution of 
dichloromethane/ethyl acetate (1:1 v/v): 1H NMR (CD3CN, 400 MHz, 298 K): 8.72 (d, J 
= 1.9 Hz, 1H), 8.47 (d, J = 1.9 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 8.05 (d, J = 9.0 Hz, 4H), 
8.01 (dd, J = 8.7 Hz, J = 1.9 Hz, 2H), 7.83 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 9.2 Hz, 2H), 
7.52 (d, J = 9.2 Hz, 2H), 7.33 (d, J = 9.0 Hz, 4H), 7.06 (d, J = 9.2 Hz, 2H), 7.05 (d, J = 
9.2 Hz, 2H), 3.83 (s, 3H), 3.82 (s, 3H), 1.39 (s, 9H), 1.38 (s, 9H); 19F NMR (CD3CN, 400 
MHz, 298 K): δ -79.30 (s, OTf); HRMS (ESI): calcd. for C26H26IN2O3 [M-OTf]+ 
541.0988 found 541.1009. 
 
N-tert-Butyloxycarbonyl-2-phenylbenzimidazole (17): 
 
In a 100 mL round-bottom flask with a stirbar, 2-phenylbenzimidazole (0.500 g, 2.57 
mmol) was suspended in acetonitrile (20 mL; dried over 3Å molecular sieves) with 
triethylamine (1.4 mL, 10.28 mmol; dried over potassium hydroxide).  N,N-
dimethylaminopyridine (0.063 g, 0.771 mmol) was added in portions.  Di-tert-butyl 
N
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dicarbonate (1.124 g, 5.14 mmol) was added slowly, in portions.  The mixture was 
stirred, under N2, for 12–24 hours.  Solvent was removed in vacuo and the resulting oil 
was diluted with dichloromethane.  The mixture was washed twice with a mixture of 
saturated aqueous ammonium chloride and brine (1:1 v/v).  The organic layer was dried 
over sodium sulfate and solvent was removed in vacuo.  The crude product was purified 
by column chromatography on silica, deactivated with triethylamine in hexanes (5% v/v), 
using ethyl acetate in dichloromethane (1% v/v), to yield a waxy colorless solid (0.728 g, 
96.2%): 1H NMR (CD3CN, 400 MHz, 298 K): 8.05 (d, J = 8.3 Hz, 1H), 7.72 (d, J = 7.2 
Hz, 1H), 7.68–7.56 (m, 2H), 7.56–7.45 (m, 3H), 7.45–7.32 (m, 2H), 1.38 (s, 9H). 
 
Bis(acetoxy)iodoanisole (18): 
 
4-Iodoanisole (2.34 g, 10.0 mmol) was dissolved in 90 mL of glacial acetic acid and 
heated to 40 ˚C with stirring. Sodium perborate tetrahydrate (13.6 g, 110.0 mmol) was 
added in portions over the course of one hour.  After addition, the reaction mixture was 
heated at 40 ˚C for 8 h.  Once cooled to r.t., the mixture was reduced to approximately 
half the volume by vacuum distillation.  The remaining mixture was mixed with 100 mL 
deionized water and the aqueous layer was extracted with dichloromethane.  The 
combined organic layers were dried over sodium sulfate.  Solvent was removed in vacuo, 
and the crude oil was triturated with hexanes, using sonication, and filtered.  The crude 
solid was dissolved in a minimal amount of dichloromethane, and dropped into a solution 
of diethyl ether in pentane (10% v/v).  The precipitate was aged for 1 h before being 
O I(OAc)2
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filtered to yield a colorless powder (2.43 g, 69.2%): 1H NMR (CD3CN, 400 MHz, 
298 K): δ 8.05 (d, J = 9.1 Hz, 2H), 7.05 (d, J = 9.1 Hz, 2H), 3.86 (s, 3H), 1.90 (s, 6H); 
13C NMR (CD3CN, 100 MHz, 298 K) δ 177.7, 163.7, 138.7, 118.0, 112.0, 56.8, 20.8; 
HRMS: (HRFAB) calcd. for C14H13NO4I [M-2OAc+(3-NBA)]+ 385.9889 found 
385.9885. 
 
4-Iodoaniline (19): 
 
In a 100 mL round-bottom flask, aniline (2.75 g, 0.030 mol) and sodium bicarbonate 
(3.75 g, 0.045 mol) were dissolved in water (25 mL).  The mixture was cooled to 12–15 
˚C by the addition of ice.  While stirring, iodine (6.35 g, 0.025 mol) was added in several 
(10–15) portions over the course of 30 min.  The mixture was stirred for an additional 30 
min until the iodine color had faded significantly.  Crude 4-iodoaniline is collected by 
vacuum filtration and dried in vacuo.  The crude product was mixed with pet ether (25 
mL) in a 100 mL round-bottom flask and brought to reflux while stirring.  After 15 
minutes the solution was cooled to just below reflux and the liquid was decanted into a 
beaker.  The beaker was cooled to -10 ˚C in an ice-salt bath and the solution stirred until 
crystalliazation was complete.  The product was isolated by filtration as colorless needles 
(0.460 g, 45.8%): 1H NMR (CDCl3, 400 MHz, 298 K): δ 7.41 (d, J = 8.8 Hz, 2H), 6.47 
(d, J = 8.8 Hz, 2H); HRMS (EI+): calcd. for C6H6IN [M]+ 218.9545 found 218.9546. 
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Brewster, R. Q. Org. Synth. 1931, 11, 62. 
 
4-Iodoacetanilide (20): 
 
In an oven-dried 100 mL round-bottom flask, 4-iodoaniline (1.00 g, 4.47 mmol) was 
suspended in acetic anhydride (10 mL), and chilled to 0 ˚C.  Concentrated sulfuric acid 
(~0.5 mL) was added dropwise.  Once the solution became homogenous, the ice bath was 
removed and the solution was as allowed to warm to room temperature.  After 3 hours, 
the solution was poured over 10 mL ice-water (~1:1).  Once the ice had melted, the 
mixture was filtered.  The solid was dried at 110 ˚C for several hours to yield the product 
as a nearly colorless solid (1.12 g, 95.0%): 1H NMR (CDCl3, 400 MHz, 298 K): δ 7.61 
(d, J = 8.6 Hz, 2H), 7.28 (d, J = 8.6 Hz, 2H), 7.24 (br s, NH), 2.16 (s, 3H); HRMS (EI+): 
calcd. for C8H8INO [M]+ 260.9651 found 260.9649. 
 
General fluorination procedure (22e and 23f): In a nitrogen-charged glove box, the 
appropriate diaryliodonium triflate (2.0 eq.) was dissolved in 0.5 mL acetonitrile-d3.  In a 
separate vial a stock solution of tetramethylammonium fluoride (2.5 eq.) was dissolved in 
1.0 mL acetonitrile-d3.  A portion of this stock solution (1.0 eq., 0.1 mL) was added to the 
diaryliodonium salt solution.  The mixture was transferred into an NMR tube fitted with a 
Teflon screw cap closure, sealed, and analyzed by 1H and 19F NMR.  Solvent was 
removed in vacuo and the tube was returned to the glove box.  Benzene-d6 (0.6 mL) was 
I
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added.  The tube was sealed, and heated in the dark until thermolysis was complete 
by 1H and 19F NMR.  Solvent was removed in vacuo and the crude oil was purified by 
column chromatography on silica, deactivated with triethylamine in hexanes (5% v/v), 
using the indicated solvents. 
 
N-tert-Butyloxycarbonyl-2-(4-tert-butylphenyl)-5-fluorobenzimidazole (22e): 
 
After thermolysis at 140 ˚C for 30 min, a mixture of two regioisomers (0.005 mmol scale, 
37.3% by NMR) was identified by 1H and 19F NMR, but not isolated: 1H NMR (C6D6, 
400 MHz, 298 K): δ 8.03–7.94 (m, 2H), 7.87 (dd, J = 9.9 Hz, J = 2.2 Hz, 1H), 7.78 (dd, J 
= 9.1 Hz, J = 5.3 Hz, 1H), 7.55 (d, J = 8.0 Hz, 4H), 7.49 (d, J = 8.0 Hz, 4H), 7.32 (m, 
2H), 1.20 (s, 18H), 1.18 (s, 18H); 19F NMR (C6D6, 400 MHz, 298 K): δ -116.01 (s, 1F), -
117.82 (s, 1F). 
 
N-tert-Butyloxycarbonyl-2-(4-methylphenyl)-5-fluorobenzimidazole (22f): 
 
After thermolysis at 80 ˚C for 2 h, a mixture of two regioisomers (0.025 mmol scale, 4.3 
mg, 51.8% isolated) was obtained as a waxy solid after preparative thin-layer 
chromatography, on deactivated silica, with ethyl acetate in hexanes (12% v/v): 1H NMR 
(CD3CN, 400 MHz, 298 K): δ 8.00 (dd, J = 8.9 Hz, J = 5.1 Hz, 1H), 7.75 (dd, J = 9.7 Hz, 
N
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J = 2.7 Hz, 1H), 7.68 (dd, J = 8.9 Hz, J = 5.1 Hz, 1H), 7.51 (d, J = 7.9 Hz, 4H), 7.44 
(dd, J = 9.7 Hz, J = 2.7 Hz, 1H), 7.31 (d, J = 7.9 Hz, 4H), 7.17 (ddd, J = 18.6 Hz, J = 9.7 
Hz, J = 2.7 Hz, 2H), 2.42 (s, 6H), 1.41 (s, 18H); 19F NMR (CD3CN, 400 MHz, 298 K): δ 
-116.10 (s, 1F), -117.13 (s, 1F); HRMS (ESI): calcd. for C14H12FN2 [M-Boc+2H]+ 
227.0985 found 227.1100. 
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3.6 NMR Spectra 
 
1H NMR (CDCl3, 400 MHz, 298 K) spectrum of 4-fluoroacetanilide (1) 
 
  
-3
-2
-1
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
pp
m
2.05
6.86
6.89
6.91
7.16
7.32
7.33
7.34
7.35
7.36
7.45
3.07
2.00
2.03
0.94
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
N
A
M
E
 
 
 
 
 
J
J
K
.
4
-
f
l
u
o
r
o
a
c
e
t
a
n
i
l
i
d
e
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
F
2
 
-
 
A
c
q
u
i
s
i
t
i
o
n
 
P
a
r
a
m
e
t
e
r
s
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 
2
0
1
0
0
7
0
4
T
i
m
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
6
.
4
0
 
h
I
N
S
T
R
U
M
 
 
 
 
 
 
 
 
 
 
 
s
p
e
c
t
P
R
O
B
H
D
 
 
 
5
 
m
m
 
Q
N
P
 
1
H
/
1
3
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
 
 
z
g
3
0
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
5
5
3
6
S
O
L
V
E
N
T
 
 
 
 
 
 
 
 
 
 
 
C
D
C
l
3
N
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
2
D
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
S
W
H
 
 
 
 
 
 
 
 
 
 
 
 
8
2
7
8
.
1
4
6
 
H
z
F
I
D
R
E
S
 
 
 
 
 
 
 
 
 
0
.
2
5
2
6
2
9
 
H
z
A
Q
 
 
 
 
 
 
 
 
 
 
 
 
3
.
9
5
8
3
7
4
5
 
s
e
c
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
2
8
.
1
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
0
.
4
0
0
 
u
s
e
c
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
.
5
0
 
u
s
e
c
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
9
8
.
0
 
K
D
1
 
 
 
 
 
 
 
 
 
 
 
1
.
0
0
0
0
0
0
0
0
 
s
e
c
T
D
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
S
F
O
1
 
 
 
 
 
 
 
 
4
0
0
.
1
3
2
4
7
1
0
 
M
H
z
N
U
C
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
H
P
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
0
.
2
5
 
u
s
e
c
F
2
 
-
 
P
r
o
c
e
s
s
i
n
g
 
p
a
r
a
m
e
t
e
r
s
S
I
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
2
7
6
8
S
F
 
 
 
 
 
 
 
 
 
 
4
0
0
.
1
3
0
0
5
0
3
 
M
H
z
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
S
S
B
 
 
 
 
 
 
0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.
3
0
 
H
z
G
B
 
 
 
 
 
 
 
0
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
.
0
0
6.
9
7.
0
7.
1
7.
2
7.
3
7.
4
7.
5
7.
6
pp
m
6.86
6.89
6.91
7.16
7.32
7.33
7.34
7.35
7.36
7.45
2.00
2.03
0.94
N H
F
CH
3
O
 328 
19F NMR (CDCl3, 376 MHz, 298 K) spectrum of 4-fluoroacetanilide (1) 
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13C NMR (CDCl3, 100 MHz, 298 K) spectrum of 4-fluoroacetanilide (1) 
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1H NMR (CDCl3, 400 MHz, 298 K) spectrum of 4-fluoro-2-nitroacetanilide (2) 
 
  
-2
-1
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
pp
m
1.63
2.30
7.27
7.39
7.39
7.40
7.41
7.42
7.43
7.43
7.92
7.93
7.94
7.95
8.78
8.80
8.81
8.82
10.19
3.13
1.10
0.99
1.00
1.00
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
N
A
M
E
 
 
 
 
 
 
 
 
 
J
J
K
.
0
2
.
0
9
5
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
F
2
 
-
 
A
c
q
u
i
s
i
t
i
o
n
 
P
a
r
a
m
e
t
e
r
s
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 
2
0
1
0
0
1
1
8
T
i
m
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
3
.
5
7
 
h
I
N
S
T
R
U
M
 
 
 
 
 
 
 
 
 
 
 
s
p
e
c
t
P
R
O
B
H
D
 
 
 
5
 
m
m
 
Q
N
P
 
1
H
/
1
3
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
 
 
z
g
3
0
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
5
5
3
6
S
O
L
V
E
N
T
 
 
 
 
 
 
 
 
 
 
 
C
D
C
l
3
N
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
2
D
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
S
W
H
 
 
 
 
 
 
 
 
 
 
 
 
8
2
7
8
.
1
4
6
 
H
z
F
I
D
R
E
S
 
 
 
 
 
 
 
 
 
0
.
2
5
2
6
2
9
 
H
z
A
Q
 
 
 
 
 
 
 
 
 
 
 
 
3
.
9
5
8
3
7
4
5
 
s
e
c
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
5
6
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
0
.
4
0
0
 
u
s
e
c
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
.
5
0
 
u
s
e
c
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
9
3
.
9
 
K
D
1
 
 
 
 
 
 
 
 
 
 
 
1
.
0
0
0
0
0
0
0
0
 
s
e
c
T
D
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
S
F
O
1
 
 
 
 
 
 
 
 
4
0
0
.
1
3
2
4
7
1
0
 
M
H
z
N
U
C
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
H
P
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
2
.
0
0
 
u
s
e
c
F
2
 
-
 
P
r
o
c
e
s
s
i
n
g
 
p
a
r
a
m
e
t
e
r
s
S
I
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
2
7
6
8
S
F
 
 
 
 
 
 
 
 
 
 
4
0
0
.
1
3
0
0
0
5
4
 
M
H
z
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
S
S
B
 
 
 
 
 
 
0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.
3
0
 
H
z
G
B
 
 
 
 
 
 
 
0
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
.
0
0
7.
5
8.
0
8.
5
9.
0
9.
5
10
.0
10
.5
pp
m7.39
7.39
7.40
7.41
7.42
7.43
7.43
7.92
7.93
7.94
7.95
8.78
8.80
8.81
8.82
10.19
1.10
0.99
1.00
1.00
N H
F
NO
2
CH
3
O
 331 
19F NMR (CDCl3, 376 MHz, 298 K) spectrum of 4-fluoro-2-nitroacetanilide (2) 
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13C NMR (CDCl3, 100 MHz, 298 K) spectrum of 4-fluoro-2-nitroacetanilide (2) 
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1H NMR (CDCl3, 500 MHz, 298 K) spectrum of 4-fluoro-2-nitroaniline (3) 
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19F NMR (CDCl3, 376 MHz, 298 K) spectrum of 4-fluoro-2-nitroaniline (3) 
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13C NMR (CDCl3, 126 MHz, 298 K) spectrum of 4-fluoro-2-nitroaniline (3) 
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1H NMR (CDCl3, 400 MHz, 298 K) spectrum of N-(4-methylbenzoyl)-4-fluoro-2-
nitroaniline (5f) 
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19F NMR (CDCl3, 376 MHz, 298 K) spectrum of N-(4-methylbenzoyl)-4-fluoro-2-
nitroaniline (5f) 
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13C NMR (CDCl3, 126 MHz, 298 K) spectrum of N-(4-methylbenzoyl)-4-fluoro-2-
nitroaniline (5f) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of N-(4-methylbenzoyl)-4-fluoro-2-
aminoaniline (6f) 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of N-(4-methylbenzoyl)-4-fluoro-2-
aminoaniline (6f) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of 2-(4-methylphenyl)-5-
fluorobenzimidazole (7f) 
 
  
-3
-2
-1
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
pp
m
1.93
1.93
1.94
1.95
1.95
2.19
2.41
6.99
6.99
7.02
7.04
7.04
7.27
7.34
7.36
7.49
7.60
7.95
7.97
10.93
3.13
1.00
3.08
1.09
2.02
0.93
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
N
A
M
E
 
 
 
 
 
 
 
 
 
 
J
J
K
.
M
e
-
B
I
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
F
2
 
-
 
A
c
q
u
i
s
i
t
i
o
n
 
P
a
r
a
m
e
t
e
r
s
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 
2
0
1
0
0
7
0
1
T
i
m
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
.
1
2
 
h
I
N
S
T
R
U
M
 
 
 
 
 
 
 
 
 
 
 
s
p
e
c
t
P
R
O
B
H
D
 
 
 
5
 
m
m
 
Q
N
P
 
1
H
/
1
3
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
 
 
z
g
3
0
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
5
5
3
6
S
O
L
V
E
N
T
 
 
 
 
 
 
 
 
 
 
 
C
D
3
C
N
N
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
6
D
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
S
W
H
 
 
 
 
 
 
 
 
 
 
 
 
8
2
7
8
.
1
4
6
 
H
z
F
I
D
R
E
S
 
 
 
 
 
 
 
 
 
0
.
2
5
2
6
2
9
 
H
z
A
Q
 
 
 
 
 
 
 
 
 
 
 
 
3
.
9
5
8
3
7
4
5
 
s
e
c
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
6
2
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
0
.
4
0
0
 
u
s
e
c
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
.
5
0
 
u
s
e
c
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
9
4
.
3
 
K
D
1
 
 
 
 
 
 
 
 
 
 
 
1
.
0
0
0
0
0
0
0
0
 
s
e
c
T
D
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
S
F
O
1
 
 
 
 
 
 
 
 
4
0
0
.
1
3
2
4
7
1
0
 
M
H
z
N
U
C
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
H
P
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
0
.
2
5
 
u
s
e
c
F
2
 
-
 
P
r
o
c
e
s
s
i
n
g
 
p
a
r
a
m
e
t
e
r
s
S
I
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
2
7
6
8
S
F
 
 
 
 
 
 
 
 
 
 
4
0
0
.
1
3
0
0
1
1
5
 
M
H
z
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
S
S
B
 
 
 
 
 
 
0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.
3
0
 
H
z
G
B
 
 
 
 
 
 
 
0
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
.
0
0
7.
0
7.
5
8.
0
8.
5
9.
0
9.
5
10
.0
10
.5
11
.0
pp
m
6.99
6.99
7.02
7.04
7.04
7.27
7.34
7.36
7.49
7.60
7.95
7.97
10.93
1.00
3.08
1.09
2.02
0.93
NH N
F
CH
3
 342 
1H NMR (CD3CN, 376 MHz, 298 K) spectrum of 2-(4-methylphenyl)-5-
fluorobenzimidazole (7f) 
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1H NMR (CDCl3, 500 MHz, 298 K) spectrum of 4-bromoacetanilide (8) 
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13C NMR (CDCl3, 126 MHz, 298 K) spectrum of 4-bromoacetanilide (8) 
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1H NMR (CDCl3, 500 MHz, 298 K) spectrum of 4-bromo-2-nitroacetanilide (9) 
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13C NMR (CDCl3, 126 MHz, 298 K) spectrum of 4-bromo-2-nitroacetanilide (9) 
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1H NMR (CDCl3, 500 MHz, 298 K) spectrum of 4-bromo-2-nitroaniline (10) 
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13C NMR (CDCl3, 126 MHz, 298 K) spectrum of 4-bromo-2-nitroaniline (10) 
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1H NMR (CDCl3, 600 MHz, 298 K) spectrum of N-(4-methylbenzoyl)-4-bromo-2-
nitroaniline (11f) 
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13C NMR (CDCl3, 126 MHz, 298 K) spectrum of N-(4-methylbenzoyl)-4-bromo-2-
nitroaniline (11f) 
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1H NMR (CDCl3, 400 MHz, 298 K) spectrum of 2-(4-methylphenyl)-5-
bromobenzimidazole (13f) 
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1H NMR (CD3CN, 300 MHz, 298 K) spectrum of N-tert-butyloxycarbonyl-2-(4-
methylphenyl)-5-bromobenzimidazole (14f) 
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13C NMR (CD3CN, 75 MHz, 298 K) spectrum of N-tert-butyloxycarbonyl-2-(4-
methylphenyl)-5-bromobenzimidazole (14f) 
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1H NMR (CD3CN, 500 MHz, 298 K) spectrum of N-tert-butyloxycarbonyl-2-(4-
methylphenyl)-5-(tributylstannyl)-benzimidazole (15f) 
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13C NMR (CD3CN, 126 MHz, 298 K) spectrum of N-tert-butyloxycarbonyl-2-(4-
methylphenyl)-5-(tributylstannyl)-benzimidazole (15f) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of (N-tert-butyloxycarbonyl-2-(4-
methylphenyl)-5-benzimidazolyl)(4-methoxyphenyl)iodonium triflate (16f) 
 
  
-3
-2
-1
16
15
14
13
12
11
10
9
8
7
6
5
4
3
2
1
0
pp
m
1.38
1.39
1.93
1.93
1.94
1.95
1.95
2.18
2.42
3.82
3.83
7.04
7.05
7.06
7.07
7.31
7.32
7.33
7.51
7.52
7.53
7.54
7.82
7.84
7.99
7.99
8.00
8.00
8.01
8.02
8.02
8.02
8.04
8.04
8.06
8.06
8.13
8.15
8.47
8.47
8.72
8.72
17.62
5.90
5.95
3.99
4.01
3.98
1.00
2.00
3.92
1.04
1.02
0.93
C
u
r
r
e
n
t
 
D
a
t
a
 
P
a
r
a
m
e
t
e
r
s
N
A
M
E
 
 
 
 
 
J
J
K
.
0
4
.
4
4
_
M
e
-
O
T
f
s
a
l
t
_
p
r
e
c
i
p
E
X
P
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
P
R
O
C
N
O
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
F
2
 
-
 
A
c
q
u
i
s
i
t
i
o
n
 
P
a
r
a
m
e
t
e
r
s
D
a
t
e
_
 
 
 
 
 
 
 
 
 
 
2
0
1
2
0
8
2
9
T
i
m
e
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
2
.
3
2
 
h
I
N
S
T
R
U
M
 
 
 
 
 
 
 
 
 
 
 
s
p
e
c
t
P
R
O
B
H
D
 
 
 
5
 
m
m
 
Q
N
P
 
1
H
/
1
3
P
U
L
P
R
O
G
 
 
 
 
 
 
 
 
 
 
 
 
z
g
3
0
T
D
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
5
5
3
6
S
O
L
V
E
N
T
 
 
 
 
 
 
 
 
 
 
 
C
D
3
C
N
N
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
2
D
S
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
S
W
H
 
 
 
 
 
 
 
 
 
 
 
 
8
2
7
8
.
1
4
6
 
H
z
F
I
D
R
E
S
 
 
 
 
 
 
 
 
 
0
.
2
5
2
6
2
9
 
H
z
A
Q
 
 
 
 
 
 
 
 
 
 
 
 
3
.
9
5
8
3
7
4
5
 
s
e
c
R
G
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
2
2
.
5
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
0
.
4
0
0
 
u
s
e
c
D
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6
.
5
0
 
u
s
e
c
T
E
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2
9
3
.
5
 
K
D
1
 
 
 
 
 
 
 
 
 
 
 
4
.
0
0
0
0
0
0
0
0
 
s
e
c
T
D
0
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
S
F
O
1
 
 
 
 
 
 
 
 
4
0
0
.
1
3
2
4
7
1
0
 
M
H
z
N
U
C
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
H
P
1
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
0
.
0
0
 
u
s
e
c
F
2
 
-
 
P
r
o
c
e
s
s
i
n
g
 
p
a
r
a
m
e
t
e
r
s
S
I
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3
2
7
6
8
S
F
 
 
 
 
 
 
 
 
 
 
4
0
0
.
1
3
0
0
1
1
0
 
M
H
z
W
D
W
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
E
M
S
S
B
 
 
 
 
 
 
0
L
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.
3
0
 
H
z
G
B
 
 
 
 
 
 
 
0
P
C
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
.
0
0
7.
2
7.
4
7.
6
7.
8
8.
0
8.
2
8.
4
8.
6
pp
m7.04
7.05
7.06
7.07
7.31
7.32
7.33
7.51
7.52
7.53
7.54
7.82
7.84
7.99
7.99
8.00
8.00
8.01
8.02
8.02
8.02
8.04
8.04
8.06
8.06
8.13
8.15
8.47
8.47
8.72
8.72
3.99
4.01
3.98
1.00
2.00
3.92
1.04
1.02
0.93
NN
I
Tf
O
M
eO
CH
3
Bo
c
 357 
19F NMR (CD3CN, 376 MHz, 298 K) spectrum of (N-tert-butyloxycarbonyl-2-(4-
methylphenyl)-5-benzimidazolyl)(4-methoxyphenyl)iodonium triflate (16f) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of N-tert-butyloxycarbonyl-2-(4-
methylphenyl)-5-fluorobenzimidazole (22f) 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of N-tert-butyloxycarbonyl-2-(4-
methylphenyl)-5-fluorobenzimidazole (22f) 
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1H NMR (CD3CN, 400 MHz, 298 K) spectrum of 2-(4-methylphenyl)-5-
fluorobenzimidazole (7f) by deprotection of 22f with trifluoroacetic acid 
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19F NMR (CD3CN, 376 MHz, 298 K) spectrum of 2-(4-methylphenyl)-5-
fluorobenzimidazole (7f) by deprotection of 22f with trifluoroacetic acid 
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